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SUMMARY 
 
The protein kinase enzyme family is one of the largest super-families of homologous proteins 
and are responsible for modifying an estimated one third of the human proteome. These 
enzymes catalyze the transfer of the terminal phosphate group of ATP to a hydroxyl group of 
serine, threonine or tyrosine present in a target protein. Depending on the substrate, protein 
kinases can be classified into serine-threonine kinases and tyrosine kinases. 
According to their cellular location, both classes can be further divided into receptor kinases 
(located in the cell membrane) or cytoplasmic kinases (located within the cell). 
Protein kinases are key regulators of cell functions. They direct the activity, localization and 
other functions of many proteins, and serve to orchestrate the activity of almost all cellular 
processes. It has also been firmly demonstrated that kinase activity alterations, leading to the 
disruption of cell signalling cascades, play important roles in many diseases, including cancer, 
inflammation, neurological disorders and diabetes. For all these reasons, kinases represent 
important targets for drug therapy. It is estimated that over 30% of the drug discovery efforts 
in pharmaceutical and biotech companies are directed towards finding and validating protein 
kinase inhibitors. 
My PhD project was aimed at synthesizing inhibitors of the tyrosine kinases Src, Fyn and Hck 
and the serine-threonine kinase Sgk1. 
Src family kinases are a group of highly homologous non-receptor tyrosine kinases that are 
involved in the regulation of several phases of cell life (e.g. growth, differentiation, apoptosis). 
The hyperactivation of c-Src, a member of this family of enzymes, has been proved to be closely 
connected with the development and progression of several tumor types. In this context, the 
research group where I worked has synthesized a large library of pyrazolo[3,4-d]pyrimidines; 
many of these molecules resulted to be nanomolar inhibitors of the cytoplasmic tyrosine kinase 
c-Src. This family of compounds also showed a good antiproliferative activity against several 
cancer cell lines: neuroblastoma, chronic myeloid leukaemia, rhabdomyosarcoma, 
osteosarcoma, prostate cancer, and mesothelioma. Important results have been obtained in 
several mouse models of cancer. 
Recently, c-Src has been shown to be frequently hyperactivated or overexpressed also in 
glioblastoma, a brain tumour characterized by a high degree of proliferation, angiogenesis, 
necrosis, and invasiveness. Src inhibition reduced glioblastoma cell growth, viability and 
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migration both in vitro and in mouse models. In this context, I synthesized a library of 
pyrazolo[3,4-d]pyrimidines; some of these compounds demonstrated a good activity towards 
Src in enzymatic assays and on different glioblastoma cell lines. 
At the same time, the pyrrolo[2,3-d]pyrimidine scaffold is also being extensively investigated 
and in the last few years, many of such compounds resulted active as kinase inhibitors. For this 
reason, I synthesized a family of pyrrolo[2,3-d]pyrimidines which have been tested on Src in 
enzymatic assays and as antiproliferative agents on a specific cancer cell line. 
Fyn is another member of Src family kinases and it phosphorylates a variety of target proteins 
involved in different signalling pathways. To date, the implication of Fyn in solid and in 
hematologic malignancies has become more evident and its abnormal activity has been shown 
to be related to severe central nervous system pathologies such as Alzheimer’s and Parkinson’s 
disease.  
The research group where I worked synthesized a library of pyrazolo[3,4-d]pyrimidines active 
as Fyn inhibitors endowed with Ki values in the nanomolar range. Some of these compounds 
inhibited the phosphorylation of the protein Tau in an Alzheimer’s model cell line and showed 
antiproliferative activities against different cancer cell lines. On the basis of these interesting 
results, I decided to expand the structure-activity relationship (SAR) on this family of inhibitors 
and planned the synthesis of new compounds.  
Hematopoietic cell kinase (Hck) is another member of Src family kinases and it is expressed in 
hematopoietic cells, particularly myelomonocytic cells and B-lymphocytes. High levels of Hck 
are involved in chronic myeloid leukemia and in other hematologic tumors, but its activity is 
also connected with viral infections, including HIV-1. In this context, our research group 
developed a docking study to identify new Hck inhibitors. We screened some molecules of our 
in house library of pyrazolo[3,4-d]pyrimidines and some commercial compounds, and we 
tested, in enzymatic and cellular assays, the most promising compounds which showed an 
activity towards Hck in the low micromolar range. On the basis of these results, I synthesized 
some new pyrazolo[3,4-d]pyrimidines, analogs of the most active inhibitors, and some 
derivatives of the commercial compound, which showed the best Hck inhibitory activity, in 
detail 5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine molecules. Enzymatic assays of these 
compounds are still in progress. 
Sgk1 is a member of the serum- and glucocorticoid-regulated kinase family that is involved in 
antiapoptotic functions and in the regulation of cell survival, proliferation, and differentiation. 
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A pivotal role of Sgk1 in carcinogenesis and in resistance to anticancer therapy has been 
suggested. For all these reasons, we decided to develop an in silico screening in order to see if 
some our pyrazolo[3,4-d]pyrimidines, already active as Src and/or Abl inhibitors, were also 
active towards Sgk1. One of these compounds, showed a very interesting activity. On the basis 
of these interesting results, I synthesized a small library of pyrazolo[3,4-d]pyrimidines, 
analogue of the most active compounds, in order to develop a lead optimization study. Other 
synthesis and biological studies are in progress.  
During the third year of my PhD, I also spent a research period at the School of Pharmacy of 
the University of Nottingham under the supervision of Prof. Cameron Alexander. In these 
months, I developed a new miniaturized screening process, based on an inkjet printing 
technologies, able to identify the best formulation to enhance the apparent water solubility of 
some pyrazolo[3,4-d]pyrimidine derivatives, using as little of the sample as possible. I chosen 
five compounds of our in-house library of pyrazolo[3,4-d]pyrimidines and I synthesized a new 
analogue. Then I combined these derivatives with seven different hydrophilic commercial 
available polymers that are able to inhibit crystallization and to create an amorphous solid 
dispersion. The applied amount of compounds used in the reported strategy ranged from 5 to 
10 μg per formulation which were dispensed by an inkjet 2D printer directly into a 96-well 
plate. The selected polymer/drug formulations with high water solubility demonstrated 
improved cytotoxicity against a human lung adenocarcinoma cancer cell line (A549) compared 
to the free drugs. The enhanced efficacy was attribute to the improved apparent-solubility of 
the drug molecules achieved via this methodology. This novel miniaturized method showed 
promising results in terms of water solubility improvement of the highly hydrophobic 
pyrazolo[3,4-d]pyrimidine derivatives, requiring only a few micrograms of each drug per tested 
polymeric formulation. In addition, the reported experimental evidence may facilitate 
identification of suitable polymers for combination with drug, leading to investigations on 
biological properties or mechanisms of action in a single formulation. 
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CHAPTER 1. Introduction 
 
1.1  The protein kinase enzyme family 
Protein kinases are ATP-dependent phosphotransferases that deliver a single phosphoryl group 
from the γ-position of ATP to the hydroxyl groups of serine, threonine and tyrosine in protein 
substrates (Fig. 1). This phosphorylation process produces a signal transduction that implicates 
a biological response. Protein kinases can regulate a wide range of processes including cell 
growth, survival, division, differentiation, proliferation, apoptosis, angiogenesis and also 
carbohydrate and lipid metabolism, neurotransmitter biosynthesis, DNA transcription and 
replication, organelle trafficking and smooth muscle contraction.1  
 
 
 
 
Based on the nature of the phosphorylated OH group, these enzymes are classified as protein 
serine-threonine kinases and protein-tyrosine kinases. 
Manning et al. identified 478 typical and 40 atypical human protein kinase genes (total 518) 
that correspond to nearly 2% of all human genes and are responsible for modifying an estimated 
one third of the human proteome (Fig. 2).2 In the early 1990s, X-ray crystallography showed 
that the catalytic domains of serine/threonine and tyrosine kinases share a common architecture. 
Indeed, this is the key feature that distinguishes protein kinase family members from other 
proteins. 
 
 
 
Fig. 1. Protein kinase phosphorylation mechanism. 
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Protein phosphorylation was discovered as a regulatory mechanism by Krebs and Fischer 
(Nobel prize 1992) in the late 1950s through their studies of glycogen phosphorylase and their 
subsequent discovery of phosphorylase kinase.3  
The mechanism requires an essential bivalent metal ion, usually Mg2+ (or Mn2+) to facilitate the 
phosphoryl transfer reaction and assist in ATP-binding. Protein kinases operate on two 
substrates which are the protein and MgATP and produce the corresponding phosphoprotein 
and MgADP4. They possess extraordinary catalytic power, accelerating phosphorylation rates 
Fig. 2. Human protein kinases. (From Cell Signaling Technology®). 
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by 9-11 orders of magnitude. This finding comes from the presumption that the alkoxide of 
serine or threonine or the phenolate of tyrosine, formed by the interaction with the Mg2+ ion, 
should be a better general nucleophile than the alcohol or phenol form and, thus, would enhance 
phosphoryl group donation.  
It is known that protein kinases share a conserved region of approximately 200-250 amino acids 
that confers kinase activity and consists of two lobes, the N-terminal lobe (N-lobe) which 
contains five β strands and a universally conserved αC-helix, interacts with the ATP through 
the glycine-rich loop which coordinates the phosphate groups, and the C-terminal lobe, which 
contains mostly helices plus a β sheet and provides substrate-binding sites for ATP and 
peptides. The helical subdomain of the C lobe, which is extremely stable, forms the core of the 
kinase and the subdomain, comprising four β short strands, contains much of the catalytic 
machinery associated with the transfer of the phosphate from ATP to the protein substrate and 
is anchored through hydrophobic residues to the helical core. The C-terminal domain includes 
the activation loop (A-loop), a segment typically containing tyrosine, serine or threonine 
residues that can be phosphorylated. In its non-phosphorylated state, the A-loop tends to hinder 
substrate binding. Phosphorylation of these residues increases kinase activity. Among the 
amino acids of the conserved region, there are key residues extremely important for the 
interaction with ATP. Asp-184, a strictly conserved residue, interacts with the essential Mg2+, 
which chelates the β and  phosphates of ATP. The chelation of this ion may position the 
terminal phosphate for direct transfer to the hydroxyl acceptor. 
Another key residue is Lys-72, which interacts with α and β phosphates of ATP, giving 
additional stabilization and facilitating the phosphoryl group transfer without influencing ATP-
binding (Fig. 3). 
In addition to the catalytic domain, the structure of protein kinases includes other well 
characterized domains (e.g. SH3 and SH2 in cytoplasmic tyrosine kinases). Typically, these 
domains mediate inter- and intramolecular interactions of protein kinases, thus playing an 
important role in their functional regulation.1  
It has been demonstrated that kinase activity alterations (especially hyperactivation, 
hyperproduction or mutations), leading to the disruption of cell signalling cascades, play 
important roles in several diseases, including cancer, inflammation, neurological disorders and 
diabetes, making kinases attractive targets for several therapies.5  
Thus, kinases are the focus of intense basic and drug discovery research, and the US Food and 
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Drug Administration (FDA) and the European Medical Agency (EMA) have so far approved 
more than 30 small-molecule kinase inhibitors.6,7  
The kinase inhibitors market is expected to see a staggering growth, with the current market 
valued at USD 15 billion in 2012, and anticipated to reach USD 36 billion in 2018. This 
exponential growth is predicted due to a rise in the incidence of various cancers, a rise in aging 
population and, consequently, increased focus of pharmaceutical companies on R&D to come 
up with potential medicines for the treatments of cancers.  
 
 
 
 
 
 
 
 
 
Fig. 3. A. Structure of the conserved protein kinase core. An 
ATP molecule is bound to a deep cleft between the lobes. 
Major catalytically important loops are colored yellow. B. N-
lobe structure. Three conserved glycines are shown as red 
spheres. C. C-lobe structure. Catalytic and regulatory 
machinery is bound to the rigid helical core. 
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1.1.1 Tyrosine kinases  
Tyrosine kinases (TKs) are a subclass of protein kinases that catalyze phosphorylation of 
selected tyrosine residues in target proteins, using ATP.  
TKs are conserved throughout eukaryotes and regulate processes in both unicellular and 
multicellular organisms. They contain highly conserved catalytic domains similar to those of 
serine/threonine kinases, but with unique subdomain motifs typical of TKs.8 The reaction 
catalyzed by tyrosine kinases involves the transfer of the γ-phosphate of ATP to the hydroxyl 
of the substrate tyrosine and requires the presence of a divalent metal ion. In detail, the substrate 
binds to a platform on the TK C-terminal lobe, with the hydroxyl group of the tyrosine to be 
phosphorylated pointing toward the γ-phosphate of ATP. This platform is partially formed by 
residues from the activation loop (A-loop), the conformation of which is stabilized by the 
phosphorylation of one or more tyrosine residues in most tyrosine kinases. Residues important 
for catalysis or for the correct architecture of the catalytic site come from different parts of the 
structure, such as the P-loop (glycine-rich or nucleotide-binding loop), β strand 3 and αC-helix, 
all within the N-terminal lobe and the catalytic loop (β strands 6 and 7) and the A-loop (about 
20 residues located between strand 8 and αC-helix). Many of these structural elements 
correspond to regions with highly conserved sequences. 
The structures of TKs in the active state are all very similar, despite the fact that they have 
different substrate specificities and different mechanisms of control. This similarity results from 
the constraints on the spatial arrangement of residues important for catalysis. In this way, the 
structural elements on which these amino acids reside tend to have the same relative orientation. 
In cells under resting conditions, most TKs are held in an inactive state, which usually involves 
a conformation that disrupts the active arrangement of the catalytic residues or blocks the 
protein from binding cofactors or substrates. Unlike active kinases where the structures are very 
similar, inactive kinases have structurally diverse conformations. Structural biology has 
revealed several different mechanisms of self-regulation. In most cases, the position of C-helix 
and/or the A-loop is involved, and very often regions outside the kinase domain fold back to 
block the binding sites or cause conformational changes that render the kinase inactive. Many 
of these mechanisms are shared by kinases from distinct tyrosine kinase subgroups and also 
with non-tyrosine kinases.9  
TK activation regulates many key processes in cell growth, survival, organ morphogenesis, 
neovascularization, and tissue repair and regeneration.10 In normal cells, TK activity is strictly 
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regulated, while deregulation or constitutive activation of TKs has been found in a wide range 
of disease and, in particular, in cancer. The deregulated activation occurs by gain-of-function 
mutations, gene rearrangement, gene amplification, overexpression or abnormal autocrine, 
endocrine or paracrine stimulation of both enzyme and ligand, and, in some cases, it has been 
shown to correlate with the development and progression of numerous human cancers. Since 
TKs have been implicated in many aspects of the malignant phenotype, they emerged as 
promising therapeutic targets. Cancer therapy targeting TKs may be successful only if the 
targeted TK is a major regulator of cancer cell survival, but cancer cells usually contain multiple 
genetic and epigenetic abnormalities. Despite this complexity, cancer cell survival and/or 
proliferation can often be impaired by the inactivation of a single oncogene. This phenomenon, 
called “oncogene addiction”, provides a rationale for molecular targeted therapies. A 
convincing evidence for the concept of oncogene addiction comes from the increasing number 
of examples of the therapeutic efficacy of antibodies or small molecules that target a specific 
oncogene. Evidence is provided by the therapeutic efficacy of drugs that target various 
oncogenic protein kinases; examples include imatinib, which targets the Bcr-abl oncogene in 
chronic myeloid leukemia and also targets the c-kit oncogene in gastrointestinal stromal tumors, 
and gefitinib and erlotinib, which target the epidermal growth factor receptor in non-small cell 
lung cancer, pancreatic cancer, and glioblastoma.11  
Two classes of TKs are present in human cells, the transmembrane receptor TKs, and the 
cytoplasmic or non-receptor TKs.  
 
1.1.1.1 Receptor tyrosine kinases  
The family of receptor tyrosine kinases (RTKs) includes 20 subclasses (ALK, AXL, DDR, 
EGFR, EPH, FGFR, INSR, MET, MUSK, PDGFR, PTK7, RET, ROS, ROR, RYK, TIE, TRK, 
VEGFR, AATYK and the uncharacterized DKFZp761P1010). All these enzymes are 
transmembrane glycoproteins formed by an extracellular part, which works as a receptor, and 
an intracellular portion endowed with the kinase catalytic activity. The RTKs are activated by 
the binding of their cognate ligands and transduce the extracellular signal to the cytoplasm by 
phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on 
downstream signalling proteins.   
RTKs activate numerous signalling pathways within cells, leading to cell proliferation, 
differentiation, migration or metabolic changes.12  
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Activation of RTKs typically stimulates two processes: the enhancement of intrinsic catalytic 
activity and creation of binding sites to recruit downstream signalling proteins. For the majority 
of RTKs, both of these processes are accomplished by autophosphorylation on tyrosine 
residues, a consequence of ligand-mediated oligomerization. Therefore, the inactive state of 
RTKs is monomeric or oligomeric. The activation of the receptor requires the binding of its 
ligand to stabilize specific relationships between individual receptor molecules. Ligand binding 
to the extracellular portion of RTKs mediates the noncovalent oligomerization of monomeric 
receptors or induces a structural rearrangement in heterotetrameric receptors (e.g. the insulin 
receptor), facilitating tyrosine autophosphorylation in the cytoplasmic domains. All members 
of RTKs family consist of a single transmembrane domain that separates the intracellular 
tyrosine kinase region from the extracellular portion. The latter exhibit a variety of elements 
including immunoglobulin (Ig)-like or epidermal growth factor (EGF)-like domains, 
fibronectin type III repeats or cysteine-rich regions that are characteristic for each subfamily of 
RTKs. The catalytic domain is located in the intracellular portion, and displays the highest level 
of conservation, includes the ATP-binding site that catalyses receptor autophosphorylation and 
tyrosine phosphorylation of RTK substrates (Fig. 4). 13 
 
 
 
 
 
 
Fig. 4. A receptor tyrosine kinase and intracellular pathways activated by it. 
Chapter 1. Introduction 
 11 
Design, synthesis and biological evaluation of pyrazolo-pyrimidines and related isosteres  
as inhibitors of protein kinases, potential antineoplastic agents 
1.1.1.2 Non-receptor tyrosine kinases  
The family of non-receptor tyrosine kinases (NRTKs) includes 10 subfamilies (Abl, Ack, Csk, 
Fak, Fes, Frk, Jak, Src, Tec, Syn), indirectly regulated by extra-cellular signals (Fig. 5).  
Some NRTKs are anchored to the cell membrane through amino-terminal modifications, such 
as myristoylation or palmitoylation. The catalytic domain is located between the N-lobe and 
the C-lobe, as reported for other protein kinases, and shares a common structure. In addition, 
NRTKs possess domains that mediate protein-protein, protein-lipid, and protein-DNA 
interactions. The most commonly found protein-protein interaction domains in NRTKs are the 
Src homology 2 (SH2) and 3 (SH3) domains. The SH2 domain is a compact domain of ~100 
residues that binds phosphotyrosine residues in a sequence-specific manner. The smaller SH3 
domain (~60 residues) binds proline-containing sequences capable of forming a polyproline 
type II helix. Some NRTKs lack SH2 and SH3 domains but possess subfamily-specific domains 
used for protein-protein interactions. The most common theme in NRTK regulation is tyrosine 
phosphorylation. With few exceptions, phosphorylation of tyrosines in the activation loop of 
NRTKs leads to an increase in enzymatic activity. Activation loop phosphorylation occurs via 
trans-autophosphorylation or phosphorylation by a different NRTK. On the other hand, 
phosphorylation of tyrosines outside of the activation loop can negatively regulate kinase 
activity.10 A description of all cytoplasmic TKs has been reviewed by Tsygankov.14 
 
 
 
 
 
Fig. 5. Examples of non-receptor tyrosine kinases. 
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1.1.2 Serine-threonine kinases  
The serine-threonine kinases (STKs) are a subfamily of protein kinases which catalyze the 
phosphorylation of serine or threonine residues in their substrates, they have important 
functions in normal and pathological cellular processes, as they regulate cell survival, 
metabolism, motility, growth, division, and differentiation.15  
STKs have been implicated in human cancer as well. Moreover, many high-throughput 
strategies have been exploited to implicate STKs in the initiation and progression of cancer 
either by searching for activating mutations or by identifying misregulated expression in gene 
profiling experiments.16 Similarly to TKs, STKs can be divided in two classes: receptor STKs 
and cytoplasmic STKs. 
 
1.1.2.1 Receptor serine-threonine kinases 
In contrast to the large number of receptor tyrosine kinases, there are only 12 receptor serine/ 
threonine kinases.2 They are all members of a single extended family that binds ligands in the 
TGFβ family of cytokines and transduces signals that promote growth arrest and differentiation. 
Signalling by this type of receptor kinase is accomplished through the binding of a TGFβ family 
member, which induces the formation of a heterodimer containing a type I TGFβ receptor and 
a type II TGFβ receptor. Within this dimer, the constitutively active type II receptor 
phosphorylates the inactive type I receptor in the complex, and thereby activates it to 
phosphorylate downstream cytoplasmic target proteins.17,18 
 
1.1.2.2 Non-receptor serine-threonine kinases 
Non-receptor serine/threonine kinases are the largest group of eukaryotic protein kinases 
comprising 376 out of the total of 518 protein kinases in humans.2 Examples are protein kinase 
C (PKC), the mitogen activated protein kinases (MAPK), Akt (or protein kinase B, PKB) and 
Sgk (Serum- and glucocorticoid-regulated kinase). Cytoplasmic serine threonine kinases (like 
Raf, Akt, Tpl-2 and Sgk1) are also mutated or activated in several types of human 
malignancies.16 
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CHAPTER 2. Src family kinases 
 
The Src family of protein tyrosine kinases (SFKs) counts nine members: Src, Fyn, Yes, Blk, 
Yrk, Fgr, Hck, Lck, and Lyn. They play key roles in regulating signal transduction from a 
diverse set of cell surface receptors in the context of a variety of cellular environments. SFKs 
are involved in the regulation of fundamental cellular processes, including cell growth, 
differentiation, migration and survival, cell shape and specialized cell signals.19 Moreover, 
many members of this family have been identified as cellular oncogenes. The pleiotropic 
functions of Src family members underscore the importance of these kinases in physiologic and 
pathologic conditions.20  
 
2.1 c-Src structure and activation 
Human c-Src is a protein of 536 amino acids and has a structure that shares common features 
with the other SFK members. From the N- to C-terminus, Src presents a conserved domain 
organization which includes a N-terminal Src homology domain (SH4), an unique domain, a 
SH3 domain, a SH2 domain, a poly-proline type II (PPII) domain, a catalytic domain (SH1) 
and finally a short C-terminal regulatory segment (Fig. 6).21 
The SH4 domain, whose N-terminal is always myristoylated and sometimes palmitoylated,22 is 
the membrane-targeting region that allows the association between the protein and the inner 
surface of the cell membrane. The unique domain is a sequence of 50-70 residues and it is 
different among SFK members. It is probably involved in protein-protein interactions. SH2 and 
SH3 are two domains highly conserved in SFKs and play a critical role in regulating Src 
activity. SH2 (~100 amino acid residues) presents a central three-stranded β-sheet with a single 
helix packed against each side; this structure leads to the formation of two recognition pockets. 
SH3 domain (~60 amino acid residues) is a β-barrel consisting of five antiparallel β-strands and 
two loops (RT and n-Src loops) that bind the poly-proline type II domain (PPII), a linker 
segment located between the SH2 and the kinase domains. The PPII domain is characterized 
by proline-rich sequences that adopt a helical conformation in complex with the SH3 domain, 
binding with aromatic amino acid side chains on the SH3 surface. The catalytic domain SH1, 
responsible for the TK activity, presents a bilobal structure, similarly to the majority of kinases, 
with a small N-terminal lobe and a large C-terminal lobe, that form the ATP and substrate 
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binding site at the interlobe cleft.  
The N-terminal lobe is composed of five β-strands and a single α-helix (C-helix), with a 
glycine-rich G-loop (or P-loop, because of the phosphate binding site) that binds and locates 
ATP appropriately for γ-phosphate transfer to the substrate. The C-terminal lobe is mainly 
formed of α-helix. The positive regulatory activation loop (A-loop) is located in it, and contains 
the key residue Tyr419 (in human Src). The flexible chain that connects N- and C- 
lobes is called the “hinge region”.21 
 
 
 
Src exists in two forms: a closed, inactive conformation and an open and active one. There are 
two key elements that regulate Src conformation: the amino acids Tyr419 and Tyr530. When 
Tyr419 is phosphorylated and Tyr530 dephosphorylated, Src is in the active state, while, when 
Tyr 419 is dephosphorylated and Tyr530 phosphorylated, the kinase is in the inactive state.  
The inactive enzyme is forced in a closed conformation by intramolecular contacts among the 
SH2 and SH3 domains and the catalytic site. In detail, SH3 and SH2 pack against the N-lobe 
and the C-lobe, respectively, on the opposite site of the catalytic cleft. Furthermore, this closed 
conformation is stabilized by intramolecular interactions of SH3 with the PPII domain and of 
SH2 with the phosphorylated C-terminal tail. 
Although the position of the SH2 and SH3 domains does not sterically occlude the catalytic 
cleft, this conformation causes the inactivation of the enzyme, mainly for three reasons: 
 A catalytically important residue is removed from the active site as a consequence of 
the C-helix displacement.  
 In this conformation, the A-loop does not allow the phosphorylation of the positive 
regulatory Tyr419 or the protein binding. 
 The relative orientation of  N- and C-lobes is not convenient for the kinase activity.20 
The dephosphorylation of Tyr530 and the autophosphorylation of Tyr419 lead to the active and 
open conformation: the molecular associations between SH2 and SH3 are disrupted, different 
interactions are formed, and the phosphorylation of Tyr419 in the A-loop causes conformational 
Fig. 6. Human c-Src structure. 
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changes that allow the access of substrates to the catalytic site. Under basal condition in vivo, 
90-95% of Src is present in the inactive form (pTyr530). C-terminal Src kinase (Csk) and Csk 
homologous kinase (Chk) are the two kinases known up today to specifically phosphorylate Src 
on Tyr530 causing its inactivation (Fig. 7). 
 
 
 
 
On the other hand, several phosphatases can dephosphorylate Tyr530, leading to enzyme 
activation. Some transmembrane tyrosine phosphatases23 and the cytosolic proteins PTP1B 
(protein tyrosine phosphatase 1B), Shp1 and Shp2 are the enzymes involved in this reaction. 
Ligand-bound cell-surface receptors and cytoplasmatic proteins can activate Src, by binding 
the SH3 and SH2 domains and displacing such regulatory subunits from the kinase domain. 
This permits Tyr419 autophosphorylation. 
In particular, several extracellular molecules can activate Src binding receptors, such as growth 
factor receptors, integrins and other adhesion receptors, guanosine phosphate binding-coupled 
receptors (GPCRs), cytokine receptors and ion channels. Src, in response to these extracellular 
signals, becomes activated and phosphorylates various downstream targets, regulating multiple 
signal transduction pathways, including Ras/Raf, RhoGAP, PI3K/Akt pathways and many 
others (Fig. 8). 
 
Fig. 7. Src activation/inactivation. 
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2.2 Src and cancer 
SFKs have a key role in cell signalling and are involved in the development of numerous 
diseases, first of all cancer (Fig. 9).24,25 Src is the first kinase, among SFKs, which has been 
reported as implicated in cancer biology, in particular in cancer progression. An increased Src 
activity is found transiently in almost every aspect of a normal cell life in response to different 
physiological conditions, including mitogenesis, proliferation, survival, adhesion and motility, 
all of them deregulated during cancer progression.26 Malignant activation of Src is concomitant 
with a cell’s inability to downregulate such activity. Four of the six "hallmarks of the 
transformed state" (in detail, self-sufficiency in growth signals, evasion of apoptosis, sustained 
angiogenesis and tissue invasion and metastasis) are heavily dependent on tyrosine kinase 
(including Src) signalling.27  
Many studies have been performed on the oncogenic behaviour of mutated Src in the etiology 
of human cancer, starting from the discovery that v-Src, the viral homologous of c-Src, 
characterized by the lack of the C-terminal negative regulation site, causes sarcoma in chickens 
and in other animal species.28 A deregulated SFKs activity probably mainly depends on 
Fig. 8. Schematic representation of Src signalling pathway. 
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overexpression or hyperactivation of the enzyme, even if the presence of mutations in advanced 
human colon cancer has been also described.29 The point mutation introduces a stop codon 
corresponding to the amino acid 531, and this truncated form, termed Src-531, shows enhanced 
activity.  
Changes in the levels of Src and/or in its kinase activity appear to be correlated with the grade 
of malignance of tumors. Malignant activation of SFKs, characterized by constitutively high 
enzymatic levels, is present in many human cancers: breast, gastric, colon, pancreatic, ovarian, 
prostate, head, neck, lung, bladder cancer, neuronal tumors, and leukemias, lymphomas and 
myelomas.30  
 
 
2.2.1 Src and glioblastoma 
Glioblastoma (GB) is the most common and aggressive primary tumor of the central nervous 
system (CNS). According to the World Health Organization classification, GB is a grade IV 
astrocytoma31 and can develop either de novo or through the malignant progression of lower-
grade astrocytomas. About 50% of the people diagnosed with GB die within one year, while 
90% within three years.32 GB is characterized by increased proliferation and demand of nutrient 
and oxygen, as revealed by frequent evidence of microvascularity and necrosis.33  
Fig. 9. Involvement of Src in the onset and progression of tumors. Ann Oncol 200824  
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The current standard of care for GB consists of surgical resection, followed by radiotherapy 
combined with chemotherapy and, then, by an adjuvant course of chemotherapy. However, 
despite this intensive therapy, the prognosis remains extremely poor. Indeed, following the ﬁrst-
line treatment, nearly all the patients with GB experience recurrence and the available salvage 
therapies have not been proven to improve survival.  
New therapeutic targets for GB, including receptors for growth factors and other tyrosine 
kinases involved in intracellular signal transduction processes, are actively studied.34,35 
Among these, SFK members have been proposed as key kinases able to drive GB 
carcinogenesis and progression.36 Initial studies have found elevated Src activity in GB 
compared with normal brain samples, and have revealed its oncogenic properties for brain 
tumors.37 Src is a key downstream intermediate of growth factor receptors frequently 
overexpressed in brain tumors, including epidermal growth factor receptor (EGFR) and 
platelet-derived growth factor receptor (PDGFR), involved, in association with focal adhesion 
kinase (Fak), in cytoskeletal-linked cell survival and migration.38,39 In preclinical models of 
GB, genetic and pharmacologic blockade of Src resulted effective in inhibiting cell proliferation 
and invasion.40–42  
 
2.2.2 Src and neuroblastoma 
Neuroblastoma (NB) is a rare cancer of the sympathetic nervous system. It is the most common 
extracranial solid tumor in childhood and the most frequently diagnosed neoplasm during 
infancy.43 The prognosis of NB patients over 1 year of age tends to be poor, whereas that of 
patients under 1 year of age is usually more favourable, with tumors having a potential to 
differentiate or to regress spontaneously.44 The disease is characterized by a broad spectrum of 
clinical behaviour. Although during the past few decades a substantial improvement in the 
treatment of certain, well-defined, subsets of patients has been observed, the outcome of the 
disease for children with a high-risk clinical phenotype has improved modestly, with a long-
term survival less than 40%. The therapeutic options for the clinical managing of NB consist of 
a multimodality approach, which includes surgery, chemotherapy, radiotherapy, differentiation 
therapy, immunotherapy and in selected cases “careful observation only”.45 The current 
chemotherapeutic treatment for high-risk neuroblastoma uses dose-intensive cycles of cisplatin 
and etoposide, alternating with vincristine, doxorubicin, and cyclophosphamide.43   
Furthermore, isotretinoin is used during the first remission. Despite the intensive multimodal 
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therapy, the outcome of patients with advanced stage NB remains poor, and development of a 
novel therapeutic approach is warranted for these patients.  
It has been reported that c-Src also plays a key role in the differentiation, adhesion, and survival 
of NB cells, due to its hyperactivation rather than overexpression.46  c-Src was also 
hypothesized to have an oncogenic role in the progression of aggressive NB forms.47 
Addressing this kinase with small molecule inhibitors and thereby inhibiting its catalytic 
activity has recently been reported as a potential approach to the treatment of NB.48,49  
 
2.2.3 Src and medulloblastoma  
Medulloblastoma (MB) is the most common malignant brain tumor in children and accounts 
for 15-20% of pediatric brain tumors with an overall cure rate that ranges from 40% to 90% 
depending on the molecular subtype.50 The current treatment for MB consists of surgery 
followed by craniospinal irradiation and chemotherapy. Because irradiating the CNS can be 
damaging to the developing brain, radiation therapy is usually avoided in children under the 
age of three, but this can compromise disease control and survival.51 The combination of 
radiotherapy and chemotherapeutic agents, including ifosfamide, cisplatin, and etoposide, 
improved the survival rate and also reduced the risk of radiotherapy-related cognitive and 
endocrine effects.52,53  
Despite the improvements in the overall survival rate following the multimodality treatment, a 
small but significant number of patients has a recurrent or progressive disease. Several attempts 
to further reduce the morbidity and mortality associated with medulloblastoma have been 
limited by the toxicity of conventional treatments and the low permeability of the blood-brain 
barrier (BBB), which hinders the entry of hydrophilic or large lipophilic compounds into the 
brain.50,54 Therefore, it is important to develop innovative therapeutic agents that could cross 
the BBB more easily, in order to achieve a higher control of the disease and less neurocognitive 
toxic effects. Over the past decade, several discoveries have increased our understanding of 
medulloblastoma formation, identifying a crucial role for different proteins, including various 
RTKs and telomerase. Sikkema et al.55 identified a panel of tyrosine kinase associated with 
pediatric brain tumors such as medulloblastoma, astrocytoma, and ependymoma. In particular, 
the researchers showed high Src family kinase activity in these tumors, as established by high 
levels of phosphorylation, in comparison with normal tissues. This observation suggests that 
Src could have a key role in the development of medulloblastoma. It has been reported that 
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some pyrazolo[3,4-d]pyrimidines reduced the growth rate of medulloblastoma cells by 
inhibiting Src in a mouse model.56  
 
2.2.4 Src and colon cancer 
Colon cancer is one of the leading tumours in the world with lung, prostate and breast cancer.57 
Early stages of colon cancer are amenable to surgery. However, at diagnosis, colon cancer has 
often metastasized and requires chemotherapy. Chemotherapy is not very effective in these 
cases, with survival rates < 10% in the presence of metastasis. Therefore, very important 
advances have occurred in the field of treatments of this common disease: adjuvant 
chemotherapy was demonstrated to be effective, chiefly in stage III patients, and surgery was 
optimized in order to achieve the best results with a low morbidity.58  
An increased Src activity is related to colon cancer in 80% of patients, which indicates its 
importance in the disease.59,60 Gradual increases in Src activity have been observed during 
premalignant ulcerative colitis, polyps formation, invasive tumors and in metastatic lesions.61 
An activating mutation of Src gene is found in 12% of patients. This mutation accounts for only 
a small proportion of Src activation in colon cancer.30 Furthermore, several other studies have 
not detected a Src mutation in colon cancer.62 Analysis of different aspects of Src regulation 
have been performed, such as the contribution of Csk and Chk, the two negative regulators of 
the C-terminal portion of Src. Sirvent et al. reported that SFK-driven colon cancer cell invasion 
is induced by the delocalization of Csk in the membrane, defining a novel mechanism for SFK 
oncogenic activation in human colorectal cancer cells.63 The overexpression of Src in colon 
cancer cells increases cell adhesion, invasion, and migration but not cell proliferation, which 
indicates the role of Src in the progression of colon cancer.64 Therefore, the inhibition of Src 
may facilitate the treatment of colon cancer to increase the survival rate.65  
 
2.2.5 Src and breast cancer 
Breast cancer is the most frequently diagnosed life-threatening cancer in women and the leading 
cause of cancer death among women. Although several Src family members have been reported 
to be expressed in either breast cancer cells or tissues, Src has been the most widely studied 
enzyme to date, and considerable data support its role in the progression of this disease.66,67 Src 
plays a critical role in several key pathways that overall contribute to the growth of breast 
cancer. For example, through association with receptor tyrosine kinases, particularly those of 
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the EGFR family, Src acts in the regulation of cellular proliferation. Different members of the 
EGFR receptor family are overexpressed in as many as 60% of breast cancers,68 often with 
concomitant Src overexpression.69,70 Indeed, Src and EGFR have been shown to synergise, 
enhancing the neoplastic growth of mammary epithelial cells.71  
Consequently, inhibition of Src activity can prevent EGFR mediated proliferation.72,73 Src is 
also involved in heregulin-mediated growth and survival of breast cancer cells through Her2-
dependent and independent mechanisms.74 In addition, some reports have demonstrated a role 
for Src in mediating Her2–Her3 heterodimerisation, followed by an increase of their signalling 
capacity and biological function.75 Moreover, Src may be indirectly involved in the stimulation 
of c-Met receptor signalling in breast cancer through the inappropriate activation of 
transcription of its ligand, the hepatocyte growth factor (HGF).76 These data provide further 
evidence of a role for Src as a contributor to the development of a severe breast cancer 
phenotype through modulation of the activity of receptors associated with a poor prognosis.77,78 
Moreover, breast cancer cell lines expressing higher levels of Her1 and Src have also higher 
levels of phosphorylated Shc, increased activation of MAPK, and increased tumorigenicity 
compared with those that do not show overexpression of EGFR and Src.79  
Breast tumors with elevated Src activity frequently express the progesterone receptor, 
indicating the possibility that SFKs may contribute to hormone dependent cell growth 
signalling.80 Furthermore, some studies have demonstrated that Src could be activated in this 
type of cancer by a tyrosine phosphatase-dependent dephosphorylation of the regulatory 
tyrosine, involving the PTP1B.81 Recently, a clinical study has been developed to investigate 
the effect of dasatinib (a Src inhibitor) with the anti-Her2 antibody trastuzumab and paclitaxel 
as first line therapy for patients with Her2-overexpressing advanced breast cancer.82  
 
2.2.6 Src and pancreatic cancer 
Pancreatic cancer is one of the deadliest of all of the solid malignancies. An overexpression and 
hyperactivation of Src are present in pancreatic carcinoma cell lines compared to normal 
pancreatic cells.83 Several preclinical data showed that inhibition of Src should be a potentially 
effective therapeutic target in metastatic pancreatic cancer.84,85 Moreover, it has been 
demonstrated that c-Src is subjected to tyrosine nitration in pancreatic carcinoma cells, 
indicating that this nitration may contribute to c-Src activation.86 
It may be more therapeutically effective and scientifically rational to consider Src inhibition in 
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combination with cytotoxic therapies, based on the following caveats. First of all, constitutively 
active Src is associated with increased chemoresistance in pancreatic cancer cells;87,88,89 
secondly, inhibition of Src reduces tumor expression of thymidylate synthase, the target enzyme 
of 5-fluorouracil; thus, lowering thymidylate synthase levels is associated with subsequent 5-
fluorouracil chemoresistance reversal, resulting in substantially decreased in vivo tumor growth 
and inhibition of progressive distant metastases.90 Finally, Dasatinib (a Src inhibitor) can inhibit 
oxaliplatin-induced Src activation, and, consequently, Src inhibition can also increase 
oxaliplatin activity both in vitro and in vivo.91 
Therefore, all these studies demonstrate that Src inhibition represents a potentially good 
strategy for the treatment of pancreatic cancer.92 
 
2.2.7 Src and angiogenesis 
Angiogenesis is the growth of blood vessels from the existing vasculature, is regulated by both 
activator and inhibitor molecules. Different studies have demonstrated the implication and the 
importance of Src in angiogenesis.93 v-Src, the viral form of Src, induces vascular endothelial 
growth factor (VEGF) expression. VEGF is a signal protein produced by cells that stimulates 
vasculogenesis and angiogenesis, and it is part of the system that restores the oxygen supply to 
tissues when blood circulation is inadequate.94 
The induction of VEGF occurs through activation of STAT374 and c-Src is required for 
hypoxia-induced VEGF production in a number of cell types.95 Actually, SFKs are activated in 
response to stimulation by different growth factors such as VEGF and FGF, which are 
angiogenic molecules. It was also demonstrated that tumor necrosis factor (TNF)-related 
activation-induced cytokine (TRANCE), an angiogenic stimulating molecule, acts through 
activation of Src and of phospholipase C in human endothelial cells, confirming the importance 
of Src in angiogenesis.96 
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CHAPTER 3. Fyn kinase 
 
Fyn is another non-receptor or cytoplasmatic TK belonging to the SFKs. It has been identified 
and characterized by Kipta et al. in 1988 both in normal and polyoma virus transformed cells.97 
It is primarily localized to the cytoplasmatic side of the plasma membrane, where it 
phosphorylates tyrosine residues of enzymes involved in different signalling pathways and 
works downstream of several cell-surface receptors. A number of biological functions in which 
Fyn activity is involved have been reported and includes regulation of cell growth and survival, 
cell adhesion, integrin-mediated signalling, cytoskeletal remodeling, cell motility, immune 
response and axon guidance.98  Active Fyn plays different roles in growth factor and cytokine 
receptor signalling, ion channel functions, platelet activation, T-cell and B-cell receptor 
signalling, axon guidance, fertilization, entry into mitosis, differentiation of natural killer cells, 
oligodendrocytes and keratinocytes.99 Fyn is primarily involved in several transduction 
pathways in the CNS where it is involved in myelination and morphological differentiation 
associated with the formation of neurite in oligodendrocytes, oligodendrocyte differentiation, 
synapse formation and regulation.100  
Recent evidences suggest that Fyn hyperactivation/deregulation might contribute to 
Alzheimer’s disease (AD)101 and other tauopathies pathogenesis.102 It is also involved in the 
peripheral immune system, playing in this latter important roles in regulation and functions of 
T-cell development and activation.103  
Fyn is also known to mediate integrin adhesion and cell-cell interactions. For all these reasons, 
it is also involved in the onset of cancer.104,105 
 
3.1 Fyn structure and regulation 
Fyn is a 59-kDa protein comprising 537 amino acids, encoded by the Fyn gene that is located 
on chromosome 6q21. There are three isoforms of Fyn: isoform 1, or FynB, which is mainly 
expressed in the brain, isoform 2 or FynT, first identified, which tends to be expressed in T-
cells and differs from isoform 1 in the linker region between the SH2 and the SH1 domain,106 
and finally, isoform 3, also called FynDelta7, which has been found in peripheral blood 
mononuclear cells and differs from isoform type 1 as it misses the sequence 233-287.107 Even 
if most tissues express a mixture of the first two isoforms, FynB is highly expressed in the brain 
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and FynT is highly expressed in T-cell. Fyn, similarly to the other SFK members, is composed 
of several functional parts connected together in a single protein chain. These functional 
portions include the unique domain, the SH3 and the SH2 domains, and the SH1 (or catalytic) 
domain (Fig. 10).108  
 
 
 
Fyn is characterized by a common regulatory mechanism with the other SFKs. Indeed, the 
activation or inhibition of kinase activity depends on intramolecular interactions between SH2 
and SH3 with the kinase domain and on phosphorylation/dephosphorylation of two critical 
tyrosine residues. The first tyrosine is situated in the A-loop (Tyr420) and the second (Tyr531) 
in the C-terminal region. Fyn is able to interact with almost 300 different proteins and, through 
these interactions, participates in many cellular pathways, both in physiological and 
pathological situations.109–111  
 
3.2 Fyn functions in CNS 
Fyn is deeply implicated both in brain development and in adult brain physiology. Biological 
functions of Fyn in the brain have been extensively investigated using transgenic animal 
models.112,113 These studies indicated that Fyn is a key element required for the development 
and functions of CNS (Fig. 11).104 Fyn is involved in many processes critical for the 
development of the brain; it regulates neuronal migration during corticogenesis, 
oligodendrocyte maturation, myelin production, long-term potentiation, and excitatory and 
inhibitory neuronal receptors.114 Indeed, its activity in the brain is highest during the 
myelination.105 Sperber et al. demonstrated a severe myelin deficit in forebrain at all ages (from 
14 days to 1 year) in Fyn (-/-) null mutant mice, which do not express Fyn. This study, based 
on the count of oligodendrocytes and of myelinated fibres and on the use of an inactivated form 
of Fyn (bearing a single amino acid substitution), showed that Fyn plays a unique role in 
Fig. 10. Schematic representation of Fyn structure. 
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myelination.115  
Recently, Miyamoto et al. demonstrated the relation between myelination and protein markers 
and myelin ultrastructure utilizing transgenic mice, which express active Fyn under the control 
of a glial fibrillary acidic protein promoter. This promoter induces protein expression in the 
initiation stage of myelination in the peripheral nervous system (PNS).105 
 
 
 
 
 
Moreover, Fyn is involved in the morphological differentiation that leads to neurite formation 
in oligodendrocytes. Indeed, Fyn interacts with γ-tubulin, a member of the tubulin family, 
which plays a central role in neurite construction. In more detail, membrane associated γ-tubulin 
forms complex with Fyn, participating in the signalling cascade that leads to membrane-
associated microtubule nucleation. This has been demonstrated by the fact that pretreatment of 
P19 embryonal carcinoma cells with SFK inhibitors blocked the nucleation activity of the γ-
tubulin complexes.116 
This process is promoted by Fyn interaction with the cytoskeletal proteins Tau that, binding 
with tubulin, stabilizes the microtubules in the brain. Other evidences demonstrated that Tau-
Fyn interactions could play a pathogenic role in some human CNS neurodegenerative diseases 
where axonal degeneration is the key factor in clinical decline.117,118 
Fig. 11. Fyn functions in CNS.104  
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Fyn and other SFK members play important roles in synaptic transmission and plasticity at 
excitatory synapses; indeed, these enzymes are localized to the postsynaptic density (PSD), the 
primary cytoskeleton specialization at neuronal excitatory synapses, constituted by many 
proteins, including PSD95 (postsynaptic density protein 95), NMDAR (N-methyl-D-aspartate 
receptor) and AMPAR (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor).119 
Particularly, NMDAR forms a multiprotein complex in which PSD95 plays a critical role, 
directly binding to the NMDA Receptor 2 (NR2) subunit of NMDAR. PSD95 also interacts 
with the SH2 domain of Fyn and has been proposed to promote Fyn-mediated tyrosine 
phosphorylation of NMDAR subunit NR2A.120,121 In this way, Fyn (and also Src) regulates the 
NMDAR complex phosphorylation and upregulates NMDAR functions, leading to the 
production of NMDAR-dependent synaptic potentiation.122 Phosphorylation by Fyn of the 
NMDAR subunit NR2A and Fyn involvement in the interactions between NR2A and PSD95 
have been observed after brain ischemia/reperfusion; moreover, increased tyrosine 
phosphorylation of NR2A and increased interaction involving NR2A, PSD95, Src and Fyn have 
been detected in ischemic episodes.123 Fyn phosphorylates also PSD93, another protein tightly 
associated to the NMDAR complex. In more details, PSD93 serves as a membrane-anchored 
substrate of Fyn and plays a role in the regulation of Fyn mediated modification of NMDAR 
functions. This connection could explain the involvement of Fyn in brain diseases.124  
Jurd et al. demonstrated that Fyn phosphorylates the GABA(A)R (gamma aminobutyric acid A 
receptor) gamma2 subunit on Tyr365/7. This phosphorylation is an important mechanism for 
modulating inhibitory synaptic function in the mammalian brain. Tyrosine phosphorylation of 
the gamma2 subunit is significantly reduced in the hippocampus of Fyn knockout mice, 
suggesting that Fyn substantially contributes to the phosphorylation of this subunit in vivo; 
however Tyr367 phosphorylation is not completely abolished in these mice, suggesting that 
other SFKs, such as Src, also contribute to maintaining and regulating the endogenous 
phosphorylation level.125  
Fyn is also involved in the modulation of other CNS signalling proteins: it collaborates with 
Cellular apoptosis susceptibility (Cas) and with other kinases of the Fak family in regulating 
the morphology of dendritic spines, the specialized microscopic protrusion on dendrites that are 
the primary sites, where the postsynaptic components of excitatory synapses are located in the 
mammalian CNS.126 
Fyn plays also a role in the signalling pathway starting from reelin, a large glycoprotein 
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involved in cortical formation and in postnatal brain functions, such as dendrite development. 
Isosaka et al. demonstrated that the levels of several phosphoproteins, and in particular NR2A 
and NR2B subunits of NMDAR, are regulated by reelin level in a Fyn-dependent manner in the 
mouse brain.127  
Fyn activation is required for a signalling cascade which involves MAPK and lipid rafts, 
starting from the transmembrane form of the extracellular matrix heparin sulphate proteoglycan 
agrin (TM-agrin) that is primarily expressed in the CNS on axons and dendrites during the 
phase of active neurite extension.128 
Yuasa et al. demonstrated that Fyn plays an important role in memory formation in contextual 
fear conditioning.129 Accordingly, the same authors, using the SFK inhibitor PP2 showed that 
downregulation of hippocampal Fyn activity facilitates the extinction of contextual fear 
memory. Probably Fyn inhibition causes a downregulation of CDK5 (activated by Fyn-
phosphorylation on Tyr15) that facilitates extinction of contextual fear. Both Fyn and CDK5 in 
hippocampus are probably involved in fear extinction by crosstalk for synaptic remodelling 
through cytoskeletal rearrangement.130 
It has been reported that recombinant Fyn directly binds to metabotropic Glutamate Receptor 
1a (mGluR1a) at a consensus binding motif located in the intracellular C-terminus of 
mGluR1a in vitro. Similarly, endogenous Fyn interacts with mGluR1a in adult rat cerebellar 
neurons in vivo. Active Fyn phosphorylates mGluR1a at a conserved tyrosine residue in the 
C.terminus region. In cerebellar neurons and transfected HEK293T cells, the Fyn-mediated 
tyrosine phosphorylation of mGluR1a is constitutively active and acts to facilitate the surface 
expression of mGluR1a and to potentiate the mGluR1a postreceptor signalling. These results 
support mGluR1a to be a novel substrate of Fyn.131 
 
3.3 Fyn and Alzheimer’s disease 
AD is the most common causes of dementia and one of the great health-care challenges of the 
21st century.132 It is characterized by a gradual loss of neurons, particularly in the cortex and 
hippocampus and, as a consequence, by progressive impairments of memory, judgment, 
decision making, orientation to physical surroundings, and language. Pathologically, AD is 
characterized by the presence of extracellular neuritic plaques containing the β-amyloid peptide 
(Aβ) and neurofibrillary tangles (NFTs) composed of hyperphosphorylated Tau protein in the 
brain.133 In 1906, Alois Alzheimer reported the case of a woman who presented a “peculiar” 
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dementia at the age of 51 years. Alzheimer correlated the woman’s cognitive and behavioral 
features with histopathological findings of extracellular “miliary foci” (senile plaques) and 
fibrils inside the neurons (neurofibrillary tangles) in her cerebral cortex.134  
AD is classified into two subtypes according to the age of onset. About 1-5% of AD cases 
present an early-onset (before the age of 65, typically in the late 40s or early 50s) and are 
classified as having early-onset Alzheimer disease (EOAD), whereas more than 95% of patients 
develop the disease after the age of 65 years and are classified as having late-onset Alzheimer 
disease (LOAD).135  
In 1984, Glenner first proposed that cerebral Aβ drives all the subsequent pathologies, and this 
central thesis was later reinterpreted and reported as the amyloid cascade hypothesis of AD, 
which affirms that the accumulation of Aβ is the primary driver of AD-related pathogenesis, 
including neurofibrillary tangle formation, synapse loss, and neuronal cell death.136–138 
Although the amyloid cascade is only one possible mechanism proposed, the pathophysiology 
of AD is attributed to a number of factors such as the cholinergic dysfunction,139 amyloid/tau 
toxicity140 and oxidative stress/mitochondrial dysfunction.141  
As previously reported, Fyn hyperactivation/deregulation is involved in different tauopathies, 
characterized by alteration of the Tau protein, abnormally phosphorylated on serine and 
threonine residues.142 Subsequent studies indicated that Tau is phosphorylated also on tyrosine. 
Lee et al. demonstrated that Fyn phosphorylates Tau at its amino terminus on Tyr18 and that 
tyrosine phosphorylated Tau is present in the neurofibrillary tangles in AD brain, giving further 
insights in the involvement of Fyn in tauopathies.143 Recently, Lau et al. demonstrated that Fyn 
also co-localises with Tau in a proportion of neurons containing Tau tangles in AD. Hence, 
Tau-Fyn interactions could play a pathogenic role in AD. They report the identification of 
critical proline residues, Pro213, Pro216, and Pro219, located within the fifth and sixth Pro-X-
X-Pro motifs in the proline-rich region of Tau, that are important for its binding to Fyn. These 
residues in Tau are flanked by numerous phosphorylation sites. In this study, the identification 
of the binding site between tau and Fyn may facilitate the development of compounds that can 
inhibit tau-fyn interactions, as a potential alternative therapeutic strategy for AD.118  
Moreover, using transgenic mice expressing both human AAP (amyloid precursor protein) and 
Fyn, it has been demonstrated that Fyn induces synaptic and cognitive impairments in a 
transgenic mouse model of AD. Indeed, increased Fyn expression is sufficient to trigger 
prominent neuronal deficits in the context of even relatively moderate Aβ levels, and for this 
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reason inhibition of Fyn activity may help to counteract Aβ-induced impairments. These and 
other data support that Fyn takes part in the synaptotoxicity and neurotoxicity mediated by 
Aβ.112  
Ho et al. demonstrated that Fyn levels were decreased in the synapses and increased in the 
neuronal cell bodies where localized together with neurofibrillary tangles from autopsy cases, 
suggesting that alterations in Fyn localization might be associated with neurofibrillary 
pathology and synapse loss in AD.144  
Williamson et al. examined the response of primary human and rat brain cortical cultures to Aβ 
administration and they found a marked increase in the tyrosine phosphorylation content of 
several neuronal proteins, including Tau and Fak; furthermore, immunoprecipitation of Fyn 
from Aβ-treated neurons showed an increased association of Fyn with Fak. The increased 
tyrosine phosphorylation was blocked by addition of the SFK inhibitor PP2. The rapid changes 
in Fak/Fyn and Tau tyrosine phosphorylation may be critical in the early pathogenic events 
initiated by Aβ. Early cognitive deficit characteristic of early AD seems to be produced by a 
soluble form of Aβ, Aβ25-35, produced in AD patients by enzymatic cleavage of Aβ1-40.145  
Hence, Peña et al. demonstrated the involvement of Fyn in the Aβ25-35-induced disruption of 
hippocampal network activity in vitro. Interestingly, they found that such phenomenon is not 
observed in slices obtained from Fyn-knockout mice, suggesting that Aβ25-35 affects 
hippocampal function through a Fyn-dependent mechanism.146  
Further connections among Fyn-Tau-Aβ, called the toxic triad, have been proposed by Haass 
et al. Briefly, the toxicity of the triad is at least in part due to Tau and Fyn localization in the 
different compartments of the neuron (soma, axon, dendrites). Indeed, in normal conditions Tau 
protein is primarily located in neuron axons, but also interacts with Fyn targeting it into neuron 
dendrites. As reported before, Fyn phosphorylates NMDAR, resulting in the stabilization of 
this receptor’s interaction with PSD95. This stabilization, in turn, strengthens signalling by the 
excitotoxic neurotransmitter glutamate, which enhances Aβ toxicity. During AD pathogenesis 
enhanced redistribution of abnormally hyperphosphorylated Tau from axon to the soma and to 
the dendrites may increase Tau-dependent sorting of Fyn to the dendrites, leading to abnormal 
NMDA signalling and increasing the toxic effects of Aβ on neurons.147 This hypothesis takes 
shape from the work of Ittner et al., which suggested how Tau may mediate Aβ toxicity. Indeed, 
they first generated transgenic mice that overexpressed a variant of Tau (Δtau) lacking the C-
terminus and thus binding to Fyn but not to microtubules. This Tau modification caused 
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sequestration of Fyn in the soma. 
Similarly, loss of Tau also prevented postsynaptic targeting of Fyn. The reduced Fyn 
localization to dendrites decreases NMDAR signalling and consequently Aβ toxicity. The study 
also suggests that the targeting of Fyn to dendrites depends on normal Tau, even if all the factors 
involved in this Tau function are not yet completely identified. Very interestingly, this Fyn-Tau 
connection in dendritic spines could be exploited to develop new therapeutic strategies for 
treating AD. Indeed, when phosphorylation of NMDAR by Fyn is blocked by a synthetic 
peptide previously constructed, neurons are protected from excitotoxic damage. 
Consistently, when Ittner et al. treated their transgenic AD mice with this peptide,148 memory 
deficits were ameliorated and there was improved survival, similar to that observed when Fyn 
was sequestered by Δtau. Probably also other agents that inhibit Fyn activity could be offer a 
therapeutic opportunity to treat AD.148  
Recent evidence indicates that Tau phosphorylation at specific residues, and not only its 
presence or absence, can modulate the interaction among Fyn, PSD95, Tau and the NMDAR. 
Phosphorylation at T205 on Tau through activation of the p38 MAPK prevents the association 
of the Fyn-PSD95-Tau-NMDAR complex, and ameliorates Aβ toxicity both in cellular and 
mouse models of AD. The presumed effect of T205 phosphorylation is the functional inhibition 
of Fyn-mediated signalling critical to Aβ toxicity in vitro and in vivo.149  
Cellular Prion Protein (PrPC) is one of the highest affinity Aβ receptors identified, with an 
estimated Kd of 0.4 nM, exclusively engaging oligomeric Aβ.150 PrPC-interacting Aβ emerges 
at the time of cognitive impairment in several AD mouse lines, supporting a role for this specific 
Aβ assembly in the pathophysiology of  AD in preclinical models.151 Critically, PrPC 
interacting Aβ has been consistently found in human AD brain homogenates, strongly 
suggesting that the signalling cascade characterized in preclinical models of AD may also be 
present in human disease.152–154  
 
3.4 Fyn and Parkinson’s disease 
Parkinson’s disease (PD) is another complex neurological disorder. It is the second most 
common age-related neurodegenerative disease with movement disorders and is clinically 
characterized by parkinsonism and widespread Lewy body pathology in CNS, PNS, and 
autonomic nervous system (ANS). PD affects about 1% of people over 65 years and 
approximately 4% of the population aged over 80. Almost 6 million people worldwide are 
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suffering from PD, with millions of cases in the United States alone suffering from PD.155 The 
first detailed description of PD was made almost two centuries ago, but the knowledge of the 
disease continues to evolve.  
The crucial pathological feature of PD is the loss of dopaminergic neurons within the Substantia 
Nigra pars compacta (SNpc). Results of clinical-pathological correlation studies showed that 
moderate to severe dopaminergic neuronal loss within this area is probably the cause of motor 
features, bradykinesia and rigidity, in advanced PD. Findings from pathology confirm that 
moderate loss of nigral neurons is also present in early stages of the disease but also provide 
evidence for a population of potentially salvageable dopaminergic neurons.156  
Another hallmark of PD is Lewy pathology. Aggregation of abnormally folded proteins has 
emerged as a common theme in neurodegenerative diseases, including PD. Each 
neurodegenerative disease is categorised according to the protein that is most abundant in the 
associated protein inclusions. In PD, this protein was identified as α-synuclein, following the 
discovery that mutations in its gene, SNCA, cause a monogenic form of the disease. In a 
misfolded state, α-synuclein becomes insoluble and aggregates to form intracellular inclusions 
within the cell body (Lewy bodies) and processes (Lewy neurites) of neurons.157  
Two different research groups simultaneously reported that Fyn phosphorylates α-synuclein, a 
presynaptic protein of unknown function that has been implicated in the pathogenesis of several 
neurodegenerative diseases, including PD. Consistently, phosphorylation by Fyn on α-
synuclein Tyr125 was inhibited by the SFK inhibitor PP2.158,159 
Using Fyn knockout mice, it has been demonstrated that the dopamine dependent trafficking of 
striatal NMDAR requires Fyn and consequently strategies that prevent NMDAR redistribution 
through inhibition of Fyn could offer a new strategy in the treatment of PD.160,104 
Panicker et al examined the role of Fyn in microglial activation and neuroinflammatory 
mechanisms in cell culture and animal models of PD. On the basis of experimental evidence 
from cell culture, primary culture, and in vivo models using both Fyn and PKC knock-out mice 
they demonstrate that Fyn activation plays an upstream regulatory role in eliciting 
proinflammatory signalling following both acute and chronic states of microglia stimulation. 
Their mechanistic studies revealed that Fyn serves as a major upstream regulator of 
proinflammatory signalling involving PKC, MAPK, and the Nuclear factor κB (NFκB, a 
transcription factor that plays an important role in carcinogenesis as well as in the regulation of 
inflammatory response NFκB pathways). Thus, Fyn could be exploited as a potential signalling 
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node in the development of novel antineuroinflammatory drug candidates for treating PD and 
other related neurodegenerative diseases with associated microglia-mediated proinflammatory 
processes.161 
Dopamine replacement therapy with levodopa (L-DOPA) is the treatment of choice for PD; 
however, its long-term use is frequently associated with L-DOPA-induced dyskinesia (LID). 
Recently, Sanz-Blasco et al. found that mice lacking Fyn displayed reduced LID, ΔFosB 
accumulation and NR2B phosphorylation compared to wild-type (wt) control mice. Pre-
administration of saracatinib, an inhibitor of Fyn activity, also significantly reduced LID in 
dyskinetic wt mice. These results support that Fyn has a critical role in the molecular pathways 
affected during the development of LID and identify Fyn as a novel potential therapeutic target 
for the management of dyskinesia in PD.162 
 
3.5 Fyn and cancer 
Fyn is implicated (as other SFK members) in several physiological processes, including not 
only cellular growth and proliferation, but also morphogenesis and cellular motility, whose 
aberration may cause cancer development. Its role as a potential oncogene has been investigated 
since 1988, when Kawakami et al. demonstrated that Fyn overexpression induces morphologic 
transformation and anchorage-independent growth in NIH 3T3 cells. In addition, even if a 
relatively low frequency, Fyn acquired properties of a dominant-acting oncogene capable of 
inducing the fully tumorigenic phenotype.163 
Fyn is involved in several signalling pathways hyperactivated in cancer (Fig. 12). Together 
with other SFK members it is a mediator of growth-factor induced antiapoptotic activity of 
Akt/PKB (protein kinase B); indeed its overexpression results in promotion of antiapoptotic 
activity of Akt and in the regulation of Rac and Rho GTPases and of ERKs (extracellular signal–
regulated kinases)/MAPKs, that are enzymatic pathways hyperactivated in cancer, as deeply 
reported by Posadas et al.99  
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Fyn is also involved in proliferation processes of different cell lines: as an example expression 
of inactive Fyn inhibited the PDGF-induced fibroblast proliferation.164 Moreover, lymphocytes 
from Fyn-deficient mice were blocked in cytokinesis, the process in which the cytoplasm of a 
single eukaryotic cell is divided to form two daughter cells.165 Fyn is involved in matrix rigidity, 
which is important in cell motility and spreading, matrix remodelling and anchorage 
independency. All these processes, if altered, can lead to cancer development and metastasis 
formation. Indeed, an increased matrix rigidity (the cell behaviour in response to the mechanical 
properties of the environment) leads to tissue disorganization and malignant transformation.166 
Cas proteins form complexes with SFKs, including Fyn, that are implicated in the regulation of 
cytoskeleton organization and cell proliferation. In pathological conditions, Cas complexes 
deregulation has been supposed to play a role in oncogenic transformation and perhaps 
metastasis formation.167168 In more details, soon after cell attachment, Fak is activated and binds 
directly to Cas. Fak then phosphorylates Cas, creating a high affinity site for binding by the 
SH2 domain of SFKs (including Src, Lyn, Fyn).  
Kostic et al. demonstrated that the matrix rigidity response through increased spreading and 
growth correlates with the recruitment of Fyn, but not of c-Src. Moreover, the authors 
confirmed that Cas, downstream substrate of Fyn, is also required for a rigidity response and is 
phosphorylated in a Fyn-dependent process. Furthermore, increased Cas phosphorylation by 
Fyn well correlates with anchorage independency of NB-39-nu neuroblastoma cell lines. 
Fig. 12. Fyn involvement in cancer.104 
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Consistently, treatment of NB-39-nu cells with PP2 suppresses Cas phosphorylation, 
suggesting that the anchorage-independent process is associated with the activity of SFKs, in 
particular of Fyn.169 
 
3.5.1 Fyn and breast cancer 
Breast cancer cell lines (MDA-MB-231, T47D and SK-Br3) express elevated levels of different 
oncogenes, including Fyn, which may promote metastasis formation through the facilitation of 
epithelial to mesenchymal transition (EMT), a cell transformation program characterized by 
loss of cell adhesion, repression of E-cadherin expression, and increased cell mobility. A study 
reported that 48% of breast tumor specimens analyzed contained elevated expression/activity 
of SFKs, including Fyn and Yes, relative to normal tissue. Moreover, Fyn expression in breast 
cancer cells from patients is associated with poor survival and neoangiogenesis, correlated with 
c-Met and Fak kinases upregulation.170 
Elias et al. demonstrated that Fyn is upregulated in tamoxifen-resistant breast cancer cell lines 
and plays a key role in the resistance mechanism. Further, the cellular localization of Fyn within 
cancer cells of primary ER+ breast tumor tissue may serve as a prognostic marker.171 
Very recently it has been shown that the inhibition of protein phosphatase N23 promotes breast 
cancer development via activation of Fyn.172 
 
3.5.2 Fyn and ovarian cancer 
Lysophosphatidic acid (LPA), known as the “ovarian cancer activating factor” is present at high 
concentrations in the plasma and ascites of ovarian cancer patients; it causes junction dispersal 
in ovarian cancer SKOV3 cells by inducing morphological changes, including membrane 
ruffling, lamellipodia formation, cell-cell dissociation and single cell migration, events that 
could lead to the first steps of metastasis formation. 
Huang et al. demonstrated that LPA acts by activating Fyn (but not c-Src) and increasing its 
association with p120-catenin at the cell-cell junctions.173 
Yang et al., very recently, documented that the activation of Fyn can cause dissociation of cell-
cell junctions and adhesion, resulting in paracellular hypermeability. They detected high 
expression levels of Fyn in vessel endothelial cells, and suggested a possible mechanism 
(involving Fyn activity) by which the ovarian tumor cells cross the endothelial barrier and 
transform to an invasive phenotype.174 
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3.5.3 Fyn and prostate cancer 
Posadas et al. demonstrated that Fyn is upregulated in prostate cancer and is functionally 
distinct from other SFKs, since it interacts with Fak and paxillin (PXN) that are regulators of 
cell morphology and motility. Data showed a greater Fyn expression in prostate cancer than in 
normal tissue, specific for Fyn and not present for other SFKs. Expression of Fyn in prostate 
cancer cell lines (LNCaP, 22Rv1, PC3, DuPro) was detected using quantitative real-time PCR 
(qRT-PCR) and immunoblotting. Comparing normal with cancer samples, it has been detected 
a 2.1-fold increase of Fyn level, a 1.7-fold increase in Fak and a doubling in PXN. These studies 
support the hypothesis that Fyn and its related signalling partners are upregulated in prostate 
cancer, and warrant further investigation into the role of Fyn as a therapeutic target.175 In 2015, 
the same research group demonstrated that Fyn is strongly up-regulated in human 
neuroendocrine prostate cancer (NEPC) tissues and xenografts, as well as cells derived from a 
NEPC transgenic mouse model. These data indicated that the neuroendocrine differentiation 
that occurs in prostate cancer cells is, at least in part, regulated by Fyn. The understanding of 
the role of Fyn in the regulation of neuroendocrine markers should provide further support for 
ongoing clinical trials of SFK and MET inhibitors in castration-resistant PCa patients.176 Based 
on the hypothesis that the treatment with the Fyn inhibitor saracatinib would increase the time 
required to develop new metastatic lesions, the same group performed a clinical study on a 
number of prostate cancer patients. Unfortunately, this study was unable to determine if 
saracatinib had potential as metastasis inhibitor.177 
 
3.5.4 Fyn and melanoma 
Huang et al. reported that Fyn is selectively activated among SFKs in the K-1735 murine 
melanoma cell line with high metastatic potential, where significant tyrosine phosphorylation 
of cortactin (a cytoplasmatic protein promoting polymerization and rearrangement of the actin 
cytoskeleton and involved in cell migration), stable complex formation between activated Fyn 
and cortactin, and co-localization of cortactin with Fyn at cell membranes have been observed. 
The authors showed that cortactin is a specific substrate and a cooperative effector of Fyn in 
integrin-mediated signalling processes regulating metastatic potential.178 
More recently, Fyn has been also identified as a melanoma biomarker which contributes to the 
tumor development.179  
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3.5.5 Fyn and squamous cell carcinoma 
Integrin beta6 is expressed in invasive oral squamous cell carcinoma (SCC) and is correlated 
with oral tumor progression. Li et al. investigated to determine whether integrin beta6 signalling 
activates Fyn and thus promotes SCC progression and demonstrated that upon ligation of the 
integrin beta6 with fibronectin, beta6 forms a complex with Fyn and activates it. Fyn activation 
recruits and activates Fak to this complex that in turn stimulates the Raf-ERK/MAPK pathway. 
This pathway transcriptionally activates the matrix metalloproteinase-3 gene and promotes oral 
SCC cell proliferation and experimental metastasis in vivo. These findings indicate that integrin 
beta6 signalling activates Fyn and thus promotes oral cancer progression.180 Successively the 
same group also demonstrated that the activation of Fyn, as well as local growth factor 
concentration, modulates EMT in oral SCC, rendering the tumor more aggressive.181 
Recently, Lee et al. determined that SCC growth in 3-dimensional multicellular spheroid 
(MCS) approximates epithelial to mesenchymal transition. Organization of an MCS requires 
the full-length β6 integrin subunit and its maintenance requires MAPK. Limiting Fyn activation 
results in the down-regulation of E-cadherin, β-catenin and an increase in expression of N-
cadherin and SNAIL. These results indicate that the microenvironment and growth patterns in 
an MCS are complex and require MAPK and Fyn.182 
 
3.5.6 Fyn and brain tumors 
Regarding brain tumors, it has been reported that Fyn gene, together with other genes involved 
in brain development and neural differentiation, was strongly enriched in astrocytoma, a 
common and lethal human malignancy. Moreover, Fyn and c-Src are effectors of oncogenic 
EGFR signalling in GB patients and enhance invasion and tumor cell survival in vivo. 
Consistently, the pan-SFK inhibitor dasatinib inhibited invasion, promoted tumor regression, 
and induced apoptosis in vivo, significantly prolonging mice survival in an orthotopic GB 
model. This study demonstrated a mechanism linking EGFR signalling with Fyn and Src 
activation to promote tumor progression and invasion and provided the rationale for combined 
anti-EGFR and anti-SFK targeted therapies.183 
Very recently, Comba et al. confirmed that Fyn expression correlates positively with GB cell 
aggressiveness. The histopathological evaluation of gliomas indicates that loss of Fyn reduced 
malignant features such as pseudopalisades, necrosis, and hypervascularization. This study 
indicates an important role for Fyn in modulating many glioma cellular processes and its 
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relevance as a novel regulator of GB behaviour and therapy response.184 
 
3.5.7 Fyn and pancreatic cancer 
Chen et al. demonstrated that upregulation of Fyn expression is correlated with human 
pancreatic cancer metastasis. Indeed, the inhibition of Fyn activation by kinase-dead Fyn 
transfection decreased liver metastasis of PC3 pancreatic cancer cells in nude mice. Further 
analyses showed that Fyn activity modulated pancreatic cell metastasis through the regulation 
of proliferation and apoptosis.185  
In 2014, it has been demonstrated that the suppression of the messenger RNA expressions of 
Yes1, Lyn, Fyn, Frk, and Src by specific small interfering RNA transfection caused the 
suppression of cell proliferation by 16.7% to 47.3% in PANC-1 cells. Knockdown of any of 
these five SFKs suppressed proliferation in other pancreatic cancer cell lines by 3.0% to 40.5%. 
The knockdowns significantly reduced pancreatic cancer cell migration by 24.9% to 66.7% and 
completely inhibited invasion. These results suggest that the knockdown of Yes1, Lyn, Fyn, 
Frk, or Src reduce human pancreatic cancer cell proliferation, migration, and invasion.186  
Recently, Jiang et al. reported that the suppression of Fyn activity and/or overexpression of 
heterogeneous nuclear ribonucleoprotein E1 (hnRNP E1) decreased the metastasis of pancreatic 
cancer cells. The study demonstrated a novel mechanism by which Fyn/hnRNP E1 signalling 
regulates pancreatic cancer metastasis by affecting the alternative splicing of integrin β1.187 
 
3.5.8 Fyn and mesothelioma 
Menges et al., applying a phosphotyrosine proteomic screen, identified novel signalling 
molecules, including Janus kinase 1 (Jak1), STAT1, cortactin, FER, p130Cas, c-Src and Fyn, 
as tyrosine phosphorylated and activated in human malignant mesothelioma. They also 
confirmed that known signal transduction pathways previously implicated in mesothelioma, 
such as EGFR and Met, are co-activated in the majority of human mesothelioma specimens and 
tested cell lines. Since all these enzymes seem to be hyperactivated in malignant mesothelioma 
cell lines, dual or multitargeted inhibition of some of these kinases is likely to be more 
efficacious than inhibition of a single tyrosine kinase for a potential antiproliferative activity.188 
Further studies showed that double RNA interference knockdown of Fyn and Lyn induced 
apoptosis accompanied by caspase-8 activation in mesothelioma cell line.189 
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3.5.9 Fyn and leukemia 
Fyn involvement has also been shown in haematological malignancies, including chronic 
myeloid leukemia (CML), some types of acute leukemias and multiple myeloma. It has been 
reported that Hck, Lyn and Fyn strongly phosphorylate the SH3-SH2 region of Bcr-Abl, the 
constitutively active cytoplasmatic tyrosine kinase that is the etiologic agent of CML. Seven 
phosphorylation sites were identified, namely Tyr89 and Tyr134 in the Abl SH3 domain, 
Tyr147 in the SH3-SH2 connector and Tyr158, Tyr191, Tyr204 and Tyr234 in the SH2 domain. 
Tyr89 in the SH3 domain, the most prominent phosphorylation site in vitro, is strongly 
phosphorylated in CML cells in a SFK-dependent manner. The positions of these tyrosine 
residues in the crystal structure of c-Abl (the normal protein form present in healthy cells) 
together with the transformation defect of the corresponding Bcr-Abl mutants suggest that 
phosphorylation of the SH3-SH2 region by Src family kinases impacts Bcr-Abl protein 
conformation and signalling.190 Small interfering RNA experiments and pharmacologic 
approaches identified Fyn as a candidate for resistance to imatinib, the first line drug for CML. 
This study provides a comprehensive picture of the transcriptional events associated with 
imatinib and identify Fyn as a new potential target for therapeutic intervention in CML.191 
Using a tissue microarray, Chandra et al. demonstrated that Fyn expression is significantly 
increased in CML blast crisis (the terminal phase of the disease) compared with the chronic 
phase. Cells overexpressing Bcr-Abl in vitro and in vivo display an upregulation of Fyn protein 
and its mRNA. Moreover, knockdown of Fyn with short hairpin RNA (shRNA) slows leukemia 
cell growth, inhibits clonogenicity and leads to increased sensitivity to imatinib, indicating that 
Fyn mediates CML cell proliferation.192 The authors also proposed a mechanism explaining the 
heightened levels of Fyn in CML cells: Bcr-Abl is one of the several oncoproteins that raise 
ROS (reactive oxygen species) concentration; ROS is in turn responsible for the upregulation 
of Fyn mRNA and protein levels. 
The identification of these novel downstream signals is particularly important in the effort to 
overcome the unresolved problem of treatment of blast crisis CML and management of kinase 
inhibitor resistance.193 Fyn has been proposed as a putative target for treating Bcr-Abl 
expressing acute lymphoblastic leukemias; in fact together IL-15, Fyn gene has hub-like 
properties, potentially showing the highest biologic importance among other factors involved 
in the proliferation of malignant leukemic blasts.194 
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Singh et al. discovered a role of Fyn in promoting Bcr-Abl1 mediated cell growth and 
sensitivity to imatinib. They demonstrate that Fyn contributes to Bcr-Abl1 induced genomic 
instability, a feature of blast crisis CML. Bone marrow cells and mouse embryonic fibroblasts 
derived from Fyn knockout mice transduced with Bcr-Abl1 display slowed growth and 
clonogenic potential as compared to Fyn wt Bcr-Abl1 expressing counterparts.195  
Recently, Chougule et al. studied the role of Fyn in Fms-like tyrosine kinase 3 (FLT3) (a RTK) 
signalling in respect to acute myeloid leukemia (AML) and they reported that Fyn cooperates 
with the oncogenic variant FLT3-ITD (internal tandem duplication) in cellular transformation 
by selective activation of the STAT5 pathway. Therefore, Fyn inhibition, in combination with 
FLT3 inhibition, could be beneficial for AML patients.196 
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CHAPTER 4. Hck kinase  
 
The hematopoietic cell kinase (Hck) is another non-receptor or cytoplasmic TK belonging to 
the SFKs.2 Hck, together with Lyn and Fgr, is predominantly expressed in myeloid cells and 
represents the prevalent SFK member involved in inflammation.197,198 It induces production of 
multiple cytokines and chemokines such as TNF-α, interleukin-1 (IL-1), and interleukin-6 (IL-
6) in macrophages upon activation by lipopolysaccharide (LPS).199 Hck, toghether with Fgr, is 
also involved in integrin-mediated cell signalling to promote macrophage migration and 
attachment to the sites of inflammation.200 Since it has a role in the inflammatory response, Hck 
is involved in inflammatory diseases, but it also demonstrated to possess a role in other diseases, 
including several types of leukemia and in human immunodeficiency virus-1 (HIV-1) infection, 
which are caused by alterations of immune system cells. Thus Hck has been identified as a 
potential target for the treatment of CML201 and HIV-1 infection.198,202 
 
4.1 Hck structure and functions 
Human Hck, independently discovered in 1987 by two groups, shares the same overall structure 
architecture of the other SFKs and includes five distinct regions: a unique N-terminal region, 
with sequences for lipid attachment, the regulatory SH3 and SH2 domains, a catalytic domain 
SH1, followed by a negative regulatory C-terminal tail.203  
Alvarado et al. determined the crystal structure of a truncated Hck protein constituted by the 
SH2 and SH3 domains plus the linker between the SH3 and the SH2 domains. Despite the 
absence of the kinase domain, the structures and relative orientations of the SH2 and SH3 
domains in this shorter protein are very similar to those observed in the full-length Hck. 
However, the SH2 kinase linker adopts a modified topology and fails to engage the SH3 
domain. This structure suggests that the non-catalytic regions work together as a 
“conformational switch” that modulates kinase activity in a manner unique to the SH3 domain 
(Fig. 13).204  
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In humans, Hck is expressed as two isoforms, p59Hck and p61Hck, generated simultaneously 
and in equal amounts by alternative translation of a single mRNA.197 Compared to p59Hck, 
p61Hck presents an additional 21 amino acid peptide at the N-terminal end which is 
myristoylated, while the N-terminal domain of p59Hck is myristoylated or palmitoylated.205 
Thus, the two Hck isoforms only differ in a portion of their N-terminal domains, and are 100% 
identical in their other sequences, but they show different subcellular localizations and lead to 
distinct phenotypes when ectopically expressed in fibroblasts.206 In more detail, p59Hck is 
mainly associated to the plasma membrane and p61Hck to the lysosome membrane.207 
The expression of a constitutively activated variant of p61Hck induces the de novo formation 
of podosome rosettes, which are structures involved in cell adhesion and extracellular matrix 
degradation, whereas p59Hck triggers the formation of plasma membrane protrusions.208 
Hck is especially expressed in myeloid cells and is primarily involved in inflammatory 
signalling.209 Thus, Hck levels are relatively low in immature monocytes and granulocytes, but 
rise much folds as these cells differentiate. An increase in Hck expression occurs when mature 
Fig. 13. Schematic representation of Hck structure and regulation197  
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macrophages are treated with LPS, which induces transcription of genes encoding for 
proinflammatory regulators of the immune response.210 The protein levels also rise after cell 
exposure to interferon gamma and macrophage colony-stimulating factor (M-CSF), which 
activate Hck among other signalling molecules.211 Hck expression is particularly high in fully 
differentiated phagocytes (i.e. neutrophils, monocytes, macrophages, dendritic cells and mast 
cells) which are specialized cells of the immune system and are able to detect the chemotactic 
factors released by the infected tissue and/or microorganisms. In these cells, Hck plays 
important roles in phagocytosis, adhesion and migration, and regulates the formation of 
membrane protrusions, lysosome exocytosis, podosome formation, and actin polymerization.212 
T-lymphocyte adhesion plays a critical role in both inflammatory and autoimmune responses. 
It has been demonstrated that Hck facilitates the phosphorylation of C3G, a Rap1 guanine 
nucleotide exchange factor involved in the regulation of T-cell adhesion. These findings 
indicate that both C3G and Hck are promising potential therapeutic targets for the treatment of 
T cell-dependent autoimmune disorders.213 Asai et al. demonstrated that Hck, together with 
other factors, is involved in the regulation of antigen transcytosis across the epithelial barrier, 
a process critical in mucosal immunity.214  
Other studies evidenced new target proteins for Hck. For example, it has been reported that Hck 
plays an important role in Toll like receptor (TLR)-mediated proinflammatory cytokine 
production, and hence in the control of inflammation. TLRs are a family of transmembrane 
noncatalytic proteins, which provide specific recognition of a range of bacterial, viral, fungal 
and endogenous ligands, and are able to initiate a response against a wide range of physical and 
environmental insults.215 Increasing evidence suggests that TLRs are involved in pathologies 
such as autoimmune diseases, atherosclerosis and cancer. Using primary human macrophages 
in combination with adenoviral overexpression and small interfering RNA knockdown studies, 
Smolinska et al. showed that Hck has an important role in LPS/TLR4-induced TNF and IL-6 
production. In fact, Hck mediates TLR4-induced transcription of both TNF and IL-6. These 
data suggest the possibility of targeting this kinase for the alleviation of inflammation.216 
Several studies indicated Hck involvement not only in inflammatory pathways, but also in 
cancer development. The expression of a constitutively active form of p56Hck (a murine form 
of Hck) in HeLa cells (derived from cervical cancer) leads to membrane protrusion and F-actin 
redistribution. In addition, both p56Hck and its constitutive active form enhance cell motility 
and invasion.217 
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In 2015, Awad et al. demonstrated a specific interaction between the SH3 domain of Hck and 
the polyproline motif of Eukaryotic EnguLfment and cell Motility 1 (ELMO1), that is a protein 
involved in cell migration and actin remodeling.218 
 
4.2 Hck and Leukemias 
4.2.1 Hck and CML 
Several studies report the involvement of Hck in the Bcr-Abl driven transformation that 
typically occurs in CML cells. It was first observed that the hematopoietic transformation of 
IL-3-dependent myeloid cell line 32D by transfection with Bcr-Abl induces the activation of at 
least two SFK members, p53/56Lyn and p59Hck.219 It was successively demonstrated that Hck 
phosphorylates Bcr-Abl on Tyr177 within the Bcr region, providing a docking site for the 
Growth factor receptor-bound protein 2 (Grb2) SH2 domain and thus a possible link to the Ras 
pathway, whose hyperactivation is involved in many malignancies.220 Further studies indicated 
that Hck binds Bcr-Abl in at least four independent regions, one in Bcr, one in the region 
comprising the SH3 and SH2 domain of Abl, one in the SH1 domain of Abl, and one in the C-
terminal domain of Abl. In Hck, deletion of the SH2 and/or the SH3 region abolishes the 
binding to Bcr-Abl, while deletion of the Hck SH1 domain enhances the binding of Hck to Abl 
and Bcr-Abl.221 Using matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry, Chen et al. observed that seven tyrosine residues in the Bcr-Abl SH3-SH2 regions 
are phosphorylated by the SFK members Hck, Lyn and Fyn, which in this way modulate Bcr-
Abl transforming activity. In particular, Tyr89 localizes to a binding surface of the SH3 domain 
that engages the SH2-kinase linker in the crystal structure of the c-Abl core. Phosphorylation 
of this tyrosine residue by Hck disrupts negative regulatory interactions and leads to enhanced 
Abl kinase activity and cellular signalling.222 Using a kinase-defective mutant of Hck, it has 
been demonstrated that Hck participates with Bcr-Abl in cell modification to cytokine 
independence, suggesting that SFK activation may be necessary for Bcr-Abl transformation 
signalling. STAT5 is constitutively activated by Bcr-Abl. Klejman et al. got further insights in 
this activation pathway and demonstrated that the Bcr-Abl SH3 and SH2 domains interact with 
Hck, leading to the stimulation of Hck catalytic activity. Active Hck in turn phosphorylates 
STAT5B on Tyr699, which is an essential step in STAT5B activation. A kinase-dead Hck 
mutant and the Hck inhibitor PP2 abrogate Bcr-Abl-dependent activation of STAT5. This study 
indicated that Bcr-Abl-Hck-STAT5 signalling pathway plays an important role in Bcr-Abl-
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mediated transformation of myeloid cells.223 Interestingly, Hck and Src prevent nuclear 
localization of STAT5 in the presence of Bcr-Abl. Consistently, in CML cells STAT5 is 
unexpectedly present at podosome-like structures in the cytoplasm, while in normal 
macrophages it is not at podosomes but in the nucleus. Phosphorylated-STAT5 associates to 
podosomes in a process dependent on constitutive activation of Hck. This observation indicates 
that STAT5, previously classified as a transcription factor, could play another role outside the 
nucleus, elicited by the Bcr-Abl/Hck transforming pathway. The cytoplasmic retention of 
activated STAT5, mediated by Src and Hck in Bcr-Abl positive cells, has been confirmed.224 
STAT5 tyrosine phosphorylation can occur in response to genotoxic activation of Bcr-Abl, 
Hck, and Jak2, a non-receptor TK implicated in signalling by members of the type II cytokine 
receptor. Apparently, STAT5 phosphorylation occurs in a complex constituted by Bcr-Abl, 
Hck, and Jak2. Moreover, Hck together with STAT5B regulates Insulin-like Growth Factor 1 
(IGF-1) expression, which is increased in CML blast crisis, the last and fatal stage of the 
diseases.225 SFKs, in particular Hck and Fgr, interact with c-Abl in the regulation of myeloid 
cell migration. Indeed, c-Abl associates to integrin-bound Hck and Fgr and its phosphorylation 
is regulated by these SFKs. Additionally, inhibition of c-Abl activity results in a marked 
reduction of mouse macrophage and human neutrophil migration and polarization.226 A study 
performed by using a chemical-genetic approach demonstrated that Hck has a non-redundant 
function as a key downstream signalling partner for Bcr-Abl and may represent a potential drug 
target in CML (Fig. 14A).227 It has been successively confirmed that Hck mediates imatinib-
resistance in CML patients, who do not harbour Bcr-Abl mutations, and that an elevated Hck 
and Lyn kinase activity is sufficient to induce imatinib-resistance through a mechanism that 
may involve phosphorylation.228  
 
4.2.2 Hck and other haematological malignancies 
A study performed on B-lymphoid leukemia cells expressing Bcr-Abl indicates that the SFK 
members Hck, Lyn and Fgr are implicated in Ph(+) acute B lymphoblastic leukemia (B-ALL) 
and suggests that simultaneous inhibition of SFKs and Bcr-Abl may benefit patients with 
Ph(+)ALL.229 Hck also takes part in the development of human AML, interfering with the 
activation of FLT3. As briefly reported in the previous chapter, this kinase is overexpressed and 
hyperactivated by activating mutations, i.e. internal tandem duplications (ITD) in the 
juxtamembrane region in about 30% of AML patients. The mechanism of association between 
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Hck and FLT3 has been analyzed and it was demonstrated that Hck phosphorylates tyrosine 
residues 589 and 591 in the juxtamembrane region of wt FLT3 and ITD FLT3 via its SH2 
domain, and interferes with FLT3 maturation in a kinase-dependent manner.230 Saito et al., 
using immunofluorescence labelling, evaluated the expression of nine different proteins in 
leukemia stem cells (LSCs), which are cell cycle-quiescent and chemotherapy-resistant in 
human AML. The authors found that the genes encoding Hck and the transcription factor Will 
Tumor 1 (WT1) are overrepresented in the greatest proportions of LSC samples, analyzed in 
situ in the bone marrow endosteal region. This finding confirms that Hck is a promising target 
for the treatment of chemotherapy-resistant LSCs.231  
Lopez et al. reported that AML cells carrying FLT3-ITD mutations are dependent on CDK6 
for cell proliferation while CDK4 is not essential. They showed that FLT3-ITD signalling is 
responsible for CDK6 overexpression, through a pathway involving Hck. Accordingly, FLT3-
ITD failed to transform primary hematopoietic progenitor cells from Cdk6-/- mice. Their results 
demonstrate that CDK6 is the primary target of CDK4/CDK6 inhibitors in FLT3-ITD positive 
AML. Furthermore, they delineate an essential protein kinase pathway (FLT3/HCK/CDK6) in 
the context of AML with FLT3-ITD mutations.232 
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy. It 
accounts for approximately 30% of non-Hodgkin lymphomas and over 80% of aggressive 
lymphomas. Hck is overexpressed at the mRNA level in DLBCL cells. Moreover, 
phosphorylation of Src, Lyn and Hck is much higher in DLBCL cells than in resting B cells. 
This suggested a role of SFKs, including Hck, in this disease.233 Clinical data, transgenic mouse 
models and signalling studies support the role of IL-6 as the major growth factor for multiple 
myeloma (MM) cells. Hck becomes activated by IL-6 and associates with gp130, and in this 
way, it is involved in IL-6 signal transduction pathway in MM. Moreover, the expression of a 
kinase inactive Hck mutant (K269R) in 7TD1 cells (whose growth is IL-6 dependent) causes a 
dominant negative effect on cell number increase, thus providing further evidence that SFKs, 
particularly Hck, are required for gp130 signalling in MM (Fig. 14B).234,198  
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4.3 Hck and HIV 
The HIV infection, that is the cause of Acquired Immune Deficiency Syndrome (AIDS) was 
first identified in early 1980’s.235,236 The most common mode of transmission of HIV-1 is 
through sexual contact, while the second one is via blood and blood products. The third most 
common mode is maternal-fetal transmission. HIV transmission is not known to occur via 
casual, non-sexual contact or via insect vectors such as flies and mosquitoes.237 The early-stage 
of HIV is characterized by different symptoms (fever, muscle ache, enlarged glands, weakness 
and weight loss); in many cases, after this period, the initial symptoms disappear for several 
years. During this time, the virus carries on developing and damaging the immune system; if 
left untreated, HIV infection causes reduction in the numbers of CD4-bearing helper T cells 
weakening the ability to fight infections and the person becomes vulnerable to serious illnesses. 
This stage of infection is known as AIDS.238 
  
4.3.1 HIV-1 infection 
The HIV is grouped to the genus Lentivirus within the family of Retroviridae, subfamily 
Orthoretrovirinae. Retroviruses are small envelope viruses that contain a diploid, single-
stranded RNA genome. The virus particle is formed by an inner core that contains the viral 
nucleic acids, as well as enzymes required for early replication events. This inner core is 
surrounded by capsid proteins. The capsid itself is surrounded by a lipid membrane. A virus 
matrix protein is inserted into the inner surface of the membrane. The envelope glycoprotein, 
an integral membrane protein, protrudes through the membrane and forms the outer surface of 
Fig. 14. Schematic Hck signaling pathway in cancer cells. A. Interaction 
with Bcr-Abl. B. Interaction with IL-6. 
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the virus particle.239  
Infection begins when a virus particle or a cell-producing virus encounters a cell with a high-
affinity receptor for the virus. A specific high-affinity binding reaction occurs between the virus 
surface envelope glycoprotein and the CD4 molecule. CD4 is a surface glycoprotein found on 
a variety of cells of hematopoietic origin. The CD4 protein is present in low concentration on 
monocytes, macrophages, and antigen presenting dendritic cells. Entry occurs by fusion of virus 
and cell membranes. The envelope proteins gp120 and gp41 bind to CD4+ cell receptors and 
coreceptors on the outside of CD4+ cells and macrophages. The C-C chemokine receptors type 
5 (CCR5) and C-X-C chemokine receptor type 4 (CXCR4) facilitate viral entry. T-cell tropic 
viruses require CXCR4 to bind, and macrotropic strains of the virus require CCR5. The joining 
of the proteins and the receptors and coreceptors fuses the HIV membrane with the CD4+ cell 
membrane, and the virus enters the CD4+ cell and macrophage. The HIV membrane and the 
envelope proteins remain outside of the CD4+ cell, whereas the core of the virus enters the 
CD4+ cell. CD4+ cell enzymes interact with the viral core and stimulate the release of viral 
RNA and the viral enzymes reverse transcriptase, integrase, and protease. The HIV RNA must 
be converted to DNA before it can be incorporated into the DNA of the CD4+ cell. This 
incorporation must occur for the virus to multiply. The conversion of HIV RNA to DNA is 
known as reverse transcription and is mediated by the HIV enzyme reverse transcriptase. The 
result is the production of a single strand of DNA from the viral RNA. The single strand of this 
new DNA then undergoes replication into double-stranded HIV DNA. Once reverse 
transcription has occurred, the viral DNA can enter the nucleus of the CD4+ cell. The viral 
enzyme integrase then inserts the viral DNA into the CD4+ cell’s DNA. This process is known 
as integration. The CD4+ cell has now been changed into a factory used to produce more HIV. 
The new DNA, which has been formed by the integration of the viral DNA into the CD4+ cell, 
causes the production of messenger RNA that initiates the synthesis of HIV proteins. The HIV 
proteins and viral RNA, all the components needed to make a new virus, gather at the CD4+ 
cell membrane to form new viruses. These new viruses push through the different parts of the 
cell wall by budding. They leave the CD4+ cell and contain all the components necessary to 
infect other CD4+ cells. The new virus has all the components necessary to infect other CD4+ 
cells, after a process of maturation. During this process, the HIV protease enzyme cuts the long 
HIV proteins of the virus into smaller functional units that then reassemble to form a mature 
virus (Fig. 15).240 
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4.3.2 Role of Hck in HIV infection and AIDS 
There are some viral accessory proteins that act late in the virus life cycle with different 
functions, such as assisting virus maturation, releasing and increasing the virus particle 
infectivity and viability. These proteins are Nef (Negative regulatory factor), Vif (Virus 
infectivity factor), Vpu (Viral protein U) and Vpr (Viral protein R).198,241 Nef, the most 
important regarding the link with Hck, has no known catalytic function and is believed to 
promote viral pathogenicity by altering signalling pathways in infected cells through its 
interactions with surface receptors and cellular proteins.242 Initially, it was thought that Nef was 
an inhibitor of viral pathogenesis, since it was shown to decrease viral transcription and 
replication in culture and was thus named “negative factor”. Successively, much evidence has 
demonstrated the strongly positive effect of Nef on HIV pathogenesis, including enhancing 
infected cell survival and optimized host environment for viral replication and infectivity. Even 
if more recent advances in the field reported that Nef effects range from inhibition to activation 
on T-cell antigen receptor (TCR) signalling cascade, it has been generally demonstrated that 
Nef is essential for AIDS pathogenesis.243 
When hematopoietic differentiated cells derived from mesenchymal stem cells become 
permissive to HIV infection, an increased Hck expression has been observed.244  
Nef has been shown to interact with the Hck SH3 domain and stimulate its tyrosine kinase 
activity in vivo. Myristoylation of Nef does not affect SH3 domain binding. The crystal structure 
of Nef in complex with the Hck SH3-SH2 domains has been determined with a resolution of 
Fig. 15. Schematic diagram of the HIV life cycle. 
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1.86 Å (PDB code: 4U5W).245 Fig. 16 shows the structure of the Nef-Hck SH3-SH2 complex.  
 
 
 
 
There are two Nef-Hck SH3-SH2 domain complexes in the unit of the crystal. The SH3 domain 
of Hck binds to the PxxP (polyproline motif) loop of Nef by means of its RT-loop (region 
ranging from residue 86 to 101). In detail, hydrophobic contacts were detected between the 
PxxPxR motif and residues Tyr90, Tyr92, Trp118, Pro133 and Tyr136 of Hck. Hydrogen bonds 
involve SH3 residues Tyr136 and Trp118 with Pro72 and Val74, respectively, of Nef. 
Moreover, a salt-bridge between the conserved arginine in the Nef PxxPxR motif (Arg77) and 
the SH3 Asp99 was found. An intermolecular-intercomplex interaction was observed in the 
Nef-Hck dimeric structure involving a salt bridge between Nef Arg105 from one complex and 
the SH3 Glu93 of the opposite complex. Furthermore, each SH2 domain establishes van der 
Waals interactions with both Nef molecules of the complex and in particular with Nef residues 
Phe68, Pro69, Leu76 and Tyr115. These contacts between Nef and SH2 Hck could guide the 
proper placement of the PxxPxR motif for its interaction with the SH3 domain.245 It was 
successively confirmed that Nef specifically binds to the SH3 domain of Hck in vitro with high 
affinity.198 Furthermore, the Hck-Nef binding is blocked by proline-to-alanine mutations.246 Lee 
et al. showed that Ile96, which is in a Hck loop positioned close to conserved SH3 residues 
implicated in the binding of proline-rich motifs, forms hydrophobic interactions with a 
hydrophobic pocket within the Nef core, and the mutation of Ile96 abrogates Nef binding to 
Hck.247  
Other residues within the Nef hydrophobic pocket, such as Tyr120, have also been found to be 
Fig. 16. Crystal structure of Nef in complex with SH3-SH2 domains of Hck.245 
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critical for Nef-mediated binding and activation of Hck. Nef interactions both with Hck SH3 
domain and with Hck Ile96 are necessary, but not independently sufficient, for high affinity 
binding of Nef to the Hck SH3 domain.212  
Hck activation by Nef has been revealed also in other cell-based assays. Briggs et al. 
demonstrated that Hck SH3 engagement by Nef is sufficient to activate this kinase in rat 
fibroblasts.248 Amino acid sequence alignment with active Nef proteins revealed differences in 
regions not previously implicated in Hck activation, including a large internal flexible loop 
absent from available Nef structures. Substitution of these residues in active Nef compromises 
Hck activation without affecting SH3 domain binding. These findings show that residues at a 
distance from the SH3 domain binding site can allosterically influence Nef interactions.249  
A study by Kim et al. indicated that Hck is also implicated in CNS HIV infections, that cause 
HIV-associated neurocognitive disorders (HAND), also reported as AIDS dementia. 
Macrophages and microglia are infected by HIV-1 and play a pivotal role in the pathogenesis 
of AIDS dementia. They express CD45, which are a family of transmembrane protein tyrosine 
phosphatases. In particular, microglia expresses the two subtypes CD45RB and CD45RO. The 
authors treated the microglia with a CD45 agonist antibody (alphaCD45RO) and observed that 
it inhibits HIV-1 replication. They also demonstrated that this antibody prevents HIV-1 Nef-
induced autophosphorylation of Hck. This study showed that in myeloid lineage cells, Nef 
interacts with the Hck SH3 domain, and this activity results in autophosphorylation of Hck and 
in increased HIV-1 transcription. Thus, in microglia Hck is phosphorylated following HIV-1 
infection in a Nef-dependent manner.250 
Recently, Shinya et al. demonstrated the involvement of the association of Nef with Hck and 
p21-activated kinase 2 (PAK2), and that Hck, which is expressed strongly in dendritic cells, 
augmented this mutual interaction. Hck might be another therapeutic target to preserve the 
function of HIV-1 infected dendritic cells, which are potential reservoirs of HIV-1 even after 
antiretroviral therapy.251 
Hck is also involved in the interaction with another HIV-1 protein, Vif, which is critically 
required for the infection of host cells. Vif plays a key role in replication and transmission of 
the virus in non-permissive cells, such as primary T cells and macrophages.252 Vif interacts with 
a variety of host proteins, including Hck, and is able to cause kinase activation. In fact, using a 
yeast growth suppression assay, it has been shown that purified Vif is a potent activator of Hck 
in vitro and in vivo.253 
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CHAPTER 5. Sgk1 kinase 
 
The Sgk family consists of three members, Sgk1, Sgk2 and Sgk3, all displaying 
serine/threonine kinase activity. They are products of three distinct genes localized on different 
chromosomes.254  
 
5.1 Sgk1 structure and functions 
Sgks are members of the AGC (protein A, G, C) kinase group and share structural and 
functional similarities with Akt, PKC and S6K1–3 (Ribosomal S6 Kinase).255, 256 They present 
a conserved structure with an N-terminal variable domain, a catalytic domain and a hydrophobic 
C-terminal domain (Fig. 17).257  
 
 
 
 
For each Sgk isoform, several variants have been identified. Sgk1 has four variants that differ 
in the amino-terminus which impacts on both substrate specificity and turnover of the protein. 
Sgk2 has two variants named alpha and beta, which differ in the amino-terminus, while Sgk3 
exists in two forms, with variant 2 lacking an alternate in-frame exon, compared to variant 1, 
Fig. 17. Sgk isoforms and variants.257 
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resulting in a shorter protein. The functional consequence of the differing variants of Sgk2 and 
Sgk3 is as yet unknown. Sgk isoforms have been implicated in the regulation of a great diversity 
of cellular factors including ion channels, membrane transporters, cellular enzymes and 
transcription factors. This diversity is reflected in Sgks involvement in a wide variety of cellular 
processes including hair growth, locomotive behaviour, cell stress, survival, proliferation and 
transport of ions, nutrients and amino acids (Fig. 18).258 
 
 
 
 
 
5.2 Regulation and activation of Sgk 
Similarly to the Akt isoforms, Sgk activity is regulated by post-translational modification, most 
frequently by phosphorylation and dephosphorylation mediated via the PI3K pathway and 
protein phosphatase 2A, respectively.259 Sgk1 was originally described as a key enzyme in the 
hormonal regulation of sodium absorption by the amiloride sensitive sodium channel 
(ENaC).260 The activity of ENaC, through Sgk1, is regulated by cAMP,261 insulin,261,262 
Fig. 18. Activators of Sgk1 and Sgk3 and substrates involved in 
cell proliferation, migration and survival.257 
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glucocorticoids,263 IL-2264 and IGF-1265 and other survival signal proteins in normal and cancer 
cells. Subsequently, Sgk1 gene transcription has been shown to be upregulated by a multitude 
of different stimuli, including growth factors,266,267 the p53 tumour suppressor protein268 and 
various cellular stressors including ischaemic injury, heat shock and ultraviolet stress.269–272 It 
has been proposed that Sgk1 degradation may be mediated by the E3 ubiquitin-protein ligase 
Nedd4-2. Sgk1 phosphorylation of Nedd4-2 increases Sgk1 degradation, thus, through a 
feedback inhibition mechanism, Sgk1 is likely to induce its own degradation.273 
Sgk1 activity is strictly correlated with its post-translational modifications. It becomes a 
substrate of mTOR (mammalian target of rapamycin) kinase that phosphorylates Sgk1 
hydrophobic motif (H-motif) on Ser422. Then, 3-phosphoinositide-dependent kinase-1 (Pdk1) 
binds to the H-motif of Sgk1, at the level of phospho-Ser422, and further phosphorylates the 
protein at Thr256.274 Given the substantial homology in the hydrophobic motif between the Sgk 
isoforms, it is likely that the kinase responsible for phosphorylation of Sgk1 will also be 
responsible for Sgk2 and Sgk3 phosphorylation. In addition to the PI3K activation of Sgk1, big 
mitogen-activated protein kinase-1 (BMK-1) in response to EGF stimulation275 and p38 MAPK 
in response to interleukin IL-6 stimulation276 can activate Sgk1 through a Pdk1-independent 
phosphorylation of serine-78.257  
 
5.3 Sgk1 and cancer 
Sgk1 is a kinase that has recently gained the attention in the field of molecular oncology, its 
antiapoptotic function suggests a possible involvement in human carcinogenesis.277 Ectopic 
expression of wt Sgk1 is able to revert apoptosis mediated by growth factor withdrawal.278 
Moreover, Sgk1 mediates glucocorticoid dependent antiapoptotic signals in mammary 
epithelial and breast cancer cells279 and IL-2 dependent antiapoptotic signals in kidney cancer 
cells.264 Interestingly, active Sgk1 regulates cell survival, proliferation, and differentiation 
through Murine Double Minute 2 (MDM2), that directs p53 to ubiquitylation and proteosomal 
degradation,280 and, through RAN-binding protein 1 (RANBP1), affects mitotic stability and 
taxol sensitivity of RKO colon carcinoma cells in culture.281 Sgk1 activates N-Myc down-
regulated gene 1 (NDRG1), by catalysing its phosphorylation on Thr346. The NDRG1 factor 
is considered to be a specific Sgk1 substrate.282 NDRG1 has an important role in cell 
proliferation and differentiation283 and a debated role in oncogenesis. 
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Indeed, it mainly behaves like an oncosuppressor in several tumor models,284,285 but it appears 
to be a key determinant of resistance towards alkylating chemotherapy in malignant gliomas.286 
Moreover, it is associated with aggressive tumor behaviour in hepatocellular carcinoma (HCC), 
where NDRG1 suppression induces apoptosis.287 Taken together, these observations suggest an 
important role of Sgk1 in carcinogenesis and in resistance to hormonal therapy and 
chemotherapy.288 
An increased Sgk1 expression has been found in several human tumors, including prostate,289 
colon,290 endometrial,291 and breast cancer,292 non-small cell lung cancer (NSCLC),293 
HCC,294,295 GB.296,297  
Recently, Dattilo et al. reported that Sgk1 controls cell transformation and tumor progression. 
In detail, Sgk1 affects mitotic stability by regulating the expression of RANBP1/RAN; the 
authors demonstrated that Sgk1 fluctuations indirectly modify the maturation of precursor 
micro RNAs (pre-miRNAs) by modulating the equilibrium of the RAN/RANBP1/RANGAP1 
axis, the main regulator of nucleo-cytoplasmic transport. The levels of pre-miRNAs and mature 
miRNAs were assessed by qRT-PCR, in total extracts and after differential nuclear/cytoplasmic 
extraction. The RANBP1 expression is the limiting step in the regulation of Sgk1-SP1 
dependent nuclear export. These results were validated in tumor models and primary human 
fibroblasts and corroborated in tumor-engrafted nude mice. Experiments using RANGTP 
conformational antibodies confirmed that Sgk1, through RANBP1, decreases the level of the 
GTP-bound state of RAN. This novel mechanism may play a role in the epigenomic regulation 
of cell physiology and fate.298  
 
5.3.1 Sgk1 and prostate cancer  
Androgens, through their actions on the androgen receptor (AR), are required for the 
development of the prostate and contribute to the pathological growth dysregulation observed 
in prostate cancers. Consequently, androgen ablation has become an essential component of the 
pharmacotherapy of prostate cancer. Sherk et al. explored the utility of targeting processes 
downstream of AR as an alternate approach for therapy. Specifically, they demonstrate that 
the sgk1 gene is an androgen-regulated target gene in cellular models of prostate cancer. 
Furthermore, functional Sgk1 protein, as determined by the phosphorylation of its target 
Nedd4-2 was also increased with androgen treatment. Importantly, the authors determined that 
RNAi mediated knockdown of Sgk1 expression attenuates androgen-mediated growth of the 
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prostate cancer cell line, LNCaP. Data suggested that the androgen ablation and the inhibition 
of pathways downstream of AR are likely to have therapeutic utility in prostate cancer.299 
Szmulewitz et al. have studied the role of Sgk1 and glucocorticoid receptor (GR) in prostate 
cancer. They reported that Sgk1 expression was strong in 79% of untreated cancers versus 44% 
in androgen-deprived cancers. Conversely, GR expression was present in a higher proportion 
of androgen-deprived versus untreated cancers (78% vs. 38%). High-grade cancers were nearly 
twice as likely to have relatively low Sgk1 staining compared to low-grade cancers (13.8% vs. 
26.5%). Low Sgk1 expression in untreated tumors was associated with increased risk of cancer 
recurrence, 5-year progression-free survival 47.8% versus 72.6%. The Sgk1 expression is high 
in most untreated prostate cancers and declines with androgen deprivation. However, these data 
suggest that relatively low expression of Sgk1 is associated with higher tumor grade and 
increased cancer recurrence, and is a potential indicator of aberrant AR signalling in these 
tumors. GR expression increased with androgen deprivation, potentially providing a 
mechanism for the maintenance of androgen pathway signalling in these tumors.300 
Despite new treatments for castrate-resistant prostate cancer (CRPC), the prognosis of patients 
with CRPC remains bleak due to acquired resistance to AR-directed therapy. The GR and AR 
share several transcriptional targets, including the anti-apoptotic genes Sgk1 and MKP1 dual 
specificity phosphatase 1 (DUSP1). Because GR expression increases in a subset of primary 
PCa following androgen deprivation therapy, Isikbay et al. sought to determine whether GR 
activation can contribute to resistance to AR-directed therapy. They studied several PCa models 
before and following treatment with androgen blockade and found that increased GR expression 
and activity contributed to tumor-promoting PCa cell viability. Increased GR-regulated Sgk1 
expression appears, at least in part, to mediate enhanced PCa cell survival. Therefore, GR and/or 
Sgk1 inhibition may be useful adjuncts to AR blockade for treating CRPC.289 
Recently, Liu et al. investigated the cellular responses to GSK650394 (a competitive Sgk 
inhibitor) treatment and Skg1 silencing (or overexpression) in PCa cell lines and PC3 
xenografts using flow cytometry, western blotting, immunofluorescence, transmission electron 
microscopy and immunohistochemistry. The authors demonstrated that Sgk1 inhibition exhibits 
significant antitumour effects against PCa in vitro and in vivo.301 
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5.3.2 Sgk1 and colon cancer  
Studies on Sgk1 knockout murine models and Sgk1-specific RNA silencing in the RKO human 
colon carcinoma cell line point to this kinase as a central player in colon carcinogenesis and in 
resistance to taxanes. In this regards, Amato et al. investigated the mechanisms through which 
Sgk1 regulates cell proliferation. They adopted a proteomic approach to identify up- or 
downregulated proteins after Sgk1-specific RNA silencing. The authors reported that Sgk1-
dependent regulation of RANBP1 has functional consequences on both mitotic microtubule 
activity and taxol sensitivity of cancer cells.281 In 2015 the same group described the biologic 
effects of a recently identified kinase inhibitor, SI113, characterized by a substituted 
pyrazolo[3,4-d]pyrimidine scaffold, that shows specificity for Sgk1.290 The compound 
possesses antiproliferative activity on colon cancer cells and potentiate cell sensitivity to 
paclitaxel. 
Recently, Liang et al. developed a novel analog of GSK650394, and evaluated its effects on 
colorectal cancer cells (CRC) and tumor growth both in vitro and in vivo. They found that new 
developed GSK650394 analog QGY-5-114-A has lower IC50 value, and treatment with QGY-
5-114-A significantly inhibited CRC cell proliferation and migration in vitro. Besides that, 
QGY-5-114-A is also active in vivo.302 
 
5.3.3 Sgk1 in endometrial problems and cancer  
Sgk1 seems to be involved in unjustified infertility. Indeed, its overexpression in endometrial 
surface epithelium leads to infertility in animal models. On the other hand, during pregnancy, 
endometrial Sgk1 activity shows some protective effects. So further insights in the role of Sgk1 
in infertility and pregnancy are needed.303 
Endometrial cancer is often characterized by PI3K/Akt pathway deregulation. However, the 
role of Sgk1 in endometrial cancer has been poorly investigated. Recently, Conza et al. 
demonstrated that Sgk1 expression is increased in tissue specimens from neoplastic 
endometrium. The Sgk1 inhibitor SI113, previously cited in the context of colon cancer,290 
induced a significant reduction of endometrial cancer cells viability, measured by the (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. This effect was associated to the 
increase of autophagy, as revealed by the increase of the markers LC3B-II and beclin I, detected 
by both immunofluorescence and western blot analysis. SI113 treatment caused also apoptosis 
of endometrial cancer cells, evidenced by the cleavage of the apoptotic markers Poli ADP-
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Ribose Polymerase (PARP) and Caspase-9. Increased expression of Sgk1 in endometrial cancer 
tissues suggests a role for Sgk1 in this type of cancer, as reported for other malignancies.291 
 
5.3.4 Sgk1 and breast cancer  
Some breast cancer cell lines are resistant to Akt inhibitors. It has been reported that increased 
SGK1 expression represents one mechanism predicting Akt inhibitor resistance. For this reason, 
it would be very interesting to explore the therapeutic utility of SGK1 inhibitors or dual 
Akt/SGK1 inhibitors in treating Akt-resistant cancer cells possessing elevated SGK1.292  
Salis et al. investigated the cytotoxic effect of fluvastatin on MCF-7 breast cancer cells and 
define the transcriptional regulation of specific genes during the occurrence of this cytotoxic 
effect. Their data suggested that the antiproliferative effects of Fluvastatin may be related to the 
decreased expression levels of Sgk1 and caveolin-1 (CAV1).304 
Recently, Castel et al. demonstrated that in breast cancer cells resistant to PI3Kα inhibitors, 
targeting Sgk1 restores the antitumoral effects of PI3Ka inhibition.305 
 
5.3.5 Sgk1 and non-small cell lung cancer 
Lung cancer represents one of the most frequent cause of death for cancer. In NSCLC, which 
accounts for the vast majority of this disease, only early detection and treatment, when possible, 
may significantly affect patient’s prognosis. An important role in NSCLC malignancy is 
attributed to the signal transduction pathways involving PI3K, with consequent activation of 
the Akt family factors and of Sgk1. Abbruzzese et al. used qRT-PCR and 
immunohistochemistry (IHC) to determine respectively mRNA and protein expression of Sgk1 
(total and phosphorylated/activated) in archival NSCLC samples from patients with a well-
documented clinical history. The data confirm the oncogenic role of Sgk1, since higher mRNA 
expression appears to be present in patients with worse prognostic indicators. Moreover, the 
significantly higher Sgk1 expression in the squamous cell subtype of NSCLC could indicate 
this factor as central in establishing prognostic/predictive parameters. For this reason, Sgk1 
might be employed in the management of patients with squamous cell lung cancer.293 
Recently, Shi et al., revealed that different dosing strategies of wogonin (5,7-dihydroxy-8-
methoxyflavanon, an O-methylated flavone from Scutellaria baicalensis) can induce different 
outcomes of NSCLC A549 cells, including cell cycle arrest, senescence, and apoptosis. In these 
cells, there are significant differences in Sgk1 oscillation frequency, amplitude, and cycle 
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during different cell responses. Data suggest that the timing and end point of different cell 
responses are associated with the dynamics of Sgk1. Sgk1 protein dynamics may be an 
important part of cellular signalling that directly influences cellular response decisions.306 
 
5.3.6 Sgk1 and hepatocellular carcinoma 
Analysis of gene expression in human HCC cells demonstrates that Sgk1 and Akt1 are equally 
overexpressed when compared with normal human hepatocytes, suggesting that both kinases 
might have roles in hepatocellular dysregulation.294,307  
Talarico et al. demonstrated that SI113, which was previously cited for its activity to induce 
cell death in colon carcinoma and in endometrial cancer cells,290,291 also inhibits tumour growth 
in hepatocarcinoma models in vitro and in vivo. Data show that direct Sgk1 inhibition can be 
effective in hepatic cancer models, either alone or in combination with radiotherapy.295 
Recently, Salis et al. correlated the activity of fluvastatin in reducing human hepatocellular 
carcinoma (Hep3B) cell migration with the expression of some genes, including Sgk1.308 
 
5.3.7 Sgk1 and glioblastoma 
Talarico et al. found that Sgk1 expression is correlated with high-grade glial tumors in a cohort 
of n a cohort of GB patients. Thus, they expanded the analysis of SI113 efficacy in GB cellular 
models and demonstrated that SI113 produces a dramatic decrease in cell viability by inducing 
apoptosis in GB cell lines only, sparing normal mice fibroblasts. They demonstrated that this 
Sgk1 inhibitor enhances the effects of ionizing radiations in the induction of cell death and 
distortion of cell cycle progression. Indeed, SI113 synergizes with oxidative stress, the primary 
mechanism of the radio-dependent tumor killing, and modulates the autophagic response and 
the reticulum stress. Taken together, these data demonstrate the importance of Sgk1 as 
molecular target in cancer therapy and the effectiveness of the SI113-dependent Sgk1 inhibition 
also in GB treatment, where this compound appears effective as a single agent and also in 
combination with radiotherapy.296 
The importance of copper in the metabolism of cancer cells has been widely studied in the last 
years and a clear-cut association between copper levels and cancer deregulation has been 
established. Recently, the same authors studied the combined effects of 64CuCl2 and SI113 on 
human GB cell lines with variable p53 expression. They demonstrate that 64CuCl2 is able to 
induce a time and dose dependent modulation of cell viability in highly malignant gliomas and 
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that the co-treatment with SI113 leads to additive/synergistic effects in terms of cell death. 
Evidence reported in this study underlines the therapeutic potential of the combined treatment 
with SI113 and 64CuCl2 in GB cells.
297 
A subpopulation of cells known as GB stem-like cells (GB-SCs) has the capacity to initiate and 
sustain tumor growth and possess molecular characteristics similar to the parental tumor. GB-
SCs are known to be enriched in hypoxic niches and may contribute to therapeutic resistance. 
Kulkarni et al. identified the genes required for the growth and survival of GB stem cells under 
both normoxic and hypoxic conditions and confirmed Sgk1 as a novel potential drug target for 
GB.309 
 
5.4 Sgk1 and metabolic syndrome 
Hypertension, obesity and susceptibility to develop type II diabetes are hallmarks of metabolic 
syndrome, a condition associated with enhanced morbidity and mortality from cardiovascular 
diseases and very common in developed countries. Sgk1 plays a critical role in the hypertensive 
effects of glucocorticoids.310 In humans a certain variant of the Sgk1 gene is associated with 
moderately enhanced blood pressure and with insulin-sensitivity of blood pressure increase.311 
The same Sgk1 gene variant is associated with an increased body mass index. Accordingly, the 
Sgk1 gene variant is more prevalent in patients with type II diabetes than in individuals without 
family history of diabetes.312 Sgk1 presumably participates in the pathophysiology of the 
metabolic syndrome (Fig. 19). 
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5.4.1 Sgk1 and blood pressure 
Owing to its influence on renal salt excretion and salt intake, Sgk1 is expected to participate in 
blood pressure control.313 Notably, induction of hyperinsulinemia in mice by pretreatment with 
a high-fructose diet sensitizes arterial blood pressure to high-salt intake in wt but not Sgk1-
deficient animals. Thus Sgk1 mediates the salt-sensitizing effect of hyperinsulinism on blood 
pressure.258 
 
5.4.2 Sgk1 in obesity and diabetes 
Sgk1 participates in the development of obesity,258,314 which is well known to cause insulin 
resistance and ultimately impair insulin release leading to type II diabetes. The mechanisms 
involved in the development of insulin resistance in obese individuals include intracellular 
lipid-induced inhibition of insulin-stimulated insulin-receptor substrate (IRS)-1 tyrosine 
phosphorylation, resulting in reduced IRS-1-associated PI3K activity and subsequent decrease 
of insulin-stimulated GLUT4 (glucose transporter type 4) activity.315 
Sgk1 fosters the development of obesity at least partially by stimulation of the Na+ coupled 
glucose transporter SGLT1, which accelerates the intestinal uptake of glucose. The rapid 
intestinal glucose absorption leads to excessive insulin release and fat deposition, with 
Fig. 19. Sgk1 in metabolic syndrome. 
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subsequent decrease of plasma glucose concentration, which triggers repeated glucose uptake 
and thus obesity. Conversely, obesity could be counteracted by inhibitors of SGLT1. In diabetes 
mellitus, the excessive plasma glucose concentrations could, at least in part, upregulate 
intestinal Sgk1 expression and the enhanced Sgk1-dependent stimulation of SGLT1 could 
contribute to the maintenance of obesity.316 
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CHAPTER 6. SFKs and Sgk inhibitors  
 
It has been estimated that a large part of the current research and development budget of the 
pharmaceutical industry is spent on kinases, and particularly on their inhibitors. In fact, in the 
last years, a large number of small molecule inhibitors of different kinases have received FDA 
and EMA approval and are entered into clinical therapy for the treatment of solid and 
haematological malignancies, and many other compounds are being tested both in preclinical 
and clinical trials. All these inhibitors contain at least one nitrogen heterocycle, but belong to 
very different chemical families. Some of these molecules are very promising as drug 
candidates, in particular towards mutated kinases resistant to the first generation inhibitors. 
 
6.1 Classification of TK inhibitors  
The structure of the enzyme-bound inhibitors complex is used for the classification of TK 
inhibitors, which can be divided, on the basis of the protein region they interact with in: 
 kinase domain inhibitors. This group includes the majority of inhibitors and, in turn, is 
constituted by two subtypes of inhibitors (types I and II). Type I and II inhibitors target 
the conserved catalytic cleft and are ATP-competitive. Type I inhibitors target the ATP-
binding site in the active open conformation (DFG-in). These compounds typically 
mimic the interactions of the adenine moiety of ATP, forming from 1 to 3 hydrogen 
bonds with the hinge region of the kinase. Structural studies allowed to divide the region 
occupied by these inhibitors into subregions: the hydrophobic regions I and II, the 
adenine region, the ribose region and the phosphate-binding region (Fig. 20).317 
Structural studies have also revealed that the presence of the deep hydrophobic region I 
plays important roles in the potency and selectivity of small-molecule inhibitors. The 
size and shape of this pocket vary considerably among kinases and depend on the 
activation state of the enzyme.20 Type II inhibitors target the ATP-binding site of the 
enzyme in the inactive closed conformation (DFG-out) and also occupy the adjacent 
hydrophobic pocket I (sometimes defined as allosteric pocket) that is only accessible 
when the kinase is in an inactivated configuration;317  
 allosteric inhibitors, defined as type III and type IV, have been reported for different 
kinases. They bind or the allosteric pocket near the catalytic site (type III) or a different 
allosteric pocket (type IV) far from the catalytic site. They act by inducing 
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conformational changes to modulate enzymatic activity. This type of inhibitors could 
be useful to overcome clinically acquired resistance mutations to the first generation of 
ATP-competitive kinase inhibitors;318  
 covalent inhibitors, defined as type V, bind the catalytic site forming covalent linkages. 
 
 
 
6.2 Src inhibitors 
6.2.1 PH006 
PH006 1 is an ATP-competitive Src inhibitor, which selectively inhibits c-Src with an IC50 of 
0.38 μM among a panel of 14 TKs. PH006 potently reduces c-Src phosphorylation and c-Src-
dependent signal transduction, resulting in inhibition of cell proliferation, migration, and 
invasion in human breast cancer MDA-MB-231 cells and in animal models.319 
 
 
Fig. 20. Schematic representation of subregions in the ATP-binding site. 
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6.2.2 Purine derivatives 
Huang et al. reported some purine derivatives, with potent and selective inhibitory activity 
against c-Src. These inhibitors were discovered by adopting a strategy that integrated focused 
combinatorial library design, virtual screening, chemical synthesis, and bioassays. Thirty-two 
compounds were synthesized and showed inhibitory activity against c-Src with IC50 values 
ranging from 3.14 to 0.02 μM. Among these, compound 2 was identified as the most potent and 
selective agent (IC50 of 20 nM).  
 
 
 
It is 100-fold and 300-fold less potent against Kit and c-Abl, respectively and possesses weak 
inhibitory effect on many other kinases, with IC50 values of above 10 μM.320 
 
6.2.3 KX2-391 
KX2-391 (or KX-01, 3), synthesized by Kinex Pharmaceuticals is one of the few examples of 
type III inhibitors. It is a highly selective non-ATP Src inhibitor with an IC50 value of 20 nM.
321 
KX2-391 inhibits Src catalyzed trans-phosphorylation of Fak, Shc, PXN as well as Src kinase 
autophosphorylation, while it does not have any effect on PDGFR, EGFR, Jak1, Jak2 and Lck. 
It is also found to be an inhibitor of tubulin polymerization through binding to the unique 
conformation on heterodimeric tubulin. In cellular assays, KX2-391 shows growth inhibition 
in NIH3T3/c-Src527F and SYF/c-Src527F cells.321,322 KX2-391 is efficient against a variety of 
solid tumors and many leukaemia types. It inhibits primary tumor growth and suppresses 
metastasis and is currently being tested in 9 clinical trials for different tumors. 
(https://clinicaltrials.gov/ct2/results?cond=&term=KX2-391&cntry1=&state1=&recrs=).323 
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6.2.4 WH-4-124-2 
Moroco et al. discovered a new c-Src inhibitor using a screening on a kinase-biased library with 
the aim of finding selective inhibitors of the Src/Fak complex versus c-Src alone. This approach 
led to the identification an aminopyrimidinyl carbamate compound, WH-4-124-2 4, with 
nanomolar activity for c-Src. Molecular docking studies indicate that WH-4-124-2 may 
preferentially inhibit the DFG-out conformation of the kinase active site.324 
 
 
 
 
6.2.5 Bisubstrate inhibitors 
Bisubstrate or bivalent inhibitor are molecules, which interact both with the ATP and protein 
substrate-binding sites. This kind of inhibition represent a promising strategy for the 
identification of kinase inhibitors with increased potency and selectivity. However, in the 
literature there are few examples where the potency and selectivity advantages are fully 
realized.325–328 
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In this context, Brandvold et al. have developed a modular approach to bisubstrate inhibition 
of TKs. Their strategy utilizes a promiscuous ATP-competitive inhibitor that is then linked to 
a peptide derived from known substrates for the target kinase. They applied our methodology 
to c-Src and identified a highly selective bisubstrate inhibitor for this target, compound 5, which 
showed a Kd value of 0.28 nM. In addition, they developed a novel screening methodology to 
identify non-ATP-competitive inhibitors of c-Src and they discovered one of the most potent 
non-ATP-competitive inhibitor reported to date, compound 6.329 
 
 
 
6.3 Dual Src/Abl inhibitors 
Because of the high structural homology between Src and Abl (another cytoplasmic TK), 
several compounds originally synthesized as Src inhibitors have also been shown to be potent 
Abl inhibitors, useful in overcoming the onset of some types of resistance to drugs that only 
target Bcr-Abl. The excellent clinical results and the observation that dual or multi-targeted 
inhibitors might be better than selective inhibitors encouraged the development of such 
compounds. Indeed, even if a selective inhibitor reduces the risk of undesired effects, multi-
targeted compounds, usually inhibiting different cell pathways or compensatory mechanisms, 
could be more effective than selective inhibitors, especially in tumors, where different 
mechanisms and pathways are generally involved. Several clinical trials on dual Src/Abl 
inhibitors are ongoing or just terminated, while others are recruiting patients both with 
hematological and solid tumors. Some dual Src/Abl inhibitors reported below have been 
approved for the treatment of CML. Notwithstanding the promise shown by these inhibitors, it 
is not clear whether dual Src/Abl inhibitors will provide a viable strategy for the treatment of 
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solid tumors. Indeed, some clinical trials have been disappointing and the future of clinical 
applications is uncertain.330 
 
6.3.1 PP1 and PP2 
The pyrazolo[3,4-d]pyrimidines PP1 7 and PP2 8, by Pfizer, are the first dual inhibitors reported 
in literature,331 and showed IC50 values of ~1 μM and 0.5 μM, respectively, for Src and of 0.3 
μM and 0.5 μM, respectively, for Abl. They have been discovered during a program to find 
specific inhibitors for SFK members; only later, the activity towards Abl was found out, 
opening a new field of research.332 These compounds remain the references for the synthesis of 
new molecules targeting SFKs, even if they have not been developed as therapeutic agents. On 
the other hand, their activities are still investigated as demonstrated by several published 
articles. For example, Kong et al. showed that PP2 efficiently reduced cervical cancer cell 
proliferation, inhibiting both Src and EGFR activity, two factors involved with different roles 
in this type of tumor.333 It has recently discovered PP1 and PP2 involvement in adipogenesis.334 
 
 
 
 
6.3.2 Dasatinib 
Dasatinib, (BMS-354825, SprycelTM, 9), the thiazole-carboxamide derivative synthesized by 
Bristol-Myers Squibb, is the most important dual Src/Abl inhibitor reported to date, being the 
first one used for CML therapy, also useful to overcome several imatinib-resistances, with the 
notable exception of the T315I mutation. Dasatinib is a type I inhibitor and shows IC50 values 
of 0.5 and 1 nM for Src and Abl, respectively.335 Nevertheless, the molecule is not selective for 
these two TKs, inhibiting other TKs, including Kit, PDGFR, EPHA, and the Tec kinase Btk.  
 
Chapter 6. SFKs and Sgk inhibitors 
 68 
Design, synthesis and biological evaluation of pyrazolo-pyrimidines and related isosteres  
as inhibitors of protein kinases, potential antineoplastic agents 
 
 
The importance of the dual Src/Abl inhibition in CML progenitor cells has been investigated 
and confirmed: dasatinib inhibits both Bcr-Abl-dependent and-independent Src activity (in 
contrast to imatinib that inhibited only Bcr-Abl-dependent Src activity), blocking downstream 
signalling pathways in CML progenitor cells: it suppresses CML colony-forming cells and 
long-term culture-initiating cells; nevertheless, it has been pointed out that dasatinib does not 
induce a strong proapoptotic response.336 This very interesting profile of activity, supported by 
a number of preclinical and clinical studies, culminated in 2006 with the approval of dasatinib 
by FDA and successively by EMA for the treatment of CML patients with resistance or 
intolerance to prior therapy, including imatinib mesylate, and more recently as first line CML 
therapy. Then, a large number of publications and clinical trials have been reported, 
investigating the use of dasatinib in both hematologic and solid cancers and confirming the high 
expectations for this compound.  
Lilly et al. showed that dasatinib also induced rapid hematologic and cytogenetic responses in 
adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) 
with resistance or intolerance to imatinib. Several studies investigated the application of 
dasatinib for the treatment of solid tumors and leukemia in children. A pediatric phase I trial 
was performed to evaluate the side effects and the best dose of dasatinib in treating young 
patients with recurrent or refractory solid tumors or Ph+ ALL or CML that did not respond to 
imatinib mesylate.  
Aplenc et al. concluded that disposition and tolerability of dasatinib were similar to those 
observed in adult patients (NCT00316953).337 
 
6.3.3 Bosutinib and derivatives 
Bosutinib 10 (SKI-606), a 7-alkoxy-3-quinolinecarbonitrile derivative, is an orally potent Src 
and Abl inhibitor reported by Boschelli et al. in Wyeth Pharmaceuticals.338 Bosutinib acts with 
an ATP-competitive mechanism, docking inside the active sites of both c-Src and Abl (type I 
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inhibitor). In detail the analysis of bosutinib docked into the active site of c-Src, showed the 
formation of three hydrogen bonds:  
 between the backbone NH of Met341 and N1 of quinoline; 
 between the side chain hydroxyl group of Thr338 and the nitrogen atom of the CN 
group;  
 between the quinoline C2 and the carbonyl oxygen of Glu339.  
The anilino group is positioned in the kinase-specific pocket, while the 4-methylpiperazine is 
oriented towards the solvent region (near the ribose pocket). Computational studies 
demonstrated that the orientation and hydrogen bonding interaction of bosutinib are similar in 
both Src and Abl kinases.339 
 
 
Bosutinib showed an IC50 of 1.2 nM in an enzymatic assay and an IC50 of 100 nM on Src cell 
proliferation.338 SKI-606 was found to be also an Abl kinase inhibitor with an IC50 of 1 nM in 
an Abl enzymatic assay. Moreover, this compound inhibits the growth of three Brc-Abl positive 
leukemia cell lines (K562, KU812 and MEG-01) with IC50 values of 20, 5, 20 nM, respectively. 
Once-daily oral administration of SKI-606 at 100 mg/kg for 5 days caused complete regression 
of large K562 xenografts in nude mice.340 Furthermore, bosutinib significantly decreased the 
proliferation of imatinib-resistant human cell lines, but it showed to be inactive on the T315I 
mutation.341  
The clinical efficacy of bosutinib in CML has been supported by several clinical trials and 
finally, the compound has been approved by FDA and EMA for the treatment of CML patients 
resistant to prior therapies. 
Bosutinib is also investigated for its application in solid tumors, such as breast, prostatic, 
pancreatic, lung and cervical cancers. Phase I data showed that bosutinib is generally well 
tolerated with predominantly gastrointestinal adverse effects (NCT00195260).341  
Recently, Tesar el al. conducted a phase II study to evaluate the efficacy and safety of bosutinib 
in patients with autosomal dominant polycystic kidney disease (ADPKD) which is related to 
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hyperactivation of Src. They demonstrated that bosutinib is able to reduce kidney growth in 
patients with ADPKD showing a good toxicity profile (NCT01233869).342 
 
6.3.4 Saracatinib 
The anilino-quinazoline saracatinib 11, (AZD0530) is a potent, high selective, dual Src/Abl 
inhibitor (type I) by AstraZeneca, active in the low nanomolar range against both the enzymes, 
inhibiting Src and Abl with an IC50 of 2.7 and 30 nM, respectively.
343   
Hennequin et al. reported the crystal structure of AZD0530 complexed with c-Src in the 
inactivated form: the quinazoline ring is located in the adenine region, the tetrahydropyran ring 
fits tightly in the ribose pocket and the chlorobenzodioxole moiety is buried in the hydrophobic 
pocket I. The authors pointed out that interactions with the protein are predominantly 
hydrophobic and are formed with the G-loop in the N-terminal domain (Leu273, Gly274) and 
with Leu393 and Ser345 in the C-terminal domain. 
Saracatinib is orally available, displaying excellent pharmacokinetic parameters in animals, 
with good aqueous solubility and moderate binding to plasma proteins. It inhibits tumor growth 
in a c-Src-transfected 3T3-fibroblast xenograft model in vivo and led to a significant increase 
in animal survival in an orthotopic model of human pancreatic cancer.344 
It has been reported that AZD0530 specifically inhibits the growth of CML and Ph+ ALL cell 
lines, but not the Ph- ALL; probably the antiproliferative effect of saracatinib results from the 
inhibition of both Src and Bcr-Abl kinases, with consequent downregulation of survival 
signalling pathways (STAT5, Erk, PI3K/Akt) in Ph+ cells, resistant or sensitive to imatinib. 
Moreover, AZD0530 inhibits the growth of imatinib-resistant Ba/F3 cells, expressing the 
mutations Y253F and E255K. However, AstraZeneca researchers reported that AZD0530 
activity on Abl is not currently considered sufficient to provide a strong rationale for its clinical 
development in Bcr-Abl-driven leukemias. 
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The compound inhibited tumor growth in different xenografts models. 
Obtained data suggest that the compound may provide clinical benefit by preventing or delaying 
tumor progression through inhibition of tumor cell migration and invasion, rather than by 
reduction of primary tumor growth.343 
AZD0530 inhibits Src activity in different breast cancer cell lines and interestingly suppresses 
the motile and invasive nature of endocrine-resistant breast cancer cells. Moreover, treatment 
of these cells with AZD0530 in combination with tamoxifen results in a reduction of Src and 
Fak activity together with a complete abrogation of their invasive behaviour in vitro.345 
It has been reported that the combination of saracatinib and the ER (Estrogen Receptor) 
blocking fulvestrant, led to arrest of the ER-positive breast cancer cell cycle via p27, an enzyme 
that inhibits cyclin-dependent kinases. This combination slowed xenograft tumor growth in vivo 
more than either of the drugs alone. In contrast, saracatinib monotherapy rapidly gave rise to 
drug resistance, supporting further clinical investigation of this combination for women with 
ER-positive breast cancer.346 
Saracatinib is also active in prostate cancer, it inhibited Src activation in a rapid and dose 
dependent manner in cells and reduced orthotopic DU145 xenograft growth by 45% in mice.347  
Saracatinib is currently being tested in 33 clinical trials, mainly as anticancer agent, used alone 
or in combination with other drugs.  
https://clinicaltrials.gov/ct2/results?cond=&term=saracatinib&cntry1=&state1=&recrs= 
 
6.3.5 Purine derivatives 
ARIAD Pharmaceutical researchers reported AP23464 12 as a dual Src/Abl, ATP-competitive 
inhibitor, potently active on wt Bcr-Abl and on a panel of Bcr-Abl mutants (except T315I) with 
subnanomolar IC50 values.
348 In further optimization, they focused on inhibitors bearing an N-
9 trans double bond and constructed a library of compounds bearing different C2 groups and 
aromatic/heteroaromatic moieties as double bond substituents, obtaining new cyclic and acyclic 
derivatives, which inhibited both Src and Abl at low nanomolar concentrations.  
A very interesting derivative of this series is AP24283 13, C2 unsubstituted, bearing a 
dimethylphosphinoxide substituted aniline in C6 and a vinyl-linked methylindazole group in 
N9; 13 potently inhibits Src and Abl (IC50 values < 0.46 nM) and also the proliferation of cell 
lines driven by Bcr-Abl (K562 and wt Ba/F3) with at least 10-fold greater potency than 
imatinib. Interestingly, despite early concerns about the potential metabolic instability of the 
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vinyl linkage, the compound possessed good pharmacokinetic properties. In fact, the N-linked 
double bond was not rapidly metabolized. The compound is not orally bioavailable, presumably 
due to the rapid bioconjugation of the indazole NH. From a structural point of view, its most 
important feature is the trans vinyl linkage at N9 on the purine core, which projects hydrophobic 
substituents into the selectivity pocket behind the ATP site. Moreover, docking studies 
demonstrated that the vinyl-linked 4-substituted indazole preserves the intricate series of H-
bonds observed in the crystal structure of compound 12, previously reported by the authors. 
These purines bind to the DFG-in conformation of Src and Abl in a manner similar to dasatinib. 
Subsequently, with the aim to obtain purine derivatives targeting the DFG-out conformations 
of Src and Abl, the authors inserted privileged DFG-out targeting structural fragments, i.e. 
diarylamide groups in N9, as suggested by docking studies and by the analysis of previously 
reported crystal structures. The new DFG-out targeted dual Src/Abl inhibitors bear substituents 
only at the 6 and 9 positions of the purine scaffold as opposed to the 2,6,9-trisubstitution present 
in some of the DFG-in binder purines previously reported by the same company. 
 
 
 
In particular, compound AP24226 14, bearing a 4-methyl-N-[4-(trifluoromethyl)pyridine-2-
yl]benzamide on the double bond, a C6 cyclopropylamino group instead of the 
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anilinophenylphosphine substituent (present in previously reported compounds) and C2 
unsubstituted, proved to be the most interesting of the series, inhibiting Src and Abl with IC50 
of 7 and 20 nM, respectively, in enzymatic assays and blocking K562 cell proliferation with 
potency in the low nanomolar range. Once-daily oral administration of AP24226 at a dose of 
10 mg/kg significantly prolonged the survival of mice injected intravenously with wt Bcr-Abl 
expressing Ba/F3 cells. The compound also elicited dose-dependent tumor shrinkage with 
complete tumor regression in mice bearing subcutaneous xenografts of Src Y527F expressing 
NIH 3T3 cells. It inhibited both Src and Abl (with IC50 values of 7.6 and 25 nM respectively) 
and showed antiproliferative activity against a broad panel of Ba/F3 cells expressing clinically 
relevant Bcr-Abl mutants, included the T315I mutation, for which it showed an IC50 of 420 nM. 
Another interesting compound is AP24163 15. In enzymatic assays, it showed an IC50 value of 
478 nM on T315I Abl. It is important to point out that the compound is the first DFG-out 
inhibitor that shows activity, even not high, on the mutant T315I, both in cellular and enzymatic 
assays and that it is active also on Src, differently from the majority of the DFG-out binders. 
Importantly it does not inhibit untransformed Ba/F3 cells up to a concentration of 5 μM. 
The authors performed further studies to explain the biological behaviour of AP24163. In more 
detail they reported the crystal structures of Abl in complex with their inhibitors (both type I 
and type II) and demonstrated that, at least in part, AP24163 activity on Abl T315I can be 
attributed to the incorporation of a less sterically demanding vinyl linkage proximal to the 
increased bulk due to the presence of isoleucine as gatekeeper residue. 
Moreover, a privileged DFG-out binding element (i.e. the N9 diarylamide substituent) is 
necessary to obtain activity on Abl T315I.349 
 
6.3.6 Ponatinib 
Ponatinib, AP24534, 16 is an imidazo[1,2-b]pyridazine synthesized by Ariad Pharmaceuticals 
Inc. researchers as a dual Src/Bcr-Abl kinase inhibitor that potently inhibits Src (IC50 = 4 nM) 
and Bcr-Abl in the low nanomolar range; in particular, it blocks native Abl (IC50 = 0.37 nM), 
Abl T315I (IC50 = 2.0 nM) and other clinically important Abl kinase domain mutants (IC50 = 
0.30-0.44 nM).350,351    
It has been approved by FDA for the treatment of resistant or imatinib-intolerant CML and Ph+ 
ALL patients, especially those harbouring the T315I mutation. It was soon temporarily 
suspended because of the increasing numbers of vascular occlusive events observed in 
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ponatinib-treated patients. On January 2014, the drug was re-authorized by FDA after a revised 
indication statement and a boxed warming, with alerts to the risk associated with its use.352 
 
 
 
Ponatinib activity is probably due to the inflexible acetylene linkage, a very unusual feature; 
the C-C≡C-C structural motif should be chemically and pharmacologically more stable than the 
corresponding N-C≡C-C moiety, present in other derivatives reported by the authors.  
Ponatinib binds Abl and Src in the DFG-out mode; specifically, the imidazo[1,2-b]pyridazine 
core occupies the adenine pocket of the enzyme, the methylphenyl group fits to the hydrophobic 
pocket behind the gatekeeper residue and the trifluoromethylphenyl substituent binds tightly to 
the pocket induced by the DFG-out conformation of the protein.330  
The rigid ethynyl linkage reduces steric repulsions with the bulk of the isoleucine side chain of 
the T315I mutant and is involved in favorable van der Waals interactions with Ile315.  
The piperazine tail confers excellent cellular potency and improved aqueous solubility with 
reduced plasma protein binding, leading to good pharmacokinetic properties following oral 
dosing in rats and mice. Daily oral administration of the compound significantly prolonged 
survival of mice injected intravenously with Bcr-Abl T315I-expressing Ba/F3 cells.330  
Ponatinib is a very promising drug for patients with CML and Ph+ ALL who failed with 
imatinib, dasatinib and nilotinib therapy. This activity may be attributed to its ability to inhibit 
the T315I gatekeeper mutation and also to the fact that it targets a high number of kinases.350 
 
6.3.7 HG7-85-01 
During an iterative synthesis process followed by cellular assays, Weisberg et al. identified 
HG-7-85-01 17 as a multitargeted inhibitor acting also on Abl and Src. In particular, HG-7-85-
01 has been designed as a hybrid between the type I inhibitor dasatinib and the type II inhibitor 
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nilotinib; in fact it presents the aminothiazole hinge-interacting motif of dasatinib connected 
with the N-[3(trifluoromethyl)-phenyl]benzamide substructure of nilotinib, responsible for 
inducing the DFG-out flip, that is characteristic of type II kinase inhibitors. In a high-throughput 
screening on a panel of 353 human kinases (KINOMEscan), HG- 7-85-01 inhibited several 
kinases, including wt Bcr-Abl, T315I Bcr-Abl, Src, c-Kit and PDGFR in the low nanomolar 
range (1-10 nM). HG-7-85-01 potently and selectively inhibited the proliferation of 32D and 
Ba/F3 cells expressing wt Bcr-Abl and Bcr-Abl T315I and of two CML cell lines (K562 and 
KU812F), with IC50 values in the low micromolar range (IC50 = 0.06-0.14 μM). It also inhibited 
the proliferation of Ba/F3 cells transformed with human c-Src (IC50 = 190 nM). It has been 
shown that the inhibition of proliferation is mediated by selective inhibition of kinase activity, 
induction of apoptosis, and inhibition of cell-cycle progression. Very interestingly, an in vivo 
study demonstrated that combined treatment with nilotinib and HG-7-85-01 in mice harboring 
Bcr-Abl-positive leukemia led to a greater suppression of leukemic cell growth in mice than 
either drug alone. Crystallographic studies revealed that HG-7-85-01 binds to Src in the DFG-
out inactive conformation forming the following hydrogen bonds:  
 between the cyclopropyl amide NH and the backbone carbonyl of Met341; 
 between the thiazole N and backbone NH of Tyr340 in the hinge region; 
 between the benzamide carbonyl and the backbone NH of Asp404 of the DFG-motif; 
 between the benzamide NH and side-chain carboxylate of Glu310 from the αC-helix; 
 among the distal piperazine nitrogen (presumably protonated) and the backbone 
carbonyls of Val383 and His384. 
 
 
 
The most notable difference between the binding mode of HG-7-85-01 to Src compared with 
the binding mode of other inhibitors is the lack of a hydrogen bond between HG-7-85-01 and 
the side-chain hydroxyl of the gatekeeper residue Thr338. This loss is probably compensated 
by the formation of the extra hydrogen bond to the backbone of Met341 in the hinge region of 
the kinase. The authors point out that this type II ATP-competitive inhibitor showed the ability 
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to accommodate either a gatekeeper threonine, or a larger hydrophobic amino acid (such as 
isoleucine, methionine, or phenylalanine) without becoming a promiscuous kinase inhibitor. In 
fact, despite this tolerance at the gatekeeper position, HG-7-85-01 is a considerably more 
selective inhibitor than dasatinib.353  
 
6.4 Fyn inhibitors 
As previously reported above, Fyn overexpression or hyperactivation is involved both in brain 
pathologies and in tumors; for these reasons, the search for Fyn inhibitors represents an 
expanding field of study. Selective agents could result useful for their potential clinical 
implications and, in addiction, could be essential for elucidating the biological roles of the 
targeted enzyme. Unfortunately, because of the strict similarity of SFK members in their 
catalytic domains, at the moment no selective Fyn inhibitor has been reported. Indeed, all the 
published inhibitors also act on other members of SFKs, or in some cases also on other TKs. 
The design and the synthesis of inhibitors are frequently based on the study of the structure of 
the target enzyme. Regarding Fyn, only one three-dimensional structure of the kinase domain 
(2DQ7) is present in the Protein Data Bank (PDB); this structure reports the Fyn kinase domain 
bound with the “pan-kinase” inhibitor staurosporine 18 (Fig. 21), but unfortunately shows low 
resolution (2.8 Å).354 In this structure the staurosporine molecule binds to the large groove 
between the N- and C-lobes by means of three hydrogen bonds and some hydrophobic 
interactions. The NH and keto oxygen of lactam ring of the inhibitor make a pair of hydrogen 
bonds with the backbone carbonyl oxygen of Glu343 and the backbone NH of Met345, 
respectively, defined as the hinge region, involved in the ATP-adenine ring binding. Their 
numbers in the crystal structure deposited in the PDB become respectively Glu83 and Met85. 
A third hydrogen bond occurs in the ribose binding pocket of Fyn. The methylamino nitrogen 
of the staurosporine glycosidic ring forms a hydrogen bond with Ala394 (Ala134 in the 
2DQ7).104 
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6.4.1 Pyrazolo[3,4-d]pyrimidines 
The pyrazolo[3,4-d]pyrimidines PP1 (7) and PP2 (8) were previously discussed in “dual Src 
and Abl inhibitors” section. However, they represent the first nanomolar inhibitors of Fyn (IC50 
= 4-6 nM) and they have become lead compounds for the development of new promising 
molecules. In fact, even if the poor biopharmaceutical property of PP1 and its analogs appeared 
to limit their potential use as drugs, their discovery represented a significant advance in the use 
of TK inhibitors in the study of different cell functions.  
 
6.4.2 Purines 
Derivative 19, AP23464 is a purine compound developed by Ariad, which targets c-Src with 
picomolar affinity (450 pM). The compound showed also notable activity against Abl, Fyn, 
Yes, Lck, Lyn, EGFR, FGFR, PDGFR, C-Kit, b-Raf, all kinases characterized by a small 
gatekeeper residue.355,317 
Another 2,6,9-trisubstituted purine, 20 again from Ariad, is a good Src inhibitor, even if it is 
less active than AP23464. The compound is however very interesting because incorporates in 
position 6 a bone-targeting anilino biphosphonate group that confers good affinity to 
hydroxyapatite, used by the authors to evaluate the affinity of the compound to the bone tissue. 
Fig. 21. Schematic representation of the interaction Fyn-staurosporine (2DQ7). 
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It showed an IC50 value of 41 nM for Src and similar value for Fyn, with good selectivity over 
a panel of several kinases.356 
 
   
 
6.4.3 Other pyrimidines and fused-pyrimidines  
Saracatinib (11), cited above, is active on the different members of this TK family in the low 
nanomolar range. Particularly, it inhibits Fyn with an IC50 value of 10 nM in enzymatic assay 
and it was studied in clinical trials for the treatment of AD.357,358 
Quinazoline derivatives have been also reported in the patent literature. For example, Janssen 
Pharmaceutica patented a series of such derivatives as antitumor agents, acting as SFK 
inhibitors. Compound 21 inhibits Fyn with an IC50 value of 6.69 nM.
359 
 
 
 
Moy et al. synthesized a type II inhibitor 22, which exhibits nanomolar inhibitory activity 
against multiple kinases. The compound bears a pyrazolo[1,5-a]pyrimidine core linked to a 
tetramethylpiperidine-1-oxyl radical that, possessing a very slow electronic relaxation time and 
prolonged radical stability, is able to be used in the NMR spectroscopy of the complex with the 
enzyme. This derivative is particularly active on VEGFR2 (IC50 = 3.3 nM), Abl (IC50 = 5 nM) 
Chapter 6. SFKs and Sgk inhibitors 
 79 
Design, synthesis and biological evaluation of pyrazolo-pyrimidines and related isosteres  
as inhibitors of protein kinases, potential antineoplastic agents 
and on SFKs, including Fyn (5 nM). Since the compound is very active and endowed with 
paramagnetic properties, it could represent a useful tool in a screen for non-ATP site binders.360 
 
 
 
In a wide study, Bamborough et al. at GlaxoSmithKline tested more than 500 compounds 
against a panel of over 200 protein kinases chosen to represent kinase inhibitor space. 
Significant results include the identification of hits against new kinases and the expansion of 
the inhibition profiles of several literature compounds. A detailed analysis of the data through 
the use of affinity fingerprints gave interesting indications for biological target selection, the 
choice of tool compounds for target validation, lead discovery and optimization. These results 
show how broad cross-profiling can provide important insights to assist kinase drug discovery. 
Regarding Fyn inhibitors, they found that the bis-anilinopyrimidine 23 potently inhibits also 
Fyn with an IC50 value of 0.4 nM.
361  
 
 
 
Amgen researchers synthesized a series of aminopyrimidine amides as potent, selective 
inhibitors of the lymphocyte specific kinase Lck. The compounds are active not only in Lck 
(IC50 in the subnanomolar range), but inhibit also other SFK members including c-Src and Fyn. 
The most interesting compound is 24 that possessed IC50 values of 3 nM against c-Src and Fyn 
and 0.6 nM against Lck.362 
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6.4.4 Quinolines and analogous derivatives 
Using a high-throughput yeast-based assay, Wyeth Pharmaceuticals researchers identified a 
family of 4-anilinoquinoline-3-carbonitriles as interesting SFK inhibitors. Compounds 25363 
and 26364 showed IC50 of 1.5 and 2.9 μM, respectively, in assays measuring Fyn-dependent cell 
proliferation on rat fibroblasts transfected with activated Fyn.  
 
 
 
Subsequent SAR studies led to the optimization of the substitution of the anilino moiety and to 
the introduction at C7 of a 3-(4-methylpiperazin-1-yl)propoxy group, providing the most 
interesting compound of this chemical class, 10, bosutinib, previously reported as dual Src/Abl 
inhibitor. Regarding Fyn, the compound has an IC50 value of 410 nM for the inhibition of Fyn 
dependent cell proliferation, with a selectivity for Src over Fyn of only about 4 fold in cell based 
assay.338 
4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-cabonitriles derived from structural modifications 
of 4-anilinoquinoline-3-carbonitriles, such as bosutinib, are subnanomolar and selective SFK 
inhibitors. One of the most active compounds, 27, in cell based assays showed an IC50 value of 
37 nM for Src-transformed fibroblasts and of 140 and 420 nM for Lyn- and Fyn-transformed 
fibroblasts, respectively, indicating some activity also on Fyn.365 
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6.4.5 Thieno[2,3-b]pyridine carbonitriles 
Wyeth researchers also synthesized a series of 2-alkenyl thieno[2,3-b]pyridine carbonitriles, 
bearing a thieno-pyridine core isoster to the quinolinic one of bosutinib, as potent inhibitors of 
protein kinase C theta (PKCθ), a serine/threonine kinase espressed in lymphocytes and mast 
cells and involved in the inflammatory response. In the screening to assess compounds 
selectivity, they found that the most active derivatives also inhibited SFKs. Interestingly, 
compound 28 possessed an IC50 value of 25 nM for Fyn and comparable inhibition also versus 
Hck and Lck, while the IC50 value for c-Src was significantly higher (330 nM).
366  
 
 
 
6.4.6 Thiazole-carboxamides 
Dasatinib 9, as reported above, demonstrated to be active towards Abl and many SFKs.  
Li et al. performed an enzymatic and phosphoproteomic characterization of dasatinib action in 
NSCLC and identified nearly 40 different kinase targets of dasatinib. These include SFK 
members (Lyn, Src, Fyn, Lck and Yes), other non-receptor tyrosine kinases (Frk, Brk and Ack) 
and receptor tyrosine kinases (EPH, DDR1 and EGFR). 
Using drug-resistant gatekeeper mutants, they showed that particularly Src and Fyn, as well as 
EGFR, are relevant targets for dasatinib action, getting further insight both in dasatinib action 
and in Fyn involvement in this particular malignancy.367,104 Other thiazole derivatives, in 
particular a series of 2-amino-5-carboxamido-derivatives structurally similar to dasatinib 
previously reported by Bristol-Myers Squibb researchers as Lck inhibitors, are also active on 
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Fyn and on Src: compound 29 showed IC50 values of 35, 71 and 10 nM for Lck, Fyn and Src, 
respectively.368 A family of compounds structurally related to dasatinib, bearing 2-
aminoheteroaryl groups has been reported by the same authors as potent and orally active SFK 
inhibitors. Among these, compound 30 resulted one of the most interesting derivatives, 
possessing IC50 values of 1-2 nM for all SFKs, including Fyn, and excellent selectivity against 
receptor TK and serine/threonine kinases.369  
 
 
 
6.4.7 Different heterocyclic compounds 
Indolinone derivatives represent an important family of TK inhibitors. Particularly 31, SU6656, 
synthesized by Sugen, exhibits selectivity for Src and other members of SFK, including Fyn, 
with IC50 values of 280, 170, 20, 130 nM versus Src, Fyn, Yes and Lyn, respectively.
370 
Other tetrahydroindole-based indolin-2-ones, reported by the same company, bearing an amidic 
substituent in C3 of the tetrahydroindole moiety, showed to be potent SFK inhibitors. 
Regarding Fyn inhibition, the most active compound is 32 that possessed an IC50 value of 50 
nM on Fyn and similar data also on the other SFK members with moderate/good selectivity 
versus VEGFR2 and FGFR1.371 Klic-Kurt et al. have synthesized a series of oxindole 
derivatives active as Fyn, Lyn e Hck inhibitors. Three of these compounds showed a selective 
activity toward Fyn. Docking study was developed to evaluate the receptor-binding 
properties of 33, the most active compound, and it has been demonstrated that this molecule 
inhibits Fyn with an ATP-competitive mechanism.372  
Bristol-Myers Squibb researchers synthesized a series of imidazo[1,5-a]pyrido[3,2-e]pyrazines 
as Lck inhibitors. The compounds were active on all SFK members, being 34, BMS-279700 
the most interesting derivative with IC50 values of 4, 4, 5, 0.5 nM versus Lck, Src, Fyn and Lyn, 
respectively.373 A series of (6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-
yl)phenylamines has been synthesized as inhibitors of PDGFR. One of the most active 
compounds, 35 showed some activity also on SFKs, with an IC50 value of 0.378 μM on 
Fyn.374,104 
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Rottapharm Biothec has patented a series of heterocycles active as Fyn inhibitors. In particular, 
the authors reported that these compounds should be potential drugs for Fyn-mediated diseases. 
Two of these molecules, 36 and 37 showed an inhibitory activity against Fyn with IC50 values 
of 9 nM and 4 nM, respectively.
375 
 
 
 
6.4.8 Phenolic compounds 
Caffeic acid (3,4-dihydroxycinnamic acid) 38 is present in many foods, including coffee. 
Different studies suggested that caffeic acid exerts anticarcinogenic effects, but little is known 
about the underlying molecular mechanisms and specific target proteins. Kang et al. found that 
caffeic acid suppressed UVB-induced skin carcinogenesis by directly inhibiting Fyn kinase and 
downstream MAPKs. They also demonstrated that caffeic acid directly binds with Fyn in a non-
ATP-competitive manner.376,104 
Chapter 6. SFKs and Sgk inhibitors 
 84 
Design, synthesis and biological evaluation of pyrazolo-pyrimidines and related isosteres  
as inhibitors of protein kinases, potential antineoplastic agents 
Rosmarinic acid 39, the ester of caffeic acid with 3,4-dihydroxyphenyl lactic acid, is a natural 
polyphenol antioxidant carboxylic acid found in many Lamiaceae herbs, including Salvia 
officinalis and Rosmarinus officinalis; it is responsible for antiinfective, antiinflammatory and 
antioxidative effects of these plants. It has been reported that the compound showed protective 
effects against Aβ-induced neurotoxicity in PC12 cells and reduced impairment of memory 
induced by Aβ in a mouse model. It also displayed anti-amyloidogenic effects for Alzheimer's 
Aβ fibrils in vitro. Moreover, rosmarinic acid induced apoptosis in Jurkat and peripheral T-
cells.104 Jelić et al., using immunochemical and in silico methods, discovered that rosmarinic 
acid is a Fyn inhibitor. In the homology model of Fyn prepared by the authors two possible 
binding modes of rosmarinic acid were evaluated, i.e. near to or in the ATP-binding site of Fyn 
kinase domain. Indeed, from docking experiments it resulted that rosmarinic acid could bind 
Fyn in the ATP-binding site or in the opposite site from the ATP-binding site. This “binding 
site 2” is in the kinase domain but oriented toward the linker which connects SH2 and the kinase 
domain. Enzyme kinetic experiments revealed that Fyn is inhibited in a linear-mixed non-
competitive mechanism of inhibition by rosmarinic acid, indicating that rosmarinic acid binds 
to the “binding site 2” of Fyn. Inhibition value of Fyn by rosmarinic acid was also reported: the 
compound possessed an IC50 value of 1.3 μM, tested by ELISA method.377 
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Also a number of flavonoids possessed inhibitory activity on Fyn. Dong et al. found that (-)-
epigallocatechin gallate 40 (the ester of epigallocatechin and gallic acid), a flavonoid present in 
green tea and possessing cancer preventive action, inhibited EGF-induced Fyn kinase activity 
and phosphorylation. Very interestingly, it binds to the Fyn-SH2 domain (but not to the SH3 
domain) with a Kd value of 0.367 μM in epidermal mouse skin cells (JB6 C141 cells) and 
inhibits cell transformation promoted by EGFR.378  
Myricetin 41 is a naturally occurring flavonol, present in several foods, including red wine. 
Jung et al. reported that the compound inhibits the formation of non-melanoma skin cancer 
(related to chronic exposure to UVB radiation) in the SKH-1 hairless mouse model. 
Interestingly they demonstrated that myricetin activity is due to Fyn inhibition with subsequent 
attenuation of UVB-induced phosphorylation of MAPKs. Myricetin exerted similar inhibitory 
effects to that of PP2. Mouse skin tumorigenesis data clearly showed that pretreatment with 
myricetin significantly suppressed UVB-induced skin tumor incidence in a dose-dependent 
manner. Docking data suggest that myricetin is docked to the ATP-binding site of Fyn and 
behaves as an ATP-competitive inhibitor. Therapeutic inhibition of Fyn by myricetin might 
provide clinical benefits in skin cancer treatment.379 Delphinidin 42, a major anthocyanidin 
present in red wine and berries, inhibits TNF-alpha induced COX-2 expression by directly 
inhibiting Fyn kinase activity, consequently suppressing the activation of MAPK and PI3K 
pathways. The compound inhibits Fyn kinase activity and directly binds with Fyn in a non ATP-
competitive manner. This effect suggests that delphinidin could contribute to the 
chemopreventive potential of red wine and berries.380,104 
 
6.4.9 Prenylated polyphenol inhibitors 
Prenylated natural compounds have demonstrated different biological effects and several 
studies were developed to evaluate the antioxidant and cytoprotective activity of prenylated 
polyphenol. In vitro studies and cell-based assays showed that kazinol E (43) is able to inhibit 
the Fyn phosphorylation with a similar effect to SU6656 (31). Treatment with 43 also inhibits 
the oxidative stress which is facilitated by Fyn phosphorylation.381 
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6.4.10 Cycloalkane-fused derivatives  
Koo et al. have studied the possibility of cycloalkane-fused dithiolethiones (CDTs), or other 
congeners, to increase antioxidant capacity in association with Fyn inhibition.  
It has been observed that oxidative injury caused by arachidonic acid and iron promoted the 
phosphorylation and the activation of Fyn which was decreased by SNU1A (44) treatment.   
Also SU6656 (31), a Fyn inhibitor, shows a similar effect to SNU1A. These results 
demonstrated that the reduction of Fyn activity protects the mitochondria from oxidative 
injury.382 
 
 
 
6.5 Hck inhibitors 
6.5.1 Pyrazolo[3,4-d]pyrimidines 
One of the first TK inhibitors reported to be also active on Hck is PP1 7, discussed above, which 
shows an IC50 value of 20 nM for this enzyme.
198 Sicheri et al., which determined the crystal 
structure of the autoinhibited form of Hck in complex with PP1, demonstrated that PP1 occupies 
the adenine binding pocket where establishes hydrogen bonds with Thr338, Glu339, Met341 
and Lys295. In detail, the amino group of PP1 is hydrogen bonded to the hydroxyl group of 
Thr338 as well as to the backbone carbonyl of Glu339. The nitrogen at position 5 accepts a 
hydrogen bond from the NH backbone of Met341 and the nitrogen at position 2 interacts with 
Lys295 by a water molecule (W1). In addition to polar interactions, the inhibitor makes 
hydrophobic contacts with Ala293, Leu273 and Val281 in the N lobe as well as with Met341 
and Leu393 in the C lobe. Residues 409-423 form a well-packed hydrophobic pocket, which 
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accommodates the methyl-phenyl group of PP1 and two well-ordered water molecules (W2 and 
W3). Also PP2, 8  that is closely related to PP1, potently inhibits SFKs, with an IC50  value of 
5 nM for Hck, with a similar binding mode.331 
A very active derivative, A-770041 45, shows IC50 values of 0.147, 1.22 and 1.18 μM on Lck, 
Hck and Lyn, respectively, while it is less active on the other SFK members (9.05 μM for Src 
and 44.1 μM for Fyn) and almost inactive on different TKs.  
 
 
 
Maly et al. described a new crosslinking strategy that enables rapid and quantitative profiling 
of protein kinase active sites in cell lysates and cells.383 The authors applied this methodology 
to the SFK members Src and Hck and identified a series of conformation-specific, ATP-
competitive inhibitors that have a distinct preference for the autoinhibited forms of the kinases, 
modulating binding interactions of the regulatory domains SH2 and SH3 of Src and Hck. Even 
though kinase phosphotransfer activity is essential for a huge number of cellular processes, new 
evidence suggests that kinases also have a number of important non-catalytic functions, such 
as protein scaffolding complex formation, allosteric regulation of other enzymes and 
modulation of protein-protein and protein-DNA interactions.384 First, the authors prepared a 
cell-permeable, ATP-competitive photoprobe 69 that covalently modifies the ATP-binding 
sites of protein kinases if exposed to UV light. The probe is formed by three parts:  
 a potent ATP-competitive inhibitor (dasatinib);  
 a photoreactive benzophenone crosslinker;  
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 a hexylchloride tag that selectively labels the active site of the self-labelling protein 
called HaloTag.  
 
 
 
The probe was linked both to activated Src and Hck, and to autoinhibited forms of these kinases 
(i.e. Hck SH3eng and Hck SH2eng, which are inhibited forms of Hck). Then, a number of ATP-
competitive SFK inhibitors were used in photocrosslinking competition assays with 46 and the 
purified SFK constructs. The IC50 values obtained in this test demonstrated that several 
inhibitors, including the pyrazolo[3,4-d]pyrimidines 47, 48 and 49 are more effective 
competitors of the autoinhibited Hck constructs (Hck SH3eng and Hck SH2eng) than of 
activated Hck. These data have direct implications for the pharmacological inhibition of 
multidomain protein kinases, including SFKs. These inhibitors, which stabilize an inactive 
ATP-binding site conformation and promote the intramolecular recruitment of regulatory 
interactions, could prevent several kinase activation signals, providing important insights into 
the regulation of SFKs.383  
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Saito et al. performed a combination of a high-throughput enzyme inhibition assay, in silico 
screening and X-ray crystallography with the aim of identifying small molecule Hck 
inhibitors.385 As a result, the pyrrolopyrimidine derivative 50, RK-20449, was identified by 
screening about 48,000 commercially available small molecules. The compound showed an 
IC50 value of 0.43 nM on Hck in enzymatic assays. The crystal structure of Hck in complex 
with RK-20449 confirms that the compound binds the ATP-binding pocket with the same 
orientation of PP1. The phenoxy moiety established more hydrophobic contacts than the p–
methyl group of PP1 within the hydrophobic pocket formed by Met314, Val323, Leu325, 
Ile336, Ala403, Phe405 and Leu407. In addition to the interactions with the hinge region and 
the hydrophobic pocket, the methyl-piperazine group of the ligand interacts with Asp368. These 
additional contacts are probably responsible for the higher potency of RK-20449 as compared 
to PP1 in the Hck inhibition.385 
 
 
 
Later, another crystal structure of RK-20449 and Hck, similar to Saito’s one, was reported by 
Parker et al.386 
Compound 50 had been already reported by Calderwood et al. with the name of A-419259 as a 
potent SFK inhibitor, with IC50 values in the low nanomolar range.
387 The same authors 
investigated the contribution of Hck to Bcr-Abl signalling. For this purpose, they developed an 
A-419259-resistant mutant of Hck by replacing the gatekeeper residue (Thr338) in the inhibitor 
binding site with a bulkier methionine residue (Hck-T338M). This mutation avoids the inhibitor 
from binding to the modified enzyme. Indeed, the T338M mutation induces dramatic resistance 
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to A-419259, increasing the IC50 value by almost 30-fold from 11.26 nM for wt Hck to 315.6 
nM for the T338M mutant. Expression of Hck-T338M in K562 CML and Bcr-Abl-transformed 
TF-1 myeloid cells blocks the apoptotic and antiproliferative effects of A-419259. These effects 
correlate with persistence of Hck-T338M kinase activity in the presence of the compound. In 
contrast, control cells expressing equivalent levels of wt Hck retain sensitivity to the inhibitor. 
In this study, by pairing an inhibitor-resistant SFK mutant with a broad-spectrum SFK inhibitor, 
it was established new pharmacological evidence for Hck in Bcr-Abl survival signalling.198 
Tintori et al., with the aim of identifying novel Hck inhibitors, applied a structure-based virtual 
screening protocol, which led to the selection of candidates to be tested in a cell-free assay. 
First, an in-house library of pyrazolo[3,4-d]pyrimidine derivatives, which were previously 
shown to be dual Abl and c-Src inhibitors,388,389 was analyzed by docking studies within the 
ATP-binding site of Hck to select the best candidates. Next, the same computational protocol 
was applied to screen a database of commercially available compounds. Some compounds were 
found active against Hck, with the best ones showing inhibitory activity towards isolated Hck 
in the sub-micromolar range. Interestingly, the three identified hit compounds 51 (an in house 
compounds), 52 and 53 were predicted to be able to perfectly fill the enlarged hydrophobic 
cavity, which characterizes the inactive conformation of Hck. Furthermore, selected 
compounds showed an interesting antiproliferative activity profile against the human leukemia 
cell line KU-812, and were found to block HIV-1 replication at sub-toxic concentrations.390  
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6.5.2 Type II inhibitors and photoaffinity probes 
Some compounds designed by Maly et al., based on the central chemical scaffold of imatinib, 
demonstrated a good activity even towards Hck. The most active one is DSA7, 54, which shows 
an enzymatic inhibitory activity with an IC50  value of 2.2 nM.
391  
Continuing their studies on kinases, the authors also prepared active site-directed probes for 
profiling kinases in cells. In detail, aside from compound 54, they identified a number of 
ligands, including 55, which specifically bind kinases in the DFG-out conformation. These 
inhibitors, commonly named type II inhibitors, contain moieties that make contacts similar to 
those of the adenine ring of ATP and hydrophobic substituents that occupy the pocket created 
by the movement of the Phe side chain in the DFG-motif 392. Then, the authors designed and 
synthesized the photoaffinity probes 56 and 57 derived from 54 and 55, respectively. Each 
probe contains three components:  
 a high affinity ligand that selectively recognizes the active sites of protein kinases; 
 a reactive group that is able to covalently modify probe-bound kinases; 
 a photocrosslinking group that allows visualization and/or purification. 
In the probes, 56 and 57 the 3-trifluoromethylphenyl groups of the precursors were replaced 
with 3-trifluoromethylphenyl diazirine moieties, and the para-substituents of the anilino group 
of these inhibitors were functionalized with alkyne tags. The compounds and the probes were 
tested on a panel of kinases, including Hck, on which they showed IC50 values in the low 
nanomolar range.198 
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6.5.3 Compounds inhibiting the Hck-Nef binding 
Because of its role in HIV-1 replication, Nef is an attractive target for drug discovery. Some 
derivatives have been reported to inhibit the binding Hck-Nef. Even if some of these 
compounds do not inhibit the catalytic activity of Hck, their actions are connected to the 
inhibition of Hck functions. In this regard, Smithgall et al. identified compounds that inhibit 
Nef-mediated Hck activity and also block Nef-dependent HIV-1 replication in vitro. The 
inhibitors have been discovered by a HTS (high-throughput screening) that couples Nef to the 
activation of Hck. Using this screen, the 4-amino substituted diphenylfuropyrimidine 58 was 
identified as a strong inhibitor of Nef-dependent Hck activation. This compound also exhibits 
remarkable antiretroviral effects, blocking Nef-dependent HIV replication in cell culture. 
Moreover, structurally related analogs, including 59 and 60, showed similar Nef-dependent 
antiviral activity, allowing to identify the diphenylfuropyrimidine substructure as a new 
scaffold for antiretroviral drug development. These ligands show a remarkable difference in 
both potency and efficacy for Nef-activated Hck versus Hck alone. For example, compound 60 
shows an IC50 value > 30 μM when tested versus Hck alone and of 2.0 μM when tested on Hck 
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in the presence of Nef. This may be because Nef influences the conformation of the ATP-
binding site of Hck and facilitate compound binding.393  
 
 
 
This study further demonstrated that coupling non-catalytic HIV accessory factors with host 
cell target proteins addressable by HTS may open new avenues for the discovery of anti-HIV 
agents. The same authors applied this HTS method on a larger and more diverse chemical 
library of about 220,000 compounds. Using this approach, they identified the phenylpyrazolo 
derivative 61, which blocks Nef-dependent Hck activity in the low micromolar range and is 
also active on several Nef variants. The compound exhibits remarkable selectivity for Hck 
inhibition in the presence of Nef. Indeed, it blocks the kinase activity of the Nef-Hck complex 
in vitro with an IC50 value of 2.8 μM, whereas its activity against Hck alone is > 20 mM. The 
authors determined that the compound directly interacts with Nef, and prevents its dimerization, 
a property implicated in many Nef functions.198  
Compound 62 is a small molecule that was previously shown to block several proline-rich 
motif-SH3 domain binding. Hassan et al. demonstrated that 62 is a non-kinase inhibitor that 
effectively inhibits Nef-Hck binding and blocks Nef-induced skewed Golgi localization of an 
active form of Hck (Hck-P2A), but shows no inhibition on Hck-P2A kinase activity.394 Suzu et 
al. performed further studies on compound 62, confirming that it competes for Nef binding with 
Hck and could be useful as anti-HIV agent, since it reduces Nef-mediated viral infectivity 
enhancement. In detail, this compound inhibits Hck SH3-Nef binding, and the inhibition is 
more evident when Nef was pre-incubated with 62 before its incubation with Hck, indicating 
that both Hck SH3 and 62 directly bind to Nef and that their binding sites overlap. The authors 
underlined that it remains to establish how 62 reduces Nef mediated infectivity enhancement. 
Since both 62 and the Hck SH3 domain bind directly to overlapping domains of Nef and reduce 
viral infectivity, the authors speculated that the inhibitory effects are due to the inhibition of the 
interaction of Nef with host proteins.395 
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6.5.4 Other compounds 
The anilino-quinazoline saracatinib 11 (reported above), potent and highly selective dual 
Src/Abl inhibitor previously discussed, demonstrated to reduce Hck phosphorylation in BV173 
CML cells, at a dose of 0.5 μM.396  
The ATP-based SFK inhibitor 63, AP23846 inhibits Hck with an IC50 value of 0.3 nM, with a 
good selectivity profile when tested on a panel of different kinases. 
Bristol-Myers Squibb synthesized differently substituted 5-carboxamidothiazoles as SFK 
inhibitors, also active on Hck. One of the first members of this family is derivative 64, which 
was shown to be a potent SFK inhibitor, with a good activity towards Hck (IC50 = 310 nM). 
Successively, the same researchers reported another family of thiazole-5-carboxamides, bearing 
2-aminoheteroaryl substituents, as potent and orally active Lck inhibitors. Actually, the most 
active compound, 65, inhibits all the SFK members, including Hck, with similar potency (IC50 
values in the range 1-2 nM).369 
The benzimidazolo-pyrimidine 66, PG-1009247, which was developed as a Lck inhibitor by 
Sabat et al., showed IC50 values of 46 nM towards Hck, together with a good inhibition of IL-
2 production and good aqueous solubility.198,397   
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Narita et al. patented a compound, 67, for the treatment of AML, this molecule resulted a Hck 
inhibitor and stopped the leukemic cells proliferation.398  
 
 
 
Bakuchiol 68 is a meroterpene present in the medicinal plant Psoralea corylifolia, which has 
been traditionally used in China, India, Japan and Korea for the treatment of different upsets. It 
has been recently reported that bakuchiol is able to inhibit EGF in neoplastic cells. Moreover, 
68 reduces the motility of these cells and inhibits anchorage-independent growth of A431 
human epithelial carcinoma cells. Hck, Blk and p38MAPK have been identified as targets of 
this compound.399 
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6.6 Sgk1 inhibitors  
Different studies have shown that some “selective” inhibitors are actually active on many 
kinases, e.g. indolinone derivative SU6656 31, cited above as SFKs inhibitor, has been 
demonstrated to be also an inhibitor of other kinases, including STKs. Compounds CGP57380 
69, D4476 70 and SP600125 71 are inhibitors of several kinases, including Sgk1 (IC50 in the 
micromolar range), unfortunately with low specificity.400 
 
 
 
GlaxoSmithKline has discovered some selective inhibitors of Sgk1, e.g. the pyrrol-pyridine 
GSK650394 72 which has been the first Sgk1 inhibitor, reported in literature by Sherk et al.299 
 
 
 
Initially, it has been observed that 72 was able to stop cell growth in different prostate cancer 
cell lines. More recently 72 has demonstrated, in in vivo assays, to have a synergic effect with 
cisplatin in the treatment of head and neck tumors.401 However, toxicity data have not been 
clearly reported in literature. GSK650394 is equally active on Sgk1 and Sgk2, moreover, is 30 
times more selective for Sgk1 than IGF1R, ROCK (Rho-associated protein kinase), Jak1, Jak3, 
Akt-1, Akt-2, Akt-3, DYRK1A (dual-specificity tyrosine phosphorylation-regulated kinase) 
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and Pdk1, and is 10 times more selective for Sgk1 versus Aurora kinases and JNK (c-Jun N-
terminal kinase).299,402 
EMD638683 73, a benzoylbenzohydrazinic compound, originally described as Sgk1 inhibitor 
for the metabolic syndrome therapy, has been later tested in an experimental model of colon 
cancer. The molecule shows proapoptotic activity and is able to decrease the number of colonic 
tumors following chemical carcinogenesis in Sgk1 knockout mice.403  
The specificity of EMD638683, at 1 µM concentration, has been tested on an extended group 
of kinases. Data showed that EMD638683 have an inhibitory effect also on PKA (cAMP-
dependent protein kinase), MSK1 (mitogen- and stress-activated protein kinase-1), PRK2 
(protein kinase C-related kinase 2), Sgk2 and Sgk3. In vivo tests demonstrated that  
EMD638683 inhibits Sgk1 with an IC50 value of 3 µM.
404 
 
 
 
Sanofi has patented several sulphonamide derivatives of pyrazolo-pyrazines, which showed an 
inhibitory activity of Sgk1. These compounds should be suitable for the treatment of diseases 
involving Sgk1 alteration activity. In particular, compound 74 has shown an IC50 value of 1 nM 
in enzymatic assays on Sgk1.405 
 
 
 
 
 
 
 
Chapter 7. Discussion. Synthesis of pyrazolo[3,4-d]pyrimidines and 
 pyrrolo[2,3-d]pyrimidines as Src inhibitors active towards glioblastoma models  98 
 
Design, synthesis and biological evaluation of pyrazolo-pyrimidines and related isosteres  
as inhibitors of protein kinases, potential antineoplastic agents 
CHAPTER 7. Discussion. Synthesis of pyrazolo[3,4-d]pyrimidines 
and pyrrolo[2,3-d]pyrimidines as Src inhibitors active towards 
glioblastoma models 
 
7.1 Synthesis of pyrazolo[3,4-d]pyrimidines  
7.1.1 Background 
 
 
My research group synthesized a library of 4-amino substituted pyrazolo[3,4-d]pyrimidines 
bearing in N1 an alkylphenyl chain, 75, which resulted active as ATP-competitive Src and Abl 
inhibitors, with IC50 values in the nanomolar range in enzymatic assays and a potent 
antiproliferative and proapoptotic activity toward different cancer cell lines.389,406 Different 
studies demonstrated that Src is overexpressed also in GB,36,407 which led to the decision to 
evaluate if some member of the in house pyrazolo[3,4-d]pyrimidines were active on this 
aggressive brain tumor. In particular, compound SI221, 76, (Ki = 0.62 μM on Src) was able to 
reduce significantly cell viability and migration in GB cell lines without affecting non-tumor 
cells.408 In detail, the antiproliferative activity of SI221 was evaluated in four GB cell lines (U-
373MG, U-87MG, T98G, PRT-HU2) and in non-cancer cells (primary human skin fibroblasts) 
by MTS assay; the compound significantly reduced cell viability in all the GB cell lines (IC50 
values of 17.9, 14.9, 12.5 and 14.3 μM, respectively) and didn’t show toxic effect on normal 
fibroblasts. 
Since SI221 was nearly ineffective on fibroblasts, the IC50 value for these non-tumor cells was 
not determinable at the range of concentrations used. The antiproliferative efficacy of SI221 
was also compared with that of the well-known SFK inhibitor PP2 (8). Data showed that PP2 
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was nearly ineffective on U-373MG, U-87MG, and RT-HU2 cell lines, at the concentrations 
used, and had an efficacy lower than SI221 on T98G (Fig. 22). The analysis of SI221 ability to 
exert a long-term inhibition of GB cell growth, assessed by clonogenic assay, showed that SI221 
treatment dramatically inhibited colony formation in all the GB cell lines. 
 
 
 
 
7.1.1.1 ADME properties  
SI221 was previously subjected to in vitro pharmacokinetic assays in order to preliminarily 
estimate its ADME properties388 and later, another study was conducted in order to predict 
SI221 ability to passively cross the BBB. The parallel artificial membrane permeability 
(PAMPA)-BBB assay showed that SI221 had a good capability to cross the BBB, with an 
extremely low percentage of membrane retention. SI211 showed high SI221 metabolic stability. 
Two main metabolites of the compound have been identified using human liver microsomes 
(HLM) and LC-UV-MS. One is derived from an oxidative dechlorination reaction and the other 
one from an N-dealkylation reaction. However, the two metabolites were present in low 
percentages.388  
 
7.1.2 Project 
Despite its remarkable activities, this compound suffers from a low water solubility, which 
precludes oral administration. Accordingly, a series of more soluble pyrazolo[3,4-d]pyrimidine 
derivatives has been rationally designed and synthesized by my research group, through the 
introduction of polar groups in the solvent-exposed C6 position. This study led to the 
identification of the C4-anilino derivative 77, which showed a beneficial profile in terms of 
both biological activity and ADME properties, being characterized by a high metabolic stability 
Fig. 22. Cell viability analysis by MTS assay in primary human skin 
fibroblasts, U-373MG, U-87MG, T98G, and PRT-HU2 cell lines 72 h 
after treatment with either SI221 or PP2 at the indicated concentrations.  
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(95%), good water solubility (1.7 μg/mL), an efficient membrane permeability (10 x 10−6 cm/s), 
and a potent inhibitory activity against isolated c-Src (Ki= 0.21 μM). 
 
 
 
The X-ray crystal structure of c-Src in complex with compound 77 was obtained in good 
resolution (PDB code: 4O2P) (Fig. 23). 
 
 
 
Fig. 23. A. Inhibitor 77 in complex with wild-type c-Src. B. 
Experimental electron density of chain A and B in complex with 77. 
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The solved structure confirmed the binding mode previously predicted by us for C6-substituted 
derivatives within the ATP-binding site of c-Src. Starting from this crystal structure, a 
computationally driven hit-to-lead optimization primarily guided by results of free energy 
perturbations was successfully conducted, leading to the identification of novel derivatives with 
improved potencies against c-Src.48 On the basis of these interesting results we decided to 
expand the library of pyrazolo[3,4-d]pyrimidines synthesizing compounds 78a-g and to test the 
new molecules on GB cell lines. These compounds bear a 2-chloro-2-phenylethyl or 2-
phenylethyl chain in N1, an anilino or benzylamino substituent in C4 and a thioethylmorpholino 
chain in C6. We decided also to expand the synthesis of this class of derivatives and synthesize 
compounds 79 bearing a [2-(4-methylpiperazin-1-yl)ethyl)]thio chain in C6, in order to 
improve the solubility of these molecules, following the suggestion of molecular modeling 
studies. 
 
 
 
7.1.2.1 Chemistry 
Compounds 78a-g were synthesized by reacting the opportune (2-phenylethyl)hydrazine 
80a,c409,410 with ethyl(ethoxymethylene)cyanoacetate in anhydrous toluene at 80 °C for 8 h, 
affording the ethyl 5-amino-1H-pyrazole-4-carboxylates 81a-c. These intermediates were 
treated with benzoyl isothiocyanate in anhydrous tetrahydrofuran (THF) at reflux for 18 h to 
give compounds 82a-c. These latter were cyclized to pyrazolo[3,4-d]pyrimidinones 83a-c by 
treatment with 2 N NaOH at 100 °C for 10 min, followed by acidification with acetic acid. 
Alkylation with 4-(2-chloroethyl)morpholine at position C6 in the presence of NaOH in 
anhydrous dimethylformamide (DMF) and absolute EtOH at reflux for 6 h gave compounds 
84a-c. These intermediates were treated with the Vilsmeier complex (POCl3/DMF, 1:1) in 
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CHCl3 at reflux for 8 h to obtain the halogenated compounds 85a-c. Finally, the reaction of 
85a-c with amines or anilines in opportune conditions gave the desired compounds 78a-g 
(Scheme 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Preparation of derivatives 78a-g. 
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Compound 86 was synthesized by alkylation at position C6 of intermediate 83c, using 1-(2-
chloroethyl)-4-methylpiperazine, KOH and KI in absolute EtOH at 80 °C for 12 h. The 
synthesis of the halogenated derivative 87 gave several problems and various attempts have 
been performed:compound 86 was treated with the Vilsmeier complex (POCl3/DMF, 1:1) in 
CHCl3 at reflux for 6-12 h, but the reaction formed a mixture of decomposition products; 
 another reaction was performed with POCl3 at 100 °C for 3 h but it didn’t work; 
 an attempt to directly obtain compounds 79 was made by reacting compound 86 
with PCl3 and the opportune aniline or amine in acetonitrile (ACN) at 80 °C for 5 h, 
but also this attempt failed (Scheme 2).  
 
 
 
 
 
 
 
 
Scheme 2. Attempts to obtain compounds 79. 
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Up to date, compounds 79 have not been obtained but other attempts will be made, using other 
chlorinating agents, in order to synthesize these molecules, since modeling studies show that 
compounds 79 may be good Src inhibitors endowed with better ADME properties (in particular 
solubility), than compounds 78. 
 
7.1.2.2 In vitro studies 
The enzymatic assays were performed by the group of Dr. Maga of CNR of Pavia. The cellular 
assays were carried out by the group of Prof. Giordano of Sbarro Institute for Cancer Research 
and Molecular Medicine of Philadelphia. 
Enzymatic Assay on Isolated Src: The kinase inhibition mechanism was studied in a cell free 
assay using recombinant human Src. To evaluate the affinity toward isolated c-Src the study 
was performed in a binding assay in the presence of [γ-32P]ATP and a peptide substrate. Each 
experiment was done in triplicate, and mean values were used for the interpolation. Curve fitting 
was performed with the program GraphPad Prism. Ki values are reported in Table I; compound 
77 was used as a reference.408  
Cell Proliferation/Vitality Assay: up to date, this test was performed only on compound 78e. 
U87-MG cells were treated at concentrations of 78e ranging from 1 to 25 μM. Cell viability was 
evaluated 72 h after treatment by MTS assay to evaluate the IC50 values.  
 
7.1.2.3 ADME studies 
It is well-known that many kinase inhibitors, included our pyrazolo[3,4-d]pyrimidines, are 
generally affected by solubility issues because of their lipophilic nature. Therefore, the early 
evaluation of ADME properties in this field represents a key step to guide the drug candidate 
selection. Accordingly, in vitro ADME studies were conducted on the most potent c-Src 
inhibitor, 78e, in order to early assess its absorption/stability. In particular, aqueous solubility, 
PAMPA, and human liver microsomes (HLM) stability were evaluated (Table I). Overall, 
optimal ADME properties were measured for 78e. Indeed, the metabolic stability was found to 
be higher than 90%. Moreover, the membrane permeability value was of 5.27 x 10−6 cm/s, 
highlighting a sufficient ability to cross the cell membranes. Furthermore, water solubility is 
higher to that of reference 77, with a value of 3.7 μg/mL. 
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 Biological Data In vitro ADME 
Cpd c-Src Ki 
(μM) 
U87-MG 
IC50 (μM) 
Solubility 
(μg/mL) 
PAMPA 
Papp 10-6 
cm/s 
Met. Stab. 
Human (%) 
77 0.24 ND 1.7 10.0 95 
78a NA ND ND ND ND 
78b NA ND ND ND ND 
78c NA ND ND ND ND 
78d NA ND ND ND ND 
78e 0.13 5 3.7 5.27 96 
78f 0.17 ND ND ND ND 
78g 0.29 ND ND ND ND 
 
 
 
7.1.2.4 In vitro biological activity of compound 78e 
Compound 78e, which showed an IC50 value of 5 μM on U87-MG cells and good ADME 
properties, was tested in further in vitro assays. 
Cellular assays 
U87-MG cell lines were treated with compound 78e and dasatinib to evaluate their apoptotic 
and antiproliferative effects (Fig. 24, 25). At 5 µM concentration 78e induces apoptosis in 32% 
of cells and causes a 48% reduction of cell proliferation, showing a slightly higher effect than 
dasatinib (24% and 42%, respectively). 
Compound 78e was also tested on U87-TxR GB cells that express the gene of multi-drug 
resistance. Interestingly, the compound showed an IC50 value of 3.6 µM (Fig. 26). 
Furthermore, the activity of 78e in comparison to radiotherapy (RT) has been evaluated: 78e 
alone is more effective than RT, and the association with RT determines a 73% reduction on 
the number of colonies (78e 1 µM) and an 88% reduction (78e 10 µM) (Fig. 27). 
 
 
 
Table I. Enzymatic activities, cellular activities and ADME properties of compounds 77 and 
78a-g. 
NA = Not Active; ND = Not Determined 
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Fig. 24. Apoptotic effects of compound 78e and dasatinib in U87-MG cell line. 
Fig. 25. Antiproliferative effects of compound 78e and dasatinib in U87-MG cell line. 
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7.1.2.5 In vivo assays 
Xenograft mouse models, inoculated subcutaneously with U87 cells, were treated with 78e at 
50 mg/kg daily for 60 days. 50% tumor reduction (78e alone) and 80% tumor reduction (78e 
combined with RT) were observed. Moreover, mice did not show any sign of distress or weight 
loss (Fig. 28). 
 
Fig. 27. Activity of 78e in comparison to radiotherapy (RT). 
Fig. 26. Effects of compound 78e on U87-TxR glioblastoma cells that 
express the gene of multi-drug resistance. 
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7.1.2.6 Conclusions 
In summary, for the first time an X-ray crystal structure of c-Src in complex with one of our 
patented pyrazolo[3,4-d]pyrimidines, compound 77, was obtained in good resolution. The 
solved structure confirmed the binding mode previously predicted by us for C6-substituted 
derivatives within the ATP-binding site of c-Src. 
Starting from the promising results obtained with compound 77 and other analogs active as Src 
inhibitors, and on the basis of the knowledge that c-Src is overexpressed or hyperactivated in 
GB, we synthesized and tested compounds 78a-g for their inhibitory activity on c-Src. Data 
showed that compounds 78a-d bearing a 2-phenylethyl chain are not active, while compounds 
78e-g bearing a 2-chloro-2-phenylethyl chain in N1 display activity towards Src with Ki values 
in the nanomolar or submicromolar range. Among these, compound 78e, bearing a 3-
bromoaniline substituent in C4, is the most active of the series. Given these interesting results, 
78e has been selected to further in vitro and in vivo assays, in which it shows antiproliferative 
activity on GB cell lines and a 50% tumor reduction in U87 cell xenograft mouse model.  
In conclusion, this study led to the identification of a compound with a good activity in vivo, 
which will be subjected to other studies. Furthermore, we think to design and synthesize other 
78e analogs to expand SAR evaluations. 
 
 
 
Fig. 28. In vivo effects on xenograft mouse models, inoculated with U87 cells. A. Control. B. Mice 
treated with RT. C. Mice treated with 78e alone. D. Mice treated with 78e in association with RT. 
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7.2 Synthesis of pyrrolo[2,3-d]pyrimidines  
7.2.1 Background 
In the last few years, several pyrrolo-pyrimidine derivatives have been either approved by the 
US FDA and in other countries for the treatment of different diseases or are currently in phase 
I/II clinical trials.  
The pyrrolo[2,3-d]pyrimidine scaffold is being extensively investigated and in the last few 
years many of such compounds resulted active as kinase inhibitors. To get further insight in this 
family of compounds, during my PhD course, I wrote two review articles on this topic.411,412 
The Jak kinase inhibitors tofacitinib 88,413 ruxolitinib 89414 and oclacitinib 90415 are approved 
by the US FDA and in other countries for the treatment of rheumatoid arthritis, myelofibrosis 
and canine allergic dermatitis, respectively. AEE788, 91 is a dual EGFR/VEGFR inhibitor416,417 
which was evaluated in phase I/II clinical trials for its activity in patients with recurrent or 
relapsed GB. CCT128930, 92418 and AZD5363, 93419 inhibit Akt, a STK often deregulated in 
tumors, such as GB, breast and gastric cancer. Interestingly, some pyrrolo[2,3-d]pyrimidines 
are also active on Src.420–422 
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7.2.2 Project 
Recently, different libraries of pyrazolo[3,4-d]pyrimidines active as SFK and/or Abl inhibitors 
have been synthesized.389,406 In particular, our in house compounds 94 showed Ki values in the 
nanomolar range both in enzymatic and cell assays and possessed in vivo antitumor activity on 
xenograft models derived from different cell lines.48,102,388  
 
 
 
With the aim of investigating if the deaza-isosteres of in house inhibitors 94 maintain the 
activity on Src both in enzymatic and in cell assays, we decided to synthesize a family of 
pyrrolo[2,3-d]pyrimidines 95a-j, and to test them on Src in enzymatic assays and as 
antiproliferative agents on a specific cancer cell line. Some of compounds 95a-j are strictly 
correlated with their pyrazolo[3,4-d]pyrimidine analogs 94 bearing a C2 thiomethyl group, a 
C4 amino group, and an N7 2-chloro-2-phenylethyl chain, whereas other derivatives are 
substituted in N7 with a benzylic chain, more easily accessible from a synthetic point of view.  
 
 
 
 
7.2.2.1 Chemistry 
The synthesis of compounds 95a-c was performed starting from 6-amino-2-
(methylthio)pyrimidin-4(3H)-one 96, prepared following the procedure reported by Baker and 
coll.423 Compound 96 was cyclized using an aqueous solution of chloroacetaldehyde in a 
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microwave open vessel apparatus to obtain 2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-4-ol 97 
in a higher yield compared to the literature method.424 Then compound 97 was chlorinated in 
C4 to give 4-chloro-2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidine 98 following a literature 
method.424 Intermediate 98 was alkylated in N7 using 2-bromo-1-phenylethanone at room 
temperature in the presence of sodium hydride to obtain compound 99. The latter was reduced 
to 100 with sodium borohydride in a mixture of THF and water. Intermediate 100 was in turn 
treated with the Vilsmeier complex (POCl3/DMF, 1:1) in CH2Cl2 at reflux for 8 h to obtain 
compound 101, bearing a 2-chloro-2-phenyethyl chain in N7. Finally, the reaction of 101 with 
the suitable anilines in absolute EtOH at reflux for 5 h gave the desired compounds 95a,b in 
good yields, while compound 95c was obtained by treating 101 with an excess of benzylamine 
in anhydrous toluene at room temperature for 24 h (Scheme 3). 
 
 
 
  
 
The synthesis of compounds 95d-j was performed starting from 4-chloro-2-(methylthio)-7H-
pyrrolo[2,3-d]pyrimidine 98 which was alkylated in N7 with sodium hydride and 4-
Scheme 3. Preparation of derivatives 95a-c. 
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fluorobenzyl chloride in anhydrous ACN at 50 °C for 2 h to give 4-chloro-7-(4-fluorobenzyl)-
2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidine 102. The compound was treated with the suitable 
amine in dimethylsulfoxide (DMSO) at 90-130 °C to obtain the desired compounds 95d-j 
(Scheme 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.2.2.2 Molecular modeling studies 
A molecular docking protocol has been employed in order to evaluate the ability of the new 
synthesized compounds 95a-j to interact with the ATP-binding site of c-Src kinase. For this 
purpose, the X-ray crystal structure of Src in a complex with a pyrazolo[3,4-d]pyrimidine 
derivative, 77,48 previously cited, was used for computational studies. Compound 95b has been 
scored as the best compound of the series thanks to the presence of the chlorine atom in the 
meta position on the C4 anilino substituent which interacts with Asp404 and Phe405 belonging 
to the DFG-motif.  
Despite the binding poses of compounds 95a-j present common features with those of the ligand 
77, pyrrolo-pyrimidines lack the nitrogen atom which usually interacts with the backbone of 
Met341 in the pyrazolo[3,4-d]pyrimidine analogs. The absence of this important point of 
contact with the hinge region makes our pyrrolo[2,3-d]pyrimidines less active than their 
pyrazolo counterpart, but they open the way to the study of a new promising scaffold which 
could be further optimized (Fig. 29).  
Scheme 4. Preparation of derivatives 95d-j. 
 
 
Chapter 7. Discussion. Synthesis of pyrazolo[3,4-d]pyrimidines and 
 pyrrolo[2,3-d]pyrimidines as Src inhibitors active towards glioblastoma models  113 
 
Design, synthesis and biological evaluation of pyrazolo-pyrimidines and related isosteres  
as inhibitors of protein kinases, potential antineoplastic agents 
 
 
 
7.2.2.3 Enzymatic assays 
All synthesized compounds were initially tested in a cell free assay to evaluate their affinity 
toward isolated c-Src (Table II). In agreement with our computational studies, 95b resulted 
one of the best compounds of our small library of pyrrolo[2,3-d]pyrimidines, showing a good 
inhibitory effect of the enzymatic activity with a Ki value of 0.7 mM. As expected, 95c, which 
has a longer side chain as R substituent, or 95a, which lacks the mCl substituent, reduced the 
activity of the enzyme in a less efficient way than 95b. In the series 95d-j the substitution of 
the 2-chloro-2-phenylethyl side chain in R1 with a shorter 4-fluoro-benzyl group, which lacks 
the bulky Cl atom, gives the possibility to the compounds with a longer R substituent to better 
accommodate into the ATP-binding cleft and go deeply into the HR1. This is confirmed by the 
fact that 95h also showed a good inhibitory activity against c-Src (0.5 mM), despite the presence 
of a long benzyl group as R substituent. In general, for all two series, it was observed that 
increasing the length of the linker at C4 position caused a high reduction of the inhibitory power 
against c-Src (compare 95c with 95b and 95j with 95h). On the other hand, compound 95d, 
bearing a nC4H9 substituent in C4 and a 4-fluoro-benzyl chain in N7, showed to be too small 
for effectively bind the ATP cleft of Src (Ki = 3 µM). The compounds have been also tested on 
Fyn, another member of SFKs, and showed a certain degree of activity, probably due to the 
similarity among the members of this family of kinases. The most active compound is 95i, 
which possesses a Ki value of 2 µM on this enzyme. On the other hand, the compounds resulted 
inactive when tested on a small panel of kinases, including c-Kit, Abl, AblT315I, FLT3 and 
EGFR, demonstrating a degree of selectivity toward c-Src. 
Fig. 29. Best predicted docking poses within the ATP-binding site of 4O2P crystal structure chain B of  
A. compound 95b (orange); B. compound 95h (deep teal); C. compound 95e (pale green). 
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Cpd c-Src Ki 
(μM) 
U87-MG 
IC50 (μM) 
95a 1.5 ± 0.10 27.4 ± 0.16 
95b 0.7 ± 0.20 143.1 ± 0.20 
95c 6.0 ± 0.08 50.7 ± 0.18 
95d 3.0 ± 0.10 20.7 ± 0.38 
95e 2.0 ± 0.30 51.8 ± 0.21 
95f 2.5 ± 0.30 50.7 ± 0.42 
95g 4.7 ± 0.20 20.3 ± 0.15 
95h 0.8 ± 0.06 7.1 ± 0.16 
95i 0.5 ± 0.04 13.3 ± 0.16 
95j 5.0 ± 0.10 46.1 ± 0.08 
 
7.2.2.4 Cytotoxicity assays on U87 GB cell line 
The compounds have been successively tested on U87 GB cell line, that has been chosen 
because of Src involvement in this aggressive tumor.408 The most active compound was 95h, 
with an IC50 value of 7.1 µM after 72h, while the other derivatives resulted less active with IC50 
values higher than 10 µM (Fig. 30). 
 
 
 
 
 
 
  
 
 
Table II. Enzymatic and cellular activities of 
compounds 95a-j. 
Fig. 30. Viability of U87 cell line evaluated at 72h 
is reported for the most active compound 95h and 
for 95b and 95e as examples of less active 
compounds of each series. 
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7.2.2.5 Conclusions 
A series of pyrrolo[2,3-d]pyrimidines has been synthesized and tested for their activity against 
c-Src. Molecular docking revealed our compounds possess profitable features for the binding 
to the catalytic site of c-Src, being able to act as ATP-competitive inhibitors of the enzyme. 
Compounds 95a-j have been tested on a small panel of kinases. As a result, our pyrrolo[2,3-
d]pyrimidines demonstrated a certain selectivity for c-Src, since they did not show any activity 
against other tyrosine kinases, with the only exception of 95i which turned out moderately 
active against Fyn. The compounds have been finally tested in vitro for their cytotoxicity on 
U87 GB cell line and 95h demonstrated to be active with an IC50 value of 7.1 µM. The 
inadequacy of the current therapies against GB raises the need of new drugs able to inhibit the 
growth of this aggressive tumor. In this contest, our pyrrolo[2,3-d]pyrimidine derivatives stand 
as a new promising scaffold with a good potency against GB and therefore worthy of further 
investigation. 
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CHAPTER 8. Discussion. Synthesis of pyrazolo[3,4-d]pyrimidines 
as Fyn inhibitors potentially active towards tauopathies and tumors  
 
8.1 Background 
Because of the involvement of Fyn in different tauopathies and tumors, the design and synthesis 
of Fyn inhibitors represent an expanding field of study.  
Molecular modeling studies, performed in collaboration with the University of Siena, were 
combined with organic synthesis with the aim of developing novel Fyn kinase inhibitors. A 
docking study was employed with the purpose of identifying novel ATP-competitive Fyn 
kinase inhibitors. An in house library of pyrazolo[3,4-d]pyrimidines (consisting of about 300 
structurally characterized compounds with > 98% purity) was chosen for this purpose, using 
the experimental pose of the known active ligands PP1 (7) and PP2 (8), selected as reference 
compounds. 
Pyrazolo[3,4-d]pyrimidines were virtually screened against the active site of Fyn and then 
tested in an enzymatic assay towards this kinase. Derivative 103a emerged as the most active 
compound. On the basis of this finding, a hit to lead optimization process was then initiated and 
new analogs of 103a, among which 103b-e, were synthesized. 
 
 
 
8.1.1 Enzymatic assays  
Compounds 103b-e resulted potent in vitro inhibitors of Fyn, with Ki values in the nanomolar 
range (Table III). These activities were most likely due to the contribution of a substituent in 
the para position of the C3 phenyl ring. 
Furthermore, to assess its specificity against Fyn, the most active compound, 103c, was tested 
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against a panel of kinases including other SFK members (Hck, Blk, Fgr, Fyn, Src, Lck, Lyn, 
and Yes), TKs (Abl, EGFR, IGF1R, Jak2, PDGFR, KDR), as well as some STKs. 103c proved 
to be more efficient against SFK members than towards the other investigated kinases, 
confirming such a compound as a useful probe to study SFK function. Furthermore, a high 
activity against Abl was also detected as expected for the high structural similarity between Abl 
and SFKs. Notably, 103c was not able to significantly inhibit any of the STKs tested (Pim-1, 
mTOR, JNK, CDK5, Chl1). Moreover, the compound did not inhibit the STKs DYRK1a and 
GSK3-β that are implicated in AD.425  
 
 
 
Cpd Fyn Ki (μM)  IC50 ± SD (μM) (K562 cells) 
103a 0.90 ND 
103b 0.36 12.63±14.80 
103c 0.07 0.56±0.01 
103d 0.095 0.30±0.06 
103e 1.485 ND 
     
 
8.1.2 Docking studies  
To rationalize such biological data, docking studies were carried out and the resulting binding 
modes were compared with that previously identified for the hit 103a. All studied compounds 
adopted a pose in line with that of 103a. 
 
8.1.3 Cellular assays 
In AD, Fyn mediates the phosphorylation of Tau protein on the Tyr18 residue, an early and 
crucial step in the disease progression.426 For this reason, the most interesting compounds 
identified during in vitro inhibition assays, 103c and 103d, were also evaluated for their ability 
to inhibit the Fyn mediated phosphorylation of residue Tyr18 of Tau in a cellular model of AD. 
Both compounds significantly affected amyloid beta 1-42 (Aβ42) induced Tyr18-Tau 
phosphorylation with a similar degree and in a dose-dependent manner. Moreover, the 
inhibitory activity of 103c and 103d resulted constant over time, being effective up to 6 h after 
compound administration. 
Table III. Enzymatic and cellular activities of 
compounds 103a-e, toward isolated Fyn. kinase. 
 
ND = not determined 
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The three most active compounds in terms of enzymatic activities, 103b, 103c, and 103d, were 
then evaluated for their antiproliferative activity on the human CML cell line K562 (Table III). 
The tested compounds showed an effective antiproliferative activity that well correlates with 
the Ki values determined by in vitro inhibition assays. The most active compounds, 103c and 
103d, inhibited cell viability with IC50 values in the submicromolar range (Table III). 
Moreover, the antiproliferative effect of 103c and 103d was evaluated through cell cycle 
analysis (Fig. 31).  
 
 
 
 
 
 
 
Notably, the treatment with 0.1 μM 103d induced apoptosis in about 50% of treated K562 cells. 
Compounds 103c and 103d were also tested on early hematopoietic progenitor cells (CD34+) 
from Ph+ CML patients who developed resistance to both imatinib mesylate and dasatinib. The 
percentage of apoptotic CD34+ after imatinib treatment was found equal to control, confirming 
drug resistance. By contrast, 103c and 103d increase apoptotic levels to 35% and 30%, 
respectively. It is important to note that these compounds, when tested in human normal 
fibroblasts, did not show any sign of cell toxicity. 
Furthermore, compounds 103b-e, were also evaluated on two solid human tumor cell lines, 
MDA-MD-231 (human breast cancer cell line) and U87 (human glioblastoma multiforme cell 
line). These cell lines, treated with 103c and 103d, showed similar response profiles, with a 
significant difference in cell growth starting from 20 h after treatment with respect to control 
cells, and a more evident inhibition of cell viability from 70 h after treatment. U87 cells resulted 
particularly responsive to SFKs inhibitors, indeed 103c and 103d showed IC50 values of 0.074 
and 0.78 μM, respectively. Compounds 103c and 103d also showed an effective 
Fig. 31. Analysis of the cell cycle distribution of K562 cells after treatment with increasing 
concentrations of 103c and 103d. 
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antiproliferative activity on the MDA-MD-231 cell line, with IC50s in the low micromolar range 
(3.7 and 8.3 μM for compounds 103c and 103d, respectively). 
 
8.1.4 In vitro ADME studies 
Compounds 103a-e were profiled in vitro for aqueous solubility, liver microsomal stability, and 
membrane permeability (Table IV).  
 
 
 
 
Cpd 
PAMPA Papp X 
10-6 (cm/s) 
PAMPA-BBB 
Papp X 10-6 
(cm/s) 
Water 
solubility (log 
S) 
Metabolic 
stability 
(%) 
Major metabolites 
(%) 
103a 12.8 9.5 -7.26 78.9 
M1=M-36 + 16 (18.0) 
M2=M-35 + 17 (3.0) 
103b 16.5 12.9 -7.75 95.7 
M1=M-36 + 16 (2.8) 
M2=M-35 + 17 (1.4) 
103c 9.9 8.4 -7.60 85.2 
M1=M-36 + 16 (14.7) 
M2=M-35 + 17 
(<0.10) 
103d 10.9 11.5 -7.30 90.0 
M1=M-36 + 16 (2.4) 
M2=M-35 + 17 (5.0) 
M3=M + 16 (2.6) 
103e 17.5 14.5 -8.25 95.6 
M1=M-36 + 16 (2.5) 
M2=M-35 + 17 (0.9) 
M4= -14 (0.8) 
caffeine  1.12    
 
 
The aqueous solubility of these derivatives (-log S ranging from 7.26 to 8.25) was very low and 
constituted a deleterious parameter in terms of a suitable PK profile. However, passive 
membrane permeability in PAMPA assay indicated a good cell permeability for compounds 
103a-e (ranging from 9.9 to 17.5 X 10−6 cm/s). Similarly, all these compounds were found to 
cross the BBB in a specific PAMPA-BBB assay, with good permeability values (ranging from 
8.4 to 14.5 X 10−6 cm/s). Moreover, stability tests disclosed that the compounds showed good 
(from 78.9 to 95.6%) metabolic stability in liver microsomes. Metabolite identification by LC-
Table IV. In vitro ADME profile of compounds 103a-e 
 
Caffeine used as reference compound. 
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MS analysis after incubation in human microsomes indicated the primary metabolites were 
actually the products of an oxidative dehalogenation at the chlorine atom on the N1 side chain, 
as previously reported by us for similar compounds.427    
 
8.2 Project 
On the basis of these interesting results, we decided to extend this family of compounds 103a-
e, resulted the most active in the previous studies, and, during my PhD course, I planned the 
synthesis of compounds 104a-j bearing different aromatic groups in C3. 
 
 
 
8.2.1 Chemistry 
The synthesis of compounds 104a,b started with the reaction between 5-amino-1H-pyrazolo-
4-carbonitrile 106,428 (obtained by reaction of (ethoxymethylene)-malononitrile 105 with 
hydrazine monohydrate) and formamide at 200 °C for 1 h, affording 1H-pyrazolo[3,4-
d]pyrimidin-4-amine 107.428 Reaction of 107 with N-iodosuccinimide (NIS) in dry DMF at 80 
°C for 14 h under nitrogen atmosphere gave 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
108.429 This last was in turn treated with a solution 1 M of tetrabutylammonium fluoride hydrate 
(TBAF) in anhydrous toluene at 70 °C for 1 h. Then 2-bromoacetophenone was added and the 
reaction was stirred at 70 °C for 2 h to afford 2-(4-ammino-3-iodo-1H-pyrazolo[3,4-
d]pyrimidin-1-yl)-1-phenylethanone 109. This last was reduced with NaBH4 in MeOH at 0 °C 
for 3 h to obtain 2-(4-ammino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-phenylethanol 110. 
This intermediate was treated with SOCl2 in anhydrous CH2Cl2 at room temperature for 12 h 
under nitrogen atmosphere to afford 1-(2-chloro-2-phenylethyl)-3-iodo-1H-pyrazolo[3,4-
d]pyrimidin-4-amine 111. The last reaction was performed via a Suzuki cross-coupling in 
which compound 111 was reacted with an excess of the suitable boronic acid in the presence of 
Chapter 8. Discussion. Synthesis of pyrazolo[3,4-d]pyrimidines as Fyn inhibitors  
potentially active towards tauopathies and tumors  121 
 
Design, synthesis and biological evaluation of pyrazolo-pyrimidines and related isosteres  
as inhibitors of protein kinases, potential antineoplastic agents 
Cs2CO3 and Pd(dppf)Cl2 in DME and H2O at 90 °C for 14 h to give compounds 104a,b (Scheme 
5). 
 
 
 
 
 
For the synthesis of compounds 104c,d different attempts have been performed. I tried to 
perform the Suzuki reaction both on intermediate 110 and 111 with 4-nitrophenylboronic acid 
or 5-indolylboronic acid, but no reaction was successful (Scheme 6). Other attempts will be 
performed in the future. 
 
 
 
 
 
 
 
 
Scheme 5. Preparation of derivatives 104a,b. 
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For the synthesis of compounds 104e-j a new approach has been used, since the methodology 
(Suzuki cross-coupling route) used for the previously synthesized compounds 104a,b did not 
have good yields. The new route allowed savings in time and solvents and it is feasible thanks 
to the commercial availability of the acyl chlorides, that are the building blocks used to 
introduce substituents in C3. This new method could be used, in future, to attempt again the 
synthesis of compound 104c, while, unfortunately, for compound 104d, the appropriate acyl 
chloride is not available. The synthesis of 3-substituted pyrazolo[3,4-d]pyrimidines 104e-j  was 
performed using a three component one-pot synthesis.430 Sodium hydride was added in small 
batches to a solution of malononitrile 113 in dry THF precooled at 0-5 °C; after 30 min, the 
suitable acyl chloride was added and the solution stirred at room temperature for 2-12 h. Then 
dimethylsulfate was added, and the solution was refluxed for 3-6 h. Finally, 2-hydrazino-1-
phenylethanol 80c dissolved in dry THF was added and the reaction was carried at reflux for 3-
6 h to afford intermediates 114a-f, purified by flash chromatography. Compounds 114a-f were 
Scheme 6. Attempts to obtain 104c,d. 
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suspended in formamide, and the mixture was heated at 190 °C for 3-4 h to afford the pyrazolo-
pyrimidines 115a-f, that were in turn reacted with thionyl chloride in dry CH2Cl2 at room 
temperature for 12 h under nitrogen atmosphere to give the final compounds 104e-j (Scheme 
7). 
 
 
 
 
 
 
8.2.2 Biology 
All the synthesized compounds 104a,b and 104e-j were tested in a cell-free assay to evaluate 
their affinity towards Fyn (Table V). In particular, compounds 104a and 104g, bearing a p-Br 
and a p-CH2OH substituent, respectively, on the phenyl ring in C3 showed a good in vitro 
inhibitory effect, with Ki values of 1.17 and 1.8 µM, respectively. 
Moreover, 104a,b and 104e-j were evaluated for their antiproliferative activity on different 
human lymphoma cell lines. Although the new compounds resulted less active in the cell-free 
assay than the previously reported derivatives, one of the most effective compounds, 104a 
showed very promising IC50 values as antiproliferative agents on many of the tested cell lines. 
Also derivative 104j, for which the enzymatic data is not available at the moment, is a quite 
potent antiproliferative agent on some of the tested lymphoma cell lines. 
 
 
 
Scheme 7. Preparation of derivatives 104e-j. 
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Cpd 
Ki 
(µM) 
DOHH2 
IC50 
(µM) 
FARAGE 
IC50 (µM) 
SUDHL8 
IC50 
(µM) 
SUDHL6 
IC50 
(µM) 
HUT-78 
IC50 
(µM) 
FEPD 
IC50 
(µM) 
H9 
IC50 
(µM) 
HH 
IC50 
(µM) 
104a 1.8 2.438 7.019 6.14 9.282 4.497 10.84 3.417 2.399 
104b ND ND ND ND ND ND ND ND ND 
104e 9.4 26.58 51.45 18.39 4292 210.9 38.86 38.86 1134 
104f 6.92 27.35 30.9 13.69 38914 1677000 24.89 22.07 43.12 
104g 1.17 10.99 13.61 11.85 45.64 21.05 21.7 21.7 12.44 
104h 2.1 3.677 12.64 11.46 13.17 12.03 20.46 11.61 5.235 
104i 5.75 21.18 22.74 17.47 29.68 58 21.53 24.17 21.08 
104j ND 4.382 29.36 6.717 31.11 9.899 29.15 4.735 48.53 
 
 
8.2.3 Conclusions 
Because of its central role in AD pathogenesis and in various human cancers, Fyn kinase may 
be surely considered an interesting target for therapeutic intervention. In the present work, we 
synthesized a small library of new pyrazolo[3,4-d]pyrimidines bearing substituents in the C3 
position of the heterocyclic scaffold. In particular, a differently decorated phenyl moiety has 
been introduced in this position, maintaining the primary amino group in C4 and the 2-chloro-
2-phenylethyl chain in N1, how the most active compounds obtained in the previous studies. 
Compound 104a, bearing a pCH2OH group on the phenyl ring in C3, showed activity towards 
Fyn with Ki values in the micromolar range and a good activity towards different lymphoma 
cell lines, with IC50 values in the low micromolar range. 
This study gave us the possibility to expand the SAR on this family of pyrazolo[3,4-
d]pyrimidines and to identify a new active compound 104a. At the moment, we are waiting for 
other biological results on 104a,g,h and j that are being tested in an Alzheimer cell model and 
on different cancer cells. 
 
 
 
Table V. Enzymatic and cellular activities of compounds 104a,b and 104e-j toward isolated Fyn kinase. 
 
ND = not determined 
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CHAPTER 9. Discussion. Synthesis of Hck inhibitors as hits for the 
development of antileukemia and anti-HIV agents 
 
9.1 Background 
Several studies demonstrated that high levels of Hck are associated with drug resistance in 
chronic myeloid leukemia and, furthermore, that Hck activity is connected with HIV-1. In this 
context, we employed a structure-based drug design study with the aim of identifying novel 
Hck inhibitors. First, our in house library of pyrazolo[3,4-d]pyrimidines was analyzed to select 
the most promising binders of Hck for biological investigation. Later, the same computational 
methodology was applied to screen a library of commercially available compounds. For this 
aim, we used the crystal structure of Hck in complex with 4-amino-5-(4-methylphenyl)-7-(tert-
butyl)-pyrazolo[3,4-d]pyrimidine (PP1, 7), (2.0 Å resolution, PDB ID: 1QCF).431 
From this in silico screening we identified some derivatives, both from our library and 
commercial, endowed with inhibitory activity against Hck in enzymatic assays. These findings 
demonstrated the suitability of the applied computational approach. The predicted binding 
modes for the best compounds 116 and 117 (Ki = 0.14 and 0.22 µM, respectively) are shown 
in Fig. 32A,B. 
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Evaluation of these Hck inhibitors on the KU-812 leukemia cell line indicated weak activity for 
compound 117 (IC50 = 66.5 ± 11.8 µM), while 116 was almost inactive. On the other hand, 
because Hck was shown to be a novel target for HIV, compound 117 was tested for anti HIV-
1 activity in primary monocyte-derived macrophages (MDM)432,433 and data showed that it is 
able to block viral replication with an EC50 value of 12.9 µM without significant cytotoxicity. 
Furthermore, to assess its specificity against Hck, compound 117 was tested against a panel of 
kinases including other Src family members (Blk, Fgr, Fyn, c-Src, Lck, Lyn, Syk, and Yes), 
TK (Abl and Abl-T315I), as well as some kinases important for HIV-1 (CDK9, Fak, Itk, Jak3, 
Ron).434–438 The percentage of residual enzymatic activity was measured for each kinase by 
using 117 at 10 µM, and the results are listed in Table VI. Remarkably, 117 proved to be more 
efficient against Hck than toward the other investigated kinases, confirming such a compound 
as a useful probe to study Hck function.390 
 
 
 
 
 
 
 
 
Fig. 32. Graphical representation of the predicted binding modes of compounds. A. 116 (orange), B. 117 
(warm pink) in the ATP binding site of Hck.  
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Kinase Residual activity 
Hck(h) 38 
Abl(h) 103 
Abl(T315I)(h) 83 
Blk(h) 100 
CDK9/cyclin T1(h) 104 
cSrc(h) 67 
Fak(h) 101 
Fgr(h) 105 
Fyn(h) 93 
Itk(h) 102 
Jak3(h) 92 
Lck(h) 120 
Lyn(h) 91 
Ron(h) 109 
Syk(h) 77 
Yes(h) 83 
 
 
9.2 Project 
Thanks to this study, we identified two new Hck inhibitors 116, previously synthesized by my 
research group, and the commercial compound 117. These molecules showed an inhibitory 
activity in the low micromolar concentration range in enzymatic assays. Moreover, 117 showed 
antiproliferative activity against the human leukemia cell line KU-812. Derivative 116 resulted 
inactive in cellular assays, maybe because its scarce pharmacokinetics properties. For these 
reasons, during my PhD course, I decided to synthesize a new generation of compound 118a-e 
and 119a-c in order to improve ADME properties and to expand SAR evaluations of these 
molecules. 
 
Table VI. Residual kinase activity after 
treatment with 117, expressed as percent 
of basal kinase activity. 
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Compounds 118a-e, maintain the pyrazolo[3,4-d]pyrimidine scaffold of compound 116, but in 
C6 they bring a hydrophilic N-(2-morpholin-4-ylphenyl)thioacetamidic chain, analogously to 
compound 117. Moreover, several aromatic and aliphatic amino groups were introduced in C4. 
Compounds 119a-c conserve the nucleus of compound 117 and bring different chain in C4 on 
the basis of molecular modeling suggestions.  
 
9.2.1 Chemistry 
The synthesis of compounds 118a-e was performed using a multistep convergent synthesis 
(Scheme 8). First, the intermediate 1-(2-hydroxy-2-phenyl-ethyl)-6-thioxo-1,5,6,7-tetrahydro-
pyrazolo[3,4-d]pyrimidin-4-one 83c and the building-block 120 have been synthesized and then 
these two intermediates were reacted together to obtain the final compounds 118a-e. 
 
 
 
 
The building-block 120 was synthesized reacting 2-morpholinoaniline 121 with bromoacetyl 
chloride in Et2O at room temperature for 4 h (Scheme 9).  
 
 
 
Scheme 8. Simplified retrosynthesis to obtain compounds 118a-e. 
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Afterwards, 83c and 120 were reacted in anhydrous DMF at room temperature in presence of 
K2CO3 to obtain compound 122 with a good yield. This intermediate was treated with the 
Vilsmeier complex (POCl3/DMF, 1:1) in CH2Cl2 to obtain the halogenated compound 123 and 
a little part of compound 118a. The reaction of 123 with an excess of the appropriate amine in 
anhydrous toluene at room temperature for 48 h gave the desired compounds 118b-d with a 
good yield. Compound 118e was synthesized with the reaction between 123 and the 3-
chloroaniline in absolute EtOH at reflux for 5 h (Scheme 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 9. Synthesis of building-block 120. 
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Scheme 10. Synthesis of compounds 118a-e. 
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Compounds 119a-c were synthesized with three different multistep approaches. The three 
methods have in common only the first intermediate of the synthesis, the 2-phenethyl-5,6,7,8-
tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one 125 that was synthesized reacting the 
ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 124 with 3-
phenylpropionitrile in the conditions reported by Pochetti et al. for the synthesis of an analogue 
compound (Scheme 11).439 For the synthesis of compound 119a, the intermediate 125 was 
treated with POCl3 at 80 °C for 8 h to obtain the halogenated compound 4-chloro-2-phenethyl-
5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine 126.440 This last was reacted with glycine 
ethyl ester hydrochloride, in the presence of triethylamine (TEA), in absolute EtOH at reflux 
for 48 h to give the ethyl 2-((2-phenethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-
4-yl)amino)acetate 127 in the same condition suggested by Fujita et. al. to obtain an analogue 
compound.441 The ester derivative was treated with 1 N NaOH in absolute EtOH at room 
temperature for 12 h to obtain the acid 128. Finally, the reaction between compound 128 and 
2-morpholinoaniline in presence of PCl3 in ACN at reflux for 8 h gave the final compound N-
(2-morpholinophenyl)-2-((2-phenethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-
yl)amino)acetamide 119a following the conditions reported by Lupea et al. (Scheme 12).442 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 11. Synthesis of compound 125. 
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For the synthesis of compound 119b a convergent approach was utilized. The intermediate 125 
was reacted with phosphorus pentasulfide (P2S5) in anhydrous 1,4-dioxane at reflux for 8 h, 
under nitrogen atmosphere, to obtain compound 129. At the same time, a Pd catalyzed 
hydrogenation was performed on 1-methyl-4-(2-nitrophenyl)piperazine to obtain 2-(4-
methylpiperazin-1-yl)aniline 130443 which was in turn reacted with bromoacetyl chloride to 
obtain compound 131. Finally, compounds 129 and 131 were reacted in presence of an. K2CO3 
in an. DMF at room temperature, in nitrogen atmosphere for 4 h to obtain the final compound 
N-(2-(4-methylpiperazin-1-yl)phenyl)-2-((2-phenethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3 
-d]pyrimidin-4-yl)thio)acetamide 119b (Scheme 13).  
 
 
 
Scheme 12. Synthesis of compound 119a. 
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Scheme 13. Synthesis of compound 119b. 
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For the synthesis of compound 119c the 3-methyl-1-(2-nitrophenyl)piperazine 132, (obtained 
by reaction between 2-methylpiperazine and 1-bromo-2-nitrobenzene) was treated with di-tert-
butyl dicarbonate (Boc2O), in presence of TEA, in anhydrous CH2Cl2 at room temperature for 
12 h to protect the amine group and the reaction gave compound 133. This last was reduced 
utilizing a Pd catalyzed hydrogenation to obtain compound 134. Derivative 134 was reacted 
with bromoacetyl chloride in anhydrous Et2O at room temperature for 3 h under nitrogen 
atmosphere to obtain tert-butyl 4-(2-(2-bromoacetamido)phenyl)-2-methylpiperazine-1-
carboxylate 135. Finally, compound 135 was reacted with derivative 125 in presence of an. 
K2CO3 in anhydrous DMF at room temperature under nitrogen atmosphere for 12 h to give 
compound 136 which was deprotected using trifluoroacetic acid (TFA) in anhydrous CH2Cl2 at 
room temperature under nitrogen atmosphere to obtain N-(2-(3-methylpiperazin-1-yl)phenyl)-
2-((2-phenethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)thio)acetamide 119c 
(Scheme 14).  
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9.2.2 Conclusions  
In this work, a structure-based computational study led to the identification of new ATP-
competitive Hck inhibitors which show inhibitory activity toward isolated Hck in the sub-
micromolar to low-micromolar concentration range and are endowed with an interesting 
antiproliferative activity profile against the human leukemia cell line KU-812. On the basis of 
these considerable results, during my PhD course I synthesized a second-generation compounds 
with the aim to improve the activity and SAR evaluations of this class of inhibitors. In vitro 
assays on these molecules are in progress. On the basis of their enzymatic activity, compounds 
will be tested on KU-812 cell lines. Enzymatic and cellular assays are in progress.
Scheme 14. Synthesis of compound 119c. 
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CHAPTER 10. Discussion. Synthesis of potential Sgk1 inhibitors  
 
10.1 Background 
As previously reported, Sgk1 has demonstrated to be involved in cancer development and 
resistance, and in the metabolic syndrome. For these reasons, starting from the high homology 
among kinases, an in silico screening was recently conducted, in collaboration with the 
University of Magna Graecia of Catanzaro, to assess if some members of the in house library 
of 4-amino-substituted pyrazolo[3,4-d]pyrimidines, active as Abl and Src inhibitors, were also 
active on Sgk1 and Akt through an ATP competitive mechanism. This study allowed us to 
identify different pyrazolo[3,4-d]pyrimidines endowed with a good activity toward Sgk1. In 
particular, SI113 is effective in inhibiting Sgk1 with an IC50 value of 600 nM and it is selective 
versus Akt288 (Fig. 33).  
 
 
 
 
Fig. 33. Binding mode of SI113 into Sgk1 and Akt. 
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Furthermore, SI113 showed several biological activities: it inhibits tumour growth in vitro and 
in vivo in hepatocarcinoma models,295 it reduces cell proliferation and potentiates paclitaxel 
effect in colon carcinoma cells,290 potentiates radiotherapy effects in human GB multiforme 
cells296 and induces apoptosis in endometrial cancer cells.291 
 
10.2 Project 
On the basis of these interesting results, during my PhD course I started a lead optimization 
study, synthesizing a library of SI113 derivates 137a-i.  
 
 
 
 
10.2.1 Chemistry 
For the synthesis of derivatives 137a-c, the starting compounds 139a-c were prepared from the 
appropriate hydrazino derivatives 138a-c410 and ethyl(ethoxymethylene)cyanoacetate. 
Intermediates 139a-c were reacted with formamide for 8 h at 190 °C to give intermediates 140a-
c in high yields. Treatment of these compounds with an excess of the Vilsmeier complex 
(POCl3/DMF, 1:1) for 8-12 h at reflux in CHCl3 led to the formation of the halogenated 
derivatives 141a-c. They were in turn treated with an excess of the appropriate amine in 
anhydrous toluene at room temperature for 24 h to afford compounds 142a-c, which were 
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finally dehydrohalogenated by refluxing with NaOH for 5 h to give the N1-unsaturated 
derivatives 137a-c (Scheme 15). 
 
 
 
 
 
For the synthesis of the final compound 137d, derivative 83c, reported above, was alkylated on 
the thio group in position 6 with methyl iodide in anhydrous THF at reflux. The 6-thioalkyl 
derivative 143, obtained from this reaction, was in turn treated with the Vilsmeier complex 
(POCl3:DMF, 1:1) in CHCl3 to afford the dihalogenated compound 144, bearing the chlorine 
atom both at the position 4 of the pyrimidine nucleus and on the N1 side chain. Finally, the 
regioselective substitution of the C4 chlorine atom with an excess of morpholine in anhydrous 
toluene at room temperature for 24 h afforded compound 145 in good yields. Compound 145 
was dehydrohalogenated by refluxing with NaOH to give the corresponding N1-unsaturated 
Scheme 15. Synthesis of compounds 169a-c. 
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derivative 146. Then, the oxidation of the latter with 3-chloroperoxybenzoic acid in CHCl3 gave 
the 6-methylsulfonyl derivative 147. Finally, compound 137d was obtained by nucleophilic 
substitution of the methylsulfonyl group of 147 with 2-aminoethanol in DMSO at 90 °C for 12 
h (Scheme 16).  
 
 
 
 
 
 
 
Scheme 16. Synthesis of compound 137d. 
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Compounds 137e,f were synthesized reacting compound 110, previously reported, with 
phenylacetylene in the presence of bis(triphenylphosphine)palladium(II) dichloride, CuI and 
Et3N in THF (Sonogashira reaction conditions) at reflux for 14 h affording compound 148. 
Treatment with SOCl2 in anhydrous CH2Cl2 at room temperature for 12 h under nitrogen 
atmosphere gave compound 137e. Finally, 137e was reacted with NaOH in 96% EtOH at reflux 
for 5 h affording compound 137f (Scheme 17).  
 
 
 
 
The synthesis of compound 137g,h started with the alkylation of the thio-group in position 6 of 
intermediate 83c with 2-bromopropane or bromocyclopentane and an. K2CO3 in anhydrous 
DMF at room temperature for 8 h afforded derivatives 149a,b. The suitable 4-chloro derivatives 
150a,b, obtained by treatment of 149a,b with the Vilsmeier complex (POCl3:DMF, 1:1), were 
reacted with 3-aminophenol in absolute EtOH at reflux for 3-5 h to give the desired compounds 
137g,h in good yields (Scheme 18). 
 
 
 
 
 
Scheme 17. Synthesis of compounds 137e,f. 
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For the synthesis of compound 137i (2-phenylpropyl)hydrazine 151 (prepared from 1-bromo-
2-phenylpropane)410 was reacted with ethyl(ethoxymethylene)cyanoacetate at reflux to afford 
the ethyl 5-amino-1H-pyrazole-4-carboxylate 152. The latter was treated with benzoyl 
isothiocyanate in anhydrous THF at reflux for 12 h to give intermediate 153. This compound 
was then cyclized to the pyrazolo[3,4-d]pyrimidinone 154 by treatment with 2 M NaOH at 100 
°C for 10 min, followed by acidification with acetic acid. Alkylation of the thiocarbonyl group 
of derivative 154 with iodoethane afforded the 6-alkylthio derivative 155, which was in turn 
treated with the Vilsmeier complex (POCl3/DMF, 1:1) in CH2Cl2 at reflux for 6 h to obtain 
compound 156 bearing a chlorine atom in C4. Finally, the reaction of 156 with 3-aminophenol 
in absolute EtOH at reflux for 3-5 h gave the desired compound 137i in good yield (Scheme 
19). 
 
 
 
 
Scheme 18. Synthesis of compounds 137g,h. 
 
c 
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10.3 Conclusions  
In conclusion, a new Sgk1 selective inhibitor has been identified following a multidisciplinary 
approach based on association of molecular modeling, organic synthesis, molecular biology, 
and cell biology skills. Thanks to this study, during my PhD course I synthesized nine potential 
Sgk1 inhibitors. Enzymatic assays of these compounds are in progress and, on the basis of the 
enzymatic results, we will orient future synthesis.
Scheme 19. Synthesis of compound 137i. 
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CHAPTER 11. Discussion. Water solubility enhancement of 
pyrazolo[3,4-d]pyrimidine derivatives via miniaturized polymer-
drug microarrays 
 
11.1 Background 
The pyrazolo[3,4-d]pyrimidines are readily soluble in DMSO and other organic solvents, but 
the limited solubility in water adversely affects their bioavailability and efficacy. Thus, in order 
to avoid the use of toxic organic solvents for in vitro and in vivo tests, several strategies have 
been sought to improve the aqueous solubility and pharmacokinetics of pyrazolo[3,4-
d]pyrimidine derivatives, including formation of complexes with cyclodextrins,444 
encapsulation into liposomes,445 formulation with albumin into nanoparticles446 and synthesis 
of prodrug derivatives.447  However, one of the simplest and most promising methods is to create 
an amorphous solid dispersion where the drug is molecularly dispersed in an inert carrier, 
typically a hydrophilic polymer,448–450  such that the resulting stabilised amorphous drug shows 
a higher water solubility compared to the crystal form.451 
 
11.2 Project 
For these reasons, during the four months that I spent at the School of Pharmacy at the 
University of Nottingham, under the supervision of Prof. Cameron Alexander, I have been 
developing a novel miniaturized printing technology as a screening method to evaluate drug-
polymer compatibility.452 Thanks to this work, I recently published a letter.453   
This new technique represents an efficient method to evaluate pharmaceutical formulations, 
and uses nanogram quantities of materials, which results in about 6 order of magnitude lower 
amount of active pharmaceutical ingredient (API) compared to conventional methods. In this 
regard, routinely analytical techniques such as DSC and XRPD need milligrams of samples to 
evaluate drug−polymer blend stability. 
I performed, for the first time, an efficient inkjet 2D printer-based screening process to identify 
the best polymeric carriers for aqueous solubilization of different pyrazolo[3,4-d]pyrimidine 
derivatives at minimal sample amounts. I demonstrated a complete miniaturized and fast 
analytical route to determine polymer-drug formulations for hit derivatives and validated this 
approach in a standard cytotoxicity screening. The initial work involved selection of five 
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previously reported pyrazolo[3,4-d]pyrimidines, S31,454 SI162,455 SI83,456 SI91,456 SI310102 
and synthesis of one new molecule, compound 137d.  These candidate drugs were combined 
with seven different commercially available hydrophilic polymers selected from those 
commonly used as pharmaceutical excipients.  
 
 
The initial drug and polymer stock solutions were prepared by dissolving the drugs in DMSO 
and the polymers in deionized (DI) water, in order to reach a final concentration of 10 and 1 
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mg/mL, respectively. Initially, a fixed volume of each drug solution was dispensed by a 
piezoelectric printer into a 96-well plate (each drug was formulated at drug/polymer ratio of 
10/90% w/w), used as printer target as well as a storage platform. 
 
 
 
 
 
 
 
DMSO droplets with nominal volumes ranging from 250 to 280 pL were dispensed to obtain a 
final amount of drug of 5-6 µg (Fig. 34i). Subsequently (Fig. 34ii), the different polymer 
solutions were pipetted into the different wells, by using a pipet (drug controls were prepared 
by simply adding water rather than polymer solutions). The well plates were left inside the 
printer cage to allow the DMSO-water mixture to slowly evaporate overnight at room 
temperature (from previous experience, 24 the amount of DMSO dispensed, for each well in 
the present work, evaporates completely in the employed conditions). Subsequently, in order to 
remove any possible residual trapped solvent in the solid formulations, all the well plates were 
moved into a vacuum drying oven at room temperature for two days (Fig. 34ii).  
Generally, to dispense the complete set of 6 pure drugs and to pipet the 7 polymers in triplicate, 
the entire process required around 40 minutes and around 15-18 μg per drug. The drug-polymer 
solid formulations were then analyzed for solubility by resuspension in 200 µL of DI water 
(Fig. 34iii). The quantitative determination of any UV-vis active molecule present in a solution 
(in this case the aromatic pyrazolo[3,4-d]pyrimidine derivatives) can be obtained by 
comparison with its calibration curve plotted using several solutions of known concentration. 
Fig. 34. i. High-throughput dispensing of DMSO drug solutions by an inkjet 2D printer; ii. Sequential 
addition of polymeric aqueous solutions and evaporation of water and DMSO; iii. Resuspension with water 
of the dry solid dispersions; iv. Evaluation of the apparent-solubility of the drugs in water from the 
polymeric matrixes via multiwell-reader UV-vis analysis; and v. MTT-cytotoxicity assessment of the hit 
formulations. 
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However, due to the low solubility and stability in water and DMSO, respectively, of the whole 
set of drugs, it was not possible to determine quantitatively the amount of soluble component. 
To overcome this problem in a pragmatic manner, an analytic screening based on the variation 
of the absorbance between the free drug redissolved in water and its polymer formulation was 
developed (Fig. 34iv). This was achieved by normalizing the absorbance values of the 
drug/polymer dispersions against the absorbance of the free drug in water at the same maximum 
wavelength. The resulting values (ΔA%) were then used to compare the ability of the different 
polymers to solubilize the sample set of drugs. The absorbance (A0) of the drugs alone in water 
was evaluated by using a UV-vis multiwell plate reader, which was able to measure the full 
wavelength-spectrum in the range between 200 to 1000 nm in less than 30 seconds per sample. 
As anticipated, no signals were observed from the presence of water-insoluble drugs. In parallel, 
the absorbance of the aqueous solutions of drug/polymer blends (A) was tested by using the 
absorbance of the polymer solutions as a blank. All the absorbance values were kept in the 
range 0 < A < 1 where the Beer-Lambert law can be considered valid and, thus, the correlation 
between absorbance and drug concentration. 
 
 
 
 
It is apparent from these data that two surfactants (Pluronic F-68 and Tween 80) and the 
amphiphilic copolymer PVPVA showed notably higher ΔA% average values compared to the 
homopolymers (PEG 8000-20000, PVP and HPMC). Based on these data, ΔA% average values 
were calculated and used to rank the polymers in terms of drug apparent-solubility enhancement 
(Fig. 35). This was anticipated, since as a first assumption, the trend in solubilising hydrophobic 
drugs might be attributed to the presence of hydrophobic blocks in Pluronic F-68, Tween 80 
and PVPVA, which could participate in associative interactions with the drugs. However, it is 
also interesting to highlight that, in this first-generation array, PEG chain length also affected 
the overall drug apparent-solubility (Fig. 35), which increased independently from the initial 
water solubility of the drugs.  
After this first analytical screening, on the basis of the ΔA% average results, each drug was 
formulated with two of the best performing polymers from the initial set i.e. PVPVA, Pluronic 
F-68 and Tween 80.  
∆𝐴% =  
∆𝐴
𝐴0
× 100 =
(𝐴 − 𝐴0)
𝐴0
× 100 
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The anti-proliferative activity of the pyrazolo[3,4-d]pyrimidine derivatives alone or in 
combination with polymers was assessed against a human lung adenocarcinoma cell line 
(A549), due to its high cytosolic content of tyrosine and serine-threonine kinases (Fig. 34v). As 
shown in Fig. 36, none of the drugs formulated as aqueous suspensions was cytotoxic after 24 
h treatment. Before screening the drug-polymer formulations, all the polymers were also tested 
at varying concentrations against the A549 cell line to evaluate their cytotoxicity and identify 
the least toxic polymer concentration, in order to avoid any effects of the polymer carrier on the 
final formulation killing activity. 
The data showed that the polymers were essentially non-toxic to A549 cells up to concentrations 
of 200 µg/mL. Subsequent solid dispersion cytotoxicity assays were therefore performed at 
polymer carrier concentrations below the threshold level of 200 µg/mL. 
Fig. 35. ΔA% average of polymers ranked according to their water 
apparent-solubility enhancement (high ΔA% is related a high drug 
water solubility). Error bars show standard deviation (n = 3). 
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Printing of drugs into polymer dispersions at a level of 90% polymer and assays of these 
formulations with A549 cells showed growth inhibition of ~ 20-50% (Fig. 37), and more than 
the drugs alone at 30 µg/mL. These data also showed that compounds S31 and SI162 were the 
most active drug candidates (Fig. 37). This formulation process was also used to identify a pair 
of drugs to evaluate the combined effect of two more potent active principles in a single 
polymeric blend; thus S31 (15 µg/mL) and SI162 (15 µg/mL) were formulated with PVPVA 
(drugs/polymer ratio constant at 10/90% w/w). As shown in Fig. 37 (red bar) a synergic effect 
of the combined formulation (S31 + SI162-PVPVA) was observed with respect to the single 
ones. In particular, a further 15-20% growth inhibition was reached (~60% of killing effect). 
This experimental evidence may facilitate both the future adoption of drug combinations in the 
field of kinase inhibitors and dosage of drugs with different nature and/or mechanisms of action 
in one single formulation. To further validate this methodology, traditional cell viability assays 
using DMSO drug solutions were also performed; formulations gave similar or more accurate 
cytotoxicity results than that obtained with DMSO. These latter results not only support the 
analytical evidence of an improved drug water solubility after formulation but also support the 
enhancement of availability conferred by solid dispersions. 
 
 
Fig. 36. Cytotoxicity of pure drug solutions (30 µg/mL) against human lung 
adenocarcinoma cell line (A549). Due to the low solubility of the whole set 
of drugs, no antiproliferative activity was shown in the high-throughput 
MTT assay adopted. Error bars show standard deviation (n = 4). 
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In an attempt to shed some lights upon the interactions established between drug and polymer, 
some preliminary experiments were carried out using dynamic light scattering (DLS). This was 
carried out on just the most powerful single drug formulation (S31-PVPVA) resulting from the 
biological screening reported above (Fig. 37). PVPVA showed a poor correlation curve 
indicating a highly disperse preparation, and the resulting DLS traces could be interpreted as a 
mixture of small and large polymer micelles. A similar poor correlation curve accompanied by 
the presence of big aggregates was observed for the free form of S31 as would be expected 
from its low solubility. On the other hand, the S31-PVPVA formulation showed a single 
unimodal peak in the range of 1000 nm with a discrete dispersion (PDI of 0.4). As the only peak 
in this sample, this must be a mixture of both polymer and drug, hinting at a degree of 
interaction between the hydrophilic polymeric matrix and the hydrophobic drug (Fig. 38). The 
self-assembling of the S31-PVPVA blend into nanomicro structures might explain not only the 
higher apparent-solubility of the formulation, compared to the free drug, but also the enhanced 
biological activity, due to a higher bioavailability than the free drug. This result provides 
preliminary support for the effectiveness of the new method. However, a more rigorous study 
Fig. 37. Cytotoxicity of selected prescreened formulations. The final drug concentration reached in the 
formulations was around 30 µg/mL, equal to a loading in the polymer matrix of 10% w/w. As shown in Fig., 
polymers alone showed no adverse activity against the selected cell type. Red bar: cytotoxicity of S31 + SI162-
PVPVA at 30 µg/mL in drugs (15 µg/mL, 15 µg/mL of S31 + SI162). Error bars show standard deviation (n 
= 4). 
 
Chapter 11. Discussion. Water solubility enhancement of pyrazolo[3,4-d]pyrimidine 
derivatives via miniaturized polymer-drug microarrays 150 
 
Design, synthesis and biological evaluation of pyrazolo-pyrimidines and related isosteres  
as inhibitors of protein kinases, potential antineoplastic agents 
would be needed to prove the exact nature of polymer-drug interactions and the features of any 
structure in particles of the final blend. 
 
  
 
 
 
It is worth remarking that the drugs alone have a really low water solubility, which reflects the 
neglectable availability in water (Fig. 36), while, by formulating the pyrazolo[3,4-d]pyrimidine 
derivatives as reported in the present method, the molecules become more soluble and can 
support a concentration around 30 μg/mL for the cell assays.455 
  
11.3 Conclusions  
In the present work, I have developed a new miniaturized screening process, based on an inkjet 
printing technologies, able to identify the best formulation to enhance the apparent water 
solubility of some pyrazolo[3,4-d]pyrimidine derivatives, active as kinase inhibitors. From the 
ΔA% as a single value for each combination drug-polymer or a ΔA% average value to rank 
the apparent-solubility enhancement, I have identified the best polymers able to solubilize the 
pyrazolo[3,4-d]pyrimidines in water. The low quantity of drugs used in the present experiments 
is one of the strongest points of the reported method. In fact, I have used in total less than 20 
μg for each drug. This is crucial since the synthesis of these molecules encompasses difficult 
and timeconsuming synthetic steps with long workup procedures and high organic solvent 
Fig. 38. DLS traces in DI water of untreated S31 (red), PVPVA (green) and 
S31-PVPVA (blue) as a formulation. Light scattering measurements were 
collected on suspensions prepared with a final concentration of 0.5 mg/mL 
in drug (concentration adopted due to instrumental detection limits. 
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consumption. Moreover, with this strategy, it is possible to carry out biological tests for these 
drugs without direct drug dissolution in DMSO as required in previous work.457 This method 
offers a powerful strategy to overcome the problem of the low solubility of this class of 
compounds and/or other systems involving different poorly water-soluble drugs. As a 
consequence, formulations can be readily identified for biological (in vitro-in vivo) studies and 
as a starting point for more detailed formulation work.  
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CHAPTER 12. Experimental section 
 
Starting materials were purchased from Aldrich-Italia (Milan, Italy) and Alfa Aesar 
(Lancashire, UK). Melting points were determined with a Büchi 530 apparatus and are 
uncorrected. IR spectra were measured in KBr with a Perkin-Elmer 398 spectrophotometer. 1H 
NMR spectra were recorded in a (CD3)2SO or CDCl3 solution on a Varian Gemini 200 (200 
MHz) instrument. Chemical shifts are reported as δ (ppm) relative to TMS as the internal 
standard, J in Hz. 1H patterns are described using the following abbreviations: s = singlet, d = 
doublet, dd = doublet of doublets, dt = doublet of triplets, t = triplet, q = quartet, quint = quintet, 
sex = sextet, sept = septet, m = multiplet, and br = broad. TLC was carried out using Merck 
TLC plates silica gel 60 F254. Chromatographic purifications were performed on columns 
packed with silica gel 60 Å, 220-440 mesh particle size, 35-75 µM, or using, for flash technique, 
the instrument IsoleraTM One Biotage that works with cartridge Biotage® SNAP Ultra packed 
with Biotage® HP-Sphere™ spherical silica. Mass spectra (MS) data were obtained using an 
Agilent 1100 LC/MSD VL system (G1946C) with a 0.4 mL/min flow rate using a binary solvent 
system of 95:5 methanol/water. UV detection was monitored at 254 nm. MS were acquired in 
positive and negative modes, scanning over the mass range 50-1500. The following ion source 
parameters were used: drying gas flow, 9 mL/min; nebulizer pressure, 40 psig; drying gas 
temperature, 350 °C. Analyses for C, H, N, and S were within ± 0.4% of the theoretical value. 
All target compounds possessed a purity of ≥ 95% as verified by elemental analyses by 
comparison with the theoretical values. 
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General procedure for the synthesis of compounds 81a-c. 
 
 
 
The appropriate hydrazine derivatives 80a-c (20 mmol) were added to a solution of 
ethyl(ethoxymethylene)cyanoacetate (3.38 g, 20 mmol) in anhydrous toluene (20 mL) and the 
mixture was heated at 80 °C for 8 h. The solution was concentrated under reduced pressure to 
half of the volume and allowed to cool to room temperature. The yellow pale solid was filtered 
and recrystallized from toluene to afford 81a-c as white solids. 
 
Ethyl 5-amino-1-phenylethyl-1H-pyrazole-4-carboxylate 81a. 
 
Yield: 1.55 g, 60%  
Mp: 85-86 °C 
MW = 259.30 
Anal. calcd for C14H17N3O2, C 64.85, H 6.61, N 16.21, found C 64.92, H 6.80, N 16.02.                             
1H NMR ((CD3)2SO): δ 1.25 (t, J = 7.2, 3H, CH3), 3.02 (t, J = 6.8, 2H, CH2Ar), 4.03 (t, J = 6.8, 
2H, CH2N), 4.13 (q, J = 7.2, 2H, CH2O), 4.30 (br s, 2H, NH2 disappears with D2O), 6.90-7.28 
(m, 5H Ar), 7.59 (s, 1H, H-3). 
IR (KBr): cm-1 3428, 3296 (NH2), 1685 (CO). 
MS: m/z 259 [M+1]+. 
 
Ethyl 5-amino-1-(4-fluorophenethyl)-1H-pyrazole-4-carboxylate 81b.  
 
Yield: 4.33 g, 78% 
Mp: 129-131 °C 
MW = 277.29 
Anal. calcd for C14H16N3O2, C 60.64, H 5.82, N 15.15, found C 60.44, H 5.92, N 15.32.                                                                       
1H NMR ((CD3)2SO): δ 1.27 (t, J = 7.2 Hz, 3H, CH3), 3.05 (t, J = 6.8 Hz, 2H, CH2Ar), 4.05 (t, 
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J = 6.8 Hz, 2H, CH2N), 4.16 (q, J = 7.2 Hz, 2H, CH2O), 4.36 (s all., 2H, NH2 disappears with 
D2O), 6.94-7.35 (m, 4H Ar), 7.65 (s, 1H, H-3).  
IR (KBr): cm-1 3426, 3293 (NH2), 1678 (CO). 
 
Ethyl-5-amino-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-4-carboxylate 81c. 
 
Yield: 4.40 g, 80% 
Mp: 136-137 °C 
MW = 275.30 
Anal. calcd for C14H17N3O3, C 61.08, H 6.22, N 15.26, found C 61.07, H 6.22, N 15.31.                                                                                                      
1H NMR ((CD3)2SO): δ 1.33 (t, J = 7.0, 3H, CH3), 3.53 (m, 1H, OH, disappears with D2O), 
3.92-4.20 (m, 2H, CH2N), 4.25 (q, J = 7.0, 2H, CH2O), 5.02-5.13 (m, 1H, CHOH), 5.30 (br s, 
2H, NH2, disappears with D2O), 7.23-7.42 (m, 5H Ar), 7.58 (s, 1H, H-3). 
IR (KBr): cm-1 3470, 3330 (NH2), 3300-3000 (OH), 1685 (CO).  
General procedure for the synthesis of compounds 82a-c. 
 
A suspension of the appropriate derivatives 81a-c (10 mmol) and benzoyl isothiocyanate (1.7 
g, 11 mmol) in anhydrous THF (20 mL) was refluxed for 18 h. The solvent was evaporated 
under reduced pressure, and the crude was crystallized as a white solid by adding Et2O (30 mL). 
 
Ethyl 5-{[(benzoylamino)carbonothioyl]amino}-1-(2-phenylethyl)-1H-pyrazole-4-
carboxylate 82a. 
 
Yield: 2.53 g, 60% 
Mp: 168-169 °C 
MW = 422.50 
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Anal. calcd for C22H22N4O3S, C 62.54, H 5.25, N 13.26, S 7.59, found C 62.50, H 5.41, N 13.02, 
S 7.50.                                                                                                                          
1H NMR ((CD3)2SO): δ (t, J = 7.2, 3H, CH3), 3.18 (t, J = 7.0, 2H, CH2Ar), 4.10-4.30 (m, 4H, 
CH2O + CH2N), 6.97-7.90 (m, 10H Ar), 7.94 (s, 1H, H-3), 9.30 (s, 1H, NH, disappears with 
D2O), 11.76 (s, 1H, NH, disappears with D2O). 
IR (KBr): cm-1 3366, 3127 (NH), 1707 (COOEt), 1662 (CONH). 
MS: m/z 423 [M+1]+. 
 
Ethyl 5-{[(benzoylamino)carbonothioyl]amino}-1-[2-(4-fluorophenyl)ethyl]-1H-pyrazole-4-
carboxylate 82b. 
 
Yield: 3.96 g, 90%  
Mp: 185-187 °C 
MW = 440.49 
Anal. calcd for C22H21N4O3FS, C 59.99, H 4.81, N 12.72, S 7.28, found C 60.05, H 4.75, N 
12.58, S 7.02.                                                                                                         
1H NMR ((CD3)2SO): δ 1.24 (t, J = 7.2 Hz, 3H, CH3), 3.20 (t, J = 7.0 Hz, 2H, CH2Ar), 4.12-
4.34 (m, 4H, CH2O + CH2N), 7.00-7.98 (m, 9H Ar), 7.98 (s, 1H, H-3), 9.32 (s, 1H, NH, 
disappears with D2O), 11.80 (s, 1H, NH, disappears with D2O). 
IR (KBr): cm-1 3367, 3127 (NH), 1706 (COOEt), 1662 (CONH). 
 
Ethyl 5-{[(benzoylamino)carbonothioyl]amino}-1-(2-hydroxy-2-phenethyl)-1H-pyrazole-4-
carboxylate 82c. 
 
Yield: 4.07 g, 93% 
Mp: 171-172 °C 
MW = 438.50 
Anal. calcd for C22H22N4O4S, C 60.26, H 5.06, N 12.78, S 7.31, found C 60.22, H 5.20, N 12.95, 
S 7.50.                                                                                                       
1H NMR ((CD3)2SO): δ 1.29 (t, J = 7.0, 3H, CH3), 3.97-4.20 (m, 5H, 2CH2 + OH, 1H disappears 
with D2O), 4.58-4.68 (m, 1H, CHO), 7.05-7.98 (m, 10H Ar), 8.02 (s, 1H, H-3), 8.70 (s, 1H, 
NH, disappears with D2O), 12.05 (s, 1H, NH, disappears with D2O). 
Chapter 12. Experimental section   
156 
 
Design, synthesis and biological evaluation of pyrazolo-pyrimidines and related isosteres  
as inhibitors of protein kinases, potential antineoplastic agents 
IR (KBr): cm-1 3221(NH), 3190-2940 (OH), 1708 and 1671 (2 CO). 
General procedure for the synthesis of compounds 83a-c. 
 
A solution of 82a-c (10 mmol) in 2 M NaOH (40 mL) was refluxed for 10 min and successively 
diluted with water (40 mL). The solution was acidified with glacial acetic acid. After 12 h of 
standing in a refrigerator, the crystallized solid was filtered and recrystallized from absolute 
EtOH to give a white solid. 
 
1-Phenethyl-6-thioxo-1,5,6,7-tetrahydro-pyrazolo[3,4-d]pyrimidin-4-one 83a. 
 
Yield: 1.50 g, 55% 
Mp: 200-201 °C 
MW = 272.33 
Anal. calcd for C13H12N4OS, C 57.34, H 4.44, N 20.57, S 11.77, found C 57.22, H 4.20, N 
20.30, S 11.47.                                                                                                                 
1H NMR ((CD3)2SO): δ 3.20 (t, J = 7.0, 2H, CH2Ar), 4.20 (t, J = 7.0, 2H, CH2N), 7.00-7.50 (m, 
5H Ar), 7.95 (s, 1H, H-3), 9.25 (s, 1H, NH, disappears with D2O). 
IR (KBr): cm-1 3400-3300 (NH + OH), 1660 (CO). 
MS: m/z 272 [M+1]+. 
 
1-[2-(4-Fluorophenyl)ethyl]-6-thioxo-1,5,6,7-tetrahydro-4H-pyrazolo[3,4-d]pyrimidin-4-
one 83b. 
 
Yield: 1.83 g, 63% 
Mp: 257-259 °C 
MW = 290.32 
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Anal. calcd for C13H11N4OFS, C 53.78, H 3.82, N 19.30, S 11.05, found C 54.04, H 4.04, N 
19.54, S 11.36.                                                                           
1H NMR ((CD3)2SO): δ 3.22 (t, J = 7.0 Hz, 2H, CH2Ar), 4.25 (t, J = 7.0 Hz, 2H, CH2N), 7.06-
7.51 (m, 4H Ar), 7.96 (s, 1H, H-3), 9.28 (s, 1H, NH, disappears with D2O). 
IR (KBr): cm-1 3400-3300 (NH + OH), 1694 (CO). 
 
1-(2-Hydroxy-2-phenyl-ethyl)-6-thioxo-1,5,6,7-tetrahydro-pyrazolo[3,4-d]pyrimidin-4-one 
83c.  
 
Yield: 2.3 g, 80% 
Mp: 264-265 °C 
MW = 288.32 
Anal. calcd for C13H12N4O2S, C 54.16, H 4.20, N 19.43, S 11.12, found C 54.28, H 4.27, N 
19.70, S 10.86.                                                                                                               
1H NMR ((CD3)2SO): δ 4.15-4.30 and 4.55-4.72 (2m, 2H, CH2N), 4.85-5.00 (m, 1H, CHO), 
5.66 (br s, 1H, OH, disappears with D2O), 7.20-7.51 (m, 5H Ar), 8.02 (s, 1H, H-3), 12.20 (s, 
1H, NH, disappears with D2O), 13.40 (s, 1H, NH, disappears with D2O). 
IR (KBr): cm-1 3362 (NH), 3242-2973 (OH), 1681 (CO).  
General procedure for the synthesis of compounds 84a-c. 
 
 
NaOH (0.4 g, 10 mmol) dissolved in absolute EtOH (5 mL) and 4-(2-chloroethyl)morpholine 
(2.24 g, 15 mmol) were added to a solution of intermediates 83a-c (2.88 g, 10 mmol) in 
anhydrous DMF (5 mL). The solution was refluxed for 6 h. After cooling, the solvent was 
evaporated under reduced pressure, and the crude was poured into cold water. The white solid 
was filtered, washed with water, and recrystallized from absolute EtOH. 
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6-((2-Morpholinoethyl)thio)-1-phenethyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 84a. 
 
Yield: 1.97g, 51% 
Mp: 197-198°C 
MW = 385.48 
Anal. calcd for C19H23N5O2S, C 56.56, H 5.50, N 17.36, S 7.95, found C 56.61, H 5.28, N 17.13, 
S 7.67.                                                                                                                                                  
1H NMR (CDCl3): δ 2.55-2.70 (m, 4H, 2CH2N morph.), 2.80-2.84 (m, 2H, CH2N), 3.17-3.24 
(m, 4H, CH2S + CH2Ar), 3.80-3.85 (m, 4H, 2CH2O morph.), 4.50 (t, J = 7.6 Hz, 2H, CH2N 
pyraz.), 7.10-7.26 (m, 5H Ar), 8.02 (s, 1H, H-3).  
IR (KBr): cm-1 3500-2800 (NH), 1667 (CO). 
 
1-(4-Fluorophenethyl)-6-((2-morpholinoethyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-
one 84b. 
 
Yield: 3.47g, 86% 
MW = 213-215 °C 
MW = 403.48 
Anal. calcd for C19H22N5O2FS, C 59.20, H 6.01, N 18.17, S 8.32, found C 59.27, H 6.14, N 
17.99, S 8.23.                                                                                                                                                  
1H NMR (CDCl3): 2.42-2.68 (m, 4H, 2CH2N morph.), 2.77-2.83 (m, 2H, CH2N), 3.15-3.22 (m, 
4H, CH2S + CH2Ar), 3.75-3.83 (m, 4H, 2CH2O morph.), 4.45 (t, J = 7.6 Hz, 2H, CH2N pyraz.), 
7.08-7.23 (m, 4H Ar), 8.02 (s, 1H, H-3).  
IR (KBr): cm-1 3400-2800 (NH), 1667 (CO). 
 
1-(2-Hydroxy-2-phenylethyl)-6-((2-morpholinoethyl)thio)-1H-pyrazolo[3,4-d]pyrimidin-
4(5H)-one 84c. 
 
Yield: 2.53 g, 63%  
Mp: 201-202 °C 
MW = 401.48 
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Anal. calcd for C19H23N5O3S, C 56.84, H 5.77, N 17.44, S 7.99, found C 56.68, H 5.55, N 17.48, 
S 8.00.                                                                                                                                                                                          
1H NMR (CDCl3): δ 2.36-2.50 (m, 4H, 2CH2N morph.), 3.10-3.40 (m, 4H, CH2S + CH2CH2S), 
3.45-3.56 (m, 4H, 2CH2O morph.), 4.13-4.40 (m, 2H, CH2N), 4.83-5.06 (m, 1H, CHO), 5.55 
(d, 1H, OH disappears with D2O), 7.10-7.28 (m, 5H Ar), 7.89 (s, 1H, H-3). 
IR (KBr): cm-1 3100-2850 (NH + OH), 1664 (CO). 
MS: m/z 401 [M+1]+. 
 
General procedure for the synthesis of compounds 85a,b. 
 
 
 
The Vilsmeier complex, previously prepared from POCl3 (3 g, 20 mmol) and anhydrous DMF 
(1.46 g, 20 mmol) was added to a suspension of intermediates 84a,b (1 mmol) in CHCl3 (10 
mL). The mixture was refluxed for 8 h. The solution was washed with water (2 x 20 mL), dried 
(MgSO4), and concentrated under reduced pressure. The yellow crude oil was purified by 
column chromatography (Silica gel 0.06-0200 mm, 40 Å) using Et2O as the eluant, to afford 
the pure product as a yellow oil (85a), or as white solid (85b). 
 
4-(2-((4-Chloro-1-phenethyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)thio)ethyl)morpholine 85a. 
 
Yield: 0.32 g, 80% 
MW = 403.93 
Anal. calcd for C19H22N5OClS, C 56.50, H 5.49, N 17.34, S 7.49, found C 56.43, H 5.52, N 
17.14, S 7.77.                                                                                                                                                                                                                           
1H NMR (CDCl3): δ 2.51-2.90 (m, 6H, 2CH2N morph. + CH2N), 3.22 (t, J = 7.2 Hz, 2H, 
CH2Ar), 3.30-3.40 (m, 2H, SCH2), 3.68-3.88 (m, 4H, 2CH2O morph.), 4.62 (t, J = 7.2 Hz, 2H, 
CH2N pyraz.), 7.09-7.26 (m, 5H Ar), 8.01 (s, 1H, H-3).  
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4-(2-((4-Chloro-1-(4-fluorophenethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-
yl)thio)ethyl)morpholine 85b. 
 
Yield: 0.36 g, 86% 
Mp: 101-102 °C 
MW = 421.92 
Anal. calcd for C19H21N5OClFS, C 54.09, H 5.02, N 16.60, S 7.60, found C 53.89, H 5.00, N 
16.72, S 7.34.                                                        
1H NMR (CDCl3): 2.50-2.85 (m, 6H, 2CH2N morph. + CH2N), 3.24 (t, J = 7.2 Hz, 2H, CH2Ar), 
3.33-3.45 (m, 2H, SCH2), 3.67-3.84 (m, 4H, 2CH2O morph.), 4.61 (t, J = 7.2 Hz, 2H, CH2N 
pyraz.), 7.00-7.33 (m, 4H Ar), 8.04 (s, 1H, H-3). 
 
Synthesis of 4-(2-((4-chloro-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-
yl)thio)ethyl)morpholine 85c. 
 
The Vilsmeier complex, previously prepared from POCl3 (12.27 g, 80 mmol) and anhydrous 
DMF (5.85 g, 80 mmol) was added to a suspension of intermediate 84c (4.01 g, 10 mmol) in 
CHCl3 (50 mL). The mixture was refluxed for 8 h. The solution was washed with 4 M NaOH 
(2 x 20 mL), then with water (20 mL), dried (MgSO4), and concentrated under reduced pressure. 
The yellow crude oil was crystallized as a brown solid by adding absolute EtOH and standing 
in a refrigerator. 
 
Yield: 3.29 g, 75% 
Mp: 106-107 °C 
MW = 438.37 
Anal. calcd for C19H21N5Cl2OS, C 52.06, H 4.83, N 15.98, S 7.31, found C 52.00, H 4.91, N 
16.01, S 7.52.                                                                                                
1H NMR (CDCl3): δ 2.81-3.12 (m, 4H, 2CH2N morph.), 3.18-3.81 (m, 4H, CH2S + CH2CH2S), 
3.86-4.10 (m, 4H, 2CH2O morph.), 4.60-4.78 and 5.12-5.30 (2m, 2H, CH2N), 5.36-5.50 (m, 
1H, CHCl), 7.16-7.50 (m, 5H Ar), 8.00 (s, 1H, H-3). 
MS: m/z 438 [M+1]+. 
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General procedure for the synthesis of compounds 78a-e. 
 
 
The appropriate aniline (2 mmol) was added to a solution of the opportune intermediates 85a-
e (1 mmol) in absolute EtOH (5 mL), and the mixture was refluxed for 3-5 h. After cooling to 
room temperature, the solid was filtered, washed with water, and recrystallized from absolute 
EtOH. 
 
6-((2-Morpholinoethyl)thio)-1-phenethyl-N-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
78a. 
 
Yield: 0.26 g, 57% 
Mp: 177-180 °C 
MW = 460.60   
Anal. calcd for C25H28 N6OS, C 65.19, H 6.13, N 18.25, S 6.96, found C 62.25, H 6.37, N 17.96, 
S 7.36.                                                                                                              
1H NMR (CDCl3): δ 2.53-2.55 (m, 4H, 2CH2N morph. ), 2.76 (t, J = 8.0 Hz, 2H, CH2N), 3.18 
(t, J = 7.0, 2H, CH2Ar), 3.31 (t, J = 8.0 Hz, 2H, CH2S), 3.69-3.71 (m, 4H, 2CH2O morph.), 4.53 
(t, J = 7.0, 2H, CH2N pyraz.), 7.18-7.21 and 7.24-7.29 (2m, 10H, Ar), 7.84 (s, 1H, H-3).  
IR (KBr): cm-1 3435 (NH). 
 
N-(3-fluorophenyl)-6-((2-morpholinoethyl)thio)-1-phenethyl-1H-pyrazolo[3,4-d]pyrimidin-
4-amine 78b. 
 
Yield: 0.25 g, 51% 
Mp: 160-162 °C  
MW = 478.59    
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Anal. calcd for C25H27N6FOS, C 62.74, H 5.69, N 17.56, S 6.70, found C 62.97, H 5.66, N 
17.56, S 6.63.                                                                                                                
1H NMR (CDCl3): δ 2.55-2.57 (m, 4H, 2CH2N morph. ), 2.75 (t, J = 8.0 Hz, 2H, CH2N), 3.19 
(t, J = 7.0, 2H, CH2Ar), 3.30 (t, J = 8.0 Hz, 2H, CH2S), 3.71-3.74 (m, 4H, 2 CH2O morph.), 
4.54 (t, J = 7.0, 2H, CH2N pyraz.), 7.24-7.26 and 7.28-7.33 (2 m, 10H, Ar), 7.87 (s, 1H, H-3). 
IR (KBr): cm-1 3310 (NH). 
 
N-(3-bromophenyl)-6-((2-morpholinoethyl)thio)-1-phenethyl-1H-pyrazolo[3,4-d]pyrimidin-
4-amine 78c. 
 
Yied: 0.30 g, 55% 
Mp: 140-141 °C 
MW = 539.49     
Anal. calcd for C25H27N6BrOS, C 55.66, H 5.04, N 15.58, S 5.94, found C 55.72, H 5.34, N 
15.24, S 5.38.                                                                                                                            
1H NMR (CDCl3): δ 2.50-2.52 (m, 4H, 2CH2N morph. ), 2.72 (t, J = 8.0 Hz, 2H, CH2N), 3.17 
(t, J = 7.0, 2H, CH2Ar), 3.28 (t, J = 8.0 Hz, 2H, CH2S), 3.66-3.69 (m, 4H, 2CH2O morph.), 4.52 
(t, J = 7.0, 2H, CH2N pyraz.), 7.12-7.26 and 7.34-7.44 (2 m, 10H, Ar), 7.75 (s, 1H, H-3).  
IR (KBr): cm-1 3314 (NH). 
 
N-(3-chlorophenyl)-1-(4-fluorophenethyl)-6-((2-morpholinoethyl)thio)-1H-pyrazolo[3,4-
d]pyrimidin-4-amine 78d. 
 
Yield: 0.16 g, 31% 
Mp: 127-128 °C 
MW = 513.03 
Anal. calcd for C25H26N6OClFS, C 58.53, H 5.11, N 16.38, S 6.25, found C 58.76, H 4.86, N 
16.09, S 6.46.                                                                                                                                                             
1H NMR (CDCl3): 2.44-2.69 and 2.80-2.91 (2m, 6H, 2CH2N morph. + CH2N), 3.14 (t, J = 6.8 
Hz, 2H, SCH2), 3.37-3.54 and 3.70-3.82 (2m, 6H, CH2Ar + 2CH2O morph.), 4.49 (t, J = 6.8 
Hz, 2H, CH2N pyraz.), 6.87-6.92, 7.05-7.08 and 7.28-7.36 (3m, 9H, 8 Ar + H-3). 
IR (KBr): cm-1 3300-3100 (NH). 
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N-(3-bromophenyl)-1-(2-chloro-2-phenylethyl)-6-((2-morpholinoethyl)thio)-1H-
pyrazolo[3,4-d]pyrimidin-4-amine 78e. 
 
Yield: 0.35 g, 61% 
Mp: 232-233 °C 
MW = 573.94     
Anal. calcd for C25H26N6BrClOS, C 52.32, H 4.57, N 14.64, S 5.59, found C 52.12, H 4.52, N 
14.55, S 5.52.                                                                                                                                                                          
1H NMR (CDCl3): δ 2.90-3.99 (m, 12H, 4CH2 morph. + CH2N + CH2S), 4.63-4.85 and 5.04-
5.21 (2m, 2H, CH2N pyraz.), 5.55-5.70 (m, 1H, CHCl), 7.03-8.52 (m, 10H, 9 Ar + H-3), 11.33 
(s all., 1H, NH disappears with D2O). 
IR (KBr): cm-1 3450 (NH). 
 
General procedure for the synthesis of compounds 78f,g. 
 
 
 
The appropriate amine (40 mmol) was added to a solution of the intermediate 85c (3.67 g, 10 
mmol) in anhydrous toluene (20 mL), and the mixture was stirred at room temperature for 48 
h. The organic phase was washed with water (20 mL), dried (MgSO4), and concentrated under 
reduced pressure. The obtained crude oil was crystallized by adding a mixture of Et2O/PE (bp 
40-60 °C) (1:1). 
 
1-(2-Chloro-2-phenylethyl)-N-(2-fluorobenzyl)-6-((2-morpholinoethyl)thio)-1H-
pyrazolo[3,4-d]pyrimidin-4-amine 78f. 
 
Yield: 0.27 g, 51%   
Mp: 134-135 °C 
MW = 527.06    
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Anal. calcd for C26H28N6ClFOS, C 59.25, H 5.35, N 15.95, S 6.08, found C 59.60, H 5.58, N 
15.62, S 5.94.                                                                                                                                                                                        
1H NMR (CDCl3): δ 2.53-2.55 (m, 4H, 2CH2N morph. ), 2.78 (t, J = 7.0 Hz, 2H, CH2N), 3.28 
(t, J = 7.0 Hz, 2H, CH2S), 3.66-3.69 (m, 4H, 2CH2O morph.), 4.52-4.57 (m, 4H, CH2N pyraz. 
+ CH2Ar), 5.35-5.38 (m, 1H, CHCl), 7.12-7.21 (m, 9H, Ar), 7.70 (s, 1H, H-3).  
IR (KBr): cm-1 3250 (NH). 
 
1-(2-Chloro-2-phenylethyl)-N-(2-chlorobenzyl)-6-((2-morpholinoethyl)thio)-1H-
pyrazolo[3,4-d]pyrimidin-4-amine 78g. 
 
Yield: 0.26 g, 48%  
Mp: 121-122 °C 
MW =  543.51    
Anal. calcd for C26H28N6Cl2OS, C 57.46, H 5.19, N 15.46, S 5.90, found C 57.28, H 5.39, N 
15.38, S 5.27.                                                           
1H NMR (CDCl3): δ 2.51-2.53 (m, 4H, 2CH2N morph. ), 2.77 (t, J = 7.2 Hz, 2H, CH2N), 3.28 
(t, J = 7.2 Hz, 2H, CH2S), 3.66-3.69 (m, 4H, 2 CH2O morph.), 4.51-4.55 (m, 4H, CH2N pyraz. 
+ CH2Ar), 5.34-5.37 (m, 1H, CHCl), 7.10-7.18 (m, 9H, Ar), 7.69 (s, 1H, H-3).  
IR (KBr): cm-1 3268 (NH). 
 
Synthesis of 1-(2-hydroxy-2-phenylethyl)-6-{[2-(4-methylpiperazin-1-yl)ethyl]thio}-1H-
pyrazolo[3,4-d]pyrimidin-4-ol 86. 
 
 
A suspension of 83c (1.01 g, 3.5 mmol), 1-(2-chloroethyl)-4-methylpiperazine (0.73 g, 4.2 
mmol), KOH (0.42 g, 7 mmol) and KI (0.062 g, 0.35 mmol) in absolute EtOH (50 mL) was 
stirred at 80 °C for 12 h. The solvent was evaporated under reduced pressure to obtain a crude, 
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which was purified by column chromatography using a mixture of CH2Cl2/MeOH (8:2) as the 
eluent to afford compound 86.  
 
Yield: 0.8 g, 55% 
Mp: 251.0-253.0 °C 
MW = 414.52 
Anal. calcd for C20H26N6O2S, C 57.95, H 6.32, N 20.27, S 7.74, found C 57.89, H 6.15, N 20.40, 
S 7.90.                                                           
1H NMR (CDCl3): δ (ppm) 2.5 (s, 3H, CH3), 2.55-3.40 (m, 12H, 4CH2 piperaz. + CH2CH2S + 
CH2S), 4.20-4.25 and 4.25-4.45 (2m, 2H, CH2N), 5.07 (br s, 1H, OH, disappears with D2O), 
5.60-5.80 (m, 1H, CHO),  7.20-7.40 (m, 5H Ar), 7.98 (s, 1H, H-3). 
IR (cm-1): 3332 (NH), 3087-2831 (OH), 1679 (CO). 
 
Synthesis of 2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-4-ol 97. 
 
 
 
Chloroacetaldehyde (50% aqueous solution, 1 mL, 7.87 mmol) was added to a suspension of 
intermediate 96 (0.5 g, 3.18 mmol) and sodium acetate (0.88 g, 10.69 mmol) in water (12.5 mL) 
and the mixture was heated at 80 °C for 2 min in a microwave oven (open vessel mode, 100 
W). After cooling to room temperature, acetone (3 mL) was added and the obtained solid was 
filtered. Grey solid constituted by a mixture of the C4 keto enolic forms.  
 
Yield: 0.41 g, 71% 
Mp: 265-267 °C 
MW = 181.21 
Anal. calcd for C7H7N3OS, C 46.39, H 3.89, N 23.19, S 17.69, found C 46.51, H 3.96, N 23.15, 
S 17.68.                                                                                               
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1H NMR ((CD3)2SO): δ 3.26 (s, 3H, SCH3), 7.61-7.65 (m, 1H, H-5), 7.75-7.90 (m, 1H, H-6), 
9.59 (br s, 1H disappears wih D2O), 9.92 (br s, 1H disappears with D2O).  
IR (KBr): cm-1 3330-2900 (OH), 3220 (NH), 1667 (CO).  
MS: m/z [M+1]+ 182.  
 
Synthesis of 4-chloro-2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidine 98. 
 
 
 
POCl3 (5 mL, 53.7 mmol) and TEA (0.2 mL, 1.43 mmol) were added to intermediate 97 (0.10 
g, 0.55 mmol); the mixture was heated at 130 °C for 4 h and then cooled to room temperature. 
The excess of POCl3 was removed by distillation under reduced pressure. Ice was then carefully 
added to the residue and the suspension was extracted with Et2O (3 x 20 mL). The organic phase 
was washed with water (10 mL), dried on MgSO4, filtered and concentrated under reduced 
pressure. The crude was purified by column chromatography (Florisil®, 100-200 mesh), using 
Et2O as the eluent to afford the pure product 98. 
 
Yield: 84 mg, 77% 
Mp: 207-209 °C 
MW = 199.66 
Anal. calcd for C7H6N3ClS, C 42.11, H 3.03, N 21.05, S 16.06, found C 42.29, H 3.38, N 21.14, 
S 16.36.                                                                                                                                                      
1H NMR ((CD3)2SO): δ 2.67 (s, 3H, SCH3), 6.56-6.59 (m, 1H, H-5), 7.21-7.23 (m, 1H, H-6) 
IR (KBr): cm-1 3412 (NH), 3122 (CH), 1614 (CC). 
MS: m/z [M+1]+ 201.  
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Synthesis of 2-(4-chloro-2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-
phenylethanone 99. 
 
 
Sodium hydride (60% dispersion in mineral oil, 0.04 g, 1 mmol) was added in small portions 
at 0 °C to a solution of intermediate 98 (0.2 g, 1 mmol) in anhydrous DMF and the mixture was 
stirred at room temperature for 20 min. Then 2-bromo-1-phenylethanone (0.3 g, 1 mmol) was 
added dropwise at 0 °C and the reaction was stirred at room temperature for 18 h. Then the 
mixture was poured into water (20 mL) and extracted with ethylacetate (3 x 10 mL); the organic 
phases were washed with water (2 x 10 mL), dried on MgSO4, filtered and concentrated under 
reduced pressure. The crude was purified by column chromatography (Silica gel 220-440 
mesh), using CH2Cl2 as the eluent to afford the pure product as a white solid.  
 
Yield:  0.15 g, 47% 
Mp: 157-159 °C 
MW = 317.79 
Anal. calcd for C15H12N3OClS, C 56.69, H 3.81, N 13.22, S 10.09, found C 56.65, H 3.83, N 
12.97, S 10.07.                                                                                                                                                                                                             
1H NMR (CDCl3): δ 2.65 (s, 3H, SCH3), 5.65 (s, 2H, CH2N), 6.60 (d, J = 3.6, 1H, H-5), 7.11 
(d, J = 3.6, 1H, H-6), 7.52-7.56, 7.64-7.67 and 8.03-8.05 (3m, 5H Ar).  
IR (KBr): cm-1 1694 (CO).  
MS: m/z [M+1]+ 319.  
 
Synthesis of 2-(4-chloro-2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-
phenylethanol 100. 
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A solution of sodium borohydride (0.26 g, 6.9 mmol) in water (1 mL) was slowly added at 0 
°C to a solution of intermediate 99 (0.31 g, 1 mmol) in THF (6 mL), and the reaction was stirred 
at room temperature for 3 h. Then the mixture was poured in water (20 mL) and extracted with 
Et2O (3 x 10 mL); the organic phases were washed with water (2 x 10 mL), dried on MgSO4, 
filtered and concentrated under reduced pressure to obtain an oil which crystallized by adding 
a 1:1 mixture of Et2O and PE (bp 40-60 °C) to give a white solid. 
 
Yield:  0.22 g, 69% 
Mp: 157-159 °C 
MW = 319.81 
Anal. calcd for C15H14N3OClS, C 56.33, H 4.41, N 13.14, S 10.03, found C 56.08, H 4.73, N 
13.04, S 9.98.                                                                                                 
1H NMR (CDCl3): δ 2.65 (s, 3H, SCH3), 3.91 (br s, 1H, OH disappears with D2O), 4.32-4.64 
(m, 2H, CH2N), 5.10-5.25 (m, 1H, CHOH), 6.48 (d, J = 3.6, 1H, H-5), 7.03 (d, J = 3.6, 1H, H-
6), 7.23-7.47 (m, 5H Ar).  
IR (KBr): cm-1 3500-3200 (OH). 
MS: m/z [M+1]+ 321.  
 
Synthesis of 4-chloro-7-(2-chloro-2-phenylethyl)-2-(methylthio)-7H-pyrrolo[2,3-
d]pyrimidine 101. 
 
 
The Vilsmeier complex, previously prepared from POCl3 (1.65 mL, 17.6 mmol) and DMF (1.28 
g, 17.6 mmol) was added to a suspension of intermediate 100 (0.56 g, 1.76 mmol) in CH2Cl2 
(10 mL). The mixture was refluxed for 8 h. After cooling to room temperature, the mixture was 
washed with water (2 x 20 mL), dried on MgSO4, filtered, and concentrated under reduced 
pressure. The crude oil was purified by column chromatography (Silica gel 220-440 mesh), 
using Et2O as the eluent, to afford the pure product as a white solid. 
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Yield: 0.31 g, 92% 
Mp: 87-88 °C 
MW = 338.25 
Anal. calcd for C15H13N3Cl2S, C 53.26, H 3.87, N 12.42, S 9.48, found C 53.23, H 3.81, N 
12.18, S 9.15.                                                                                                                                                        
1H NMR (CDCl3): δ 2.65 (s, 3H, SCH3), 4.66-4.80 (m, 2H, CH2N), 5.29-5.34 (m, 1H, CHCl), 
6.47 (d, J = 3.6, 1H, H-5), 6.99 (d, J = 3.6, 1H, H-6), 7.22-7.50 (m, 5H Ar).  
MS: m/z [M+1]+ 339.  
 
General procedure for the synthesis of compounds 95a,b. 
 
 
 
The appropriate aniline (2 mmol) was added to a solution of 101 (0.33 g, 1 mmol) in absolute 
EtOH (10 mL) and the reaction mixture was stirred at reflux for 5 h. After cooling, a solid 
precipitated which was filtered, washed with water and recrystallized from absolute EtOH (10 
mL) to give the final products as white solids. 
 
7-(2-Chloro-2-phenylethyl)-2-(methylthio)-N-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
95a.  
 
Yield: 0.26 g, 66% 
Mp: 157-159 °C 
MW = 394.92 
Anal. calcd for C21H19N4ClS, C 63.87, H 4.85, N 14.19, S 8.12, found C 63.81, H 4.62, N 14.38, 
S 7.99.                                                                                                   
1H NMR (CDCl3): δ 2.65 (s, 3H, SCH3), 4.72-5.22 (m, 2H, CH2N), 5.39-5.66 (m, 1H, CHCl), 
7.00-7.76 (m, 12H, H-5 + H-6 + 10Ar), 8.40 (br s, 1H, NH disappears with D2O).  
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13C NMR (MeOD): δ 168.96, 150.48, 146.94, 141.15, 138.23, 129.39, 129.08, 128.86, 127.54, 
124.04, 123.66, 120.80, 101.88, 100.01, 60.17, 53.07, 14.82.  
IR (KBr): cm-1 3000-2830 (NH).  
MS: m/z [M+1]+ 396.  
 
7-(2-Chloro-2-phenylethyl)-N-(3-chlorophenyl)-2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-
4-amine 95b.  
 
Yield: 0.26 g, 61% 
Mp: 147-149 °C 
MW = 429.37 
Anal. calcd for C21H18N4Cl2S, C 58.74, H 4.23, N 13.05, S 7.47, found C 58.76, H 4.37, N 
13.25, S 7.11.                                                                                                                                                          
1H NMR (CDCl3): δ 2.66 (s, 3H, SCH3), 4.64-5.23 (m, 2H, CH2N), 5.41-5.67 (m, 1H, CHCl), 
7.00-7.81 (m, 11H, H-5 + H- 6 + 9Ar), 9.76 (br s, 1H, NH disappears with D2O). 
13C NMR (MeOD): δ 168.96, 150.48, 146.94, 144.13, 138.23, 134.43, 130.17, 129.39, 128.86, 
127.54, 124.04, 122.58, 120.89, 120.18, 101.88, 100.01, 60.17, 53.07,14.82. 
IR (KBr): cm-1 3000-2800 (NH). 
MS: m/z [M+1]+ 430.  
 
Synthesis of N-benzyl-7-(2-chloro-2-phenylethyl)-2-(methylthio)-7H-pyrrolo[2,3-
d]pyrimidin-4-amine 95c. 
 
 
Benzylamine (0.4 g, 4 mmol) was added to a solution of intermediate 101 (0.3 g, 1 mmol) in 
anhydrous toluene (5 mL) and the mixture was stirred at room temperature for 24 h. Then, the 
organic phase was washed with water (2 x 10 mL), dried on MgSO4, and concentrated under 
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reduced pressure. The crude oil was purified by column chromatography (Silica gel 220-440 
mesh), using Et2O as the eluent. The obtained oil crystallized as a yellow solid by adding a 1:1 
mixture of Et2O and PE (bp 40-60 °C).  
 
Yield: 0.33 g, 81% 
Mp: 106-107 °C 
MW = 408.95 
Anal. calcd for C22H21N4ClS, C 64.61, H 5.18, N 13.70, S 7.84, found C 64.38, H 5.08, N 13.87, 
S 7.78.                                                                                                
1H NMR (CDCl3): δ 2.65 (s, 3H, SCH3), 4.65-4.71 (m, 4H, CH2N + CH2Ar), 5.05 (br s, 1H, 
NH disappears with D2O), 5.33-5.35 (m, 1H, CHCl), 6.45 (d, J = 3.6, 1H, H-5), 6.96 (d, J = 
3.6, 1H, H-6), 7.18-7.50 (m, 10H Ar).  
13C NMR (MeOD): δ 169.80, 153.68, 148.47, 139.85, 138.23, 129.39, 128.86, 128.43, 127.59, 
127.54, 126.92, 124.04, 103.94, 100.01, 60.17, 53.07, 43.38, 14.82. 
IR (KBr): cm-1 3100-2900 (NH).  
MS: m/z [M+1]+ 410.  
 
Synthesis of 4-chloro-7-(4-fluorobenzyl)-2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidine 
102. 
 
 
Sodium hydride (60% dispersion in mineral oil, 0.1 g, 2.5 mmol) was slowly added to a solution 
of 98 (0.19 g, 1 mmol) in anhydrous ACN (5 mL) and the mixture was stirred at room 
temperature for 20 min. Then 4-fluorobenzyl chloride (0.14 g, 1 mmol) solved in anhydrous 
ACN (5 mL) was added dropwise. The mixture was heated at 50 °C for 2 h, then cooled to room 
temperature and filtered to eliminate the little amount of solid obtained. Then the solution was 
evaporated under reduced pressure and the crude was purified by column chromatography 
(Florisil®, 100-200 mesh), using Et2O as the eluent to afford the pure compound 102 as light 
yellow solid.  
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Yield: 0.11 g, 36% 
Mp: 99-100 °C 
MW = 307.77 
Anal. calcd for C14H11N3ClFS, C 54.63, H 3.60, N 13.65, S 10.42, found C 54.41, H 3.69, N 
13.42, S 10.15.                                                                                                         
1H NMR (CDCl3): δ 2.65 (s, 3H, SCH3), 5.36 (s, 2H, CH2N), 6.53 (d, J = 3.6, 1H, H-5), 6.96-
7.04 and 7.14-7.24 (2m, 5H, 4Ar + H-6). 
MS: m/z [M+1]+ 309.  
 
General procedure for the synthesis compounds 95d-j. 
 
 
 
The suitable amine (5 mmol) was added to a solution 102 (0.31 g, 1 mmol) in DMSO (5 mL) 
and the mixture was heated at 90-130 °C (the temperature depending on the boiling point of the 
amine) for 3-5. Then the mixture was cooled to room temperature, poured in ice-water (50 mL), 
extracted with CH2Cl2 (3 x 20 mL), dried on MgSO4, filtered and concentrated under reduced 
pressure. The crude was purified by column chromatography (Florisil®, 100-200 mesh), using 
CHCl3 as the eluent to afford the pure products. 
 
4-Butyl-7-(4-fluorobenzyl)-2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidine 95d.  
 
Yield: 0.14 g, 42%,  
Mp: 99-100 °C 
MW = 329.43 
Anal. calcd for C18H21N4FS, C 62.76, H 6.15, N 16.27, S 9.31, found C 62.58, H 6.45, N 16.21, 
S 9.08.                                                                                                                     
1H NMR (CDCl3): δ 0.89 (t, J = 7.2, 3H, CH3), 1.37 (sx, J = 7.2, 2H, CH2CH2CH3), 1.59 (quint, 
J = 7.2, 2H, CH2CH2CH3), 2.52 (s, 3H, SCH3), 3.53 (q, J = 7.2, 2H, CH2NH), 5.04 (br s, 1H, 
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NH disappears with D2O), 5.21 (s, 2H, CH2N), 6.22 (d, J = 3.6, 1H, H-5), 6.65 (d, J = 3.6, 1H, 
H-6), 6.84-6.94 and 7.07-7.21 (2m, 
 4H Ar).  
13C NMR (MeOD): δ 170.01, 162.67, 154.48, 147.83, 132.42, 130.45, 125.95, 115.11, 103.01, 
101.64, 50.49, 43.71, 30.87, 20.23, 14.82, 14.02. 
IR (KBr): cm-1 3382 (NH). 
MS: m/z [M+1]+ 345.  
 
7-(4-Fluorobenzyl)-2-(methylthio)-4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine 95e. 
 
Yield: 0.18 g, 52%,  
Mp: 149-150 °C 
MW = 342.43 
Anal. calcd for C18H19N4FS, C 63.13, H 5.59, N 16.36, S 9.36, found C 63.25, H 5.69, N 16.27, 
S 9.06.                                                               
1H NMR (CDCl3): δ 1.86-2.00 (m, 4H, 2CH2 pyrr.), 2.51 (s, 3H, SCH3), 3.66-3.78 (m, 4H, 
2CH2N pyrr.), 5.22 (s, 2H, CH2N), 6.39 (d, J = 3.4, 1H, H-5), 6.61 (d, J = 3.4, 1H, H-6), 6.83-
6.96 and 7.07-7.21 (2m, 4H Ar).  
13C NMR (MeOD): δ 167.66, 162.67, 155.30, 151.11, 132.42, 130.45, 123.66, 115.11, 110.00, 
101.76, 65.59, 50.49, 45.92, 14.82. 
MS: m/z [M+1]+ 343.  
 
7-(4-Fluorobenzyl)-2-(methylthio)-4-(piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine 95f.  
 
Yield: 0.16 g, 46%,  
Mp: 73-74 °C 
MW = 356.46 
Anal. calcd for C19H21N4FS, C 64.02, H 5.94, N 15.72, S 9.00, found C 64.24, H 5.94, N 15.70, 
S 9.07.                                                                                                                      
1H NMR (CDCl3): δ 1.51-1.72 (m, 6H, 3CH2 pip.), 2.50 (s, 3H, SCH3), 3.74-3.88 (m, 4H, 
2CH2N pip.), 5.23 (s, 2H, CH2N), 6.34 (d, J = 3.6, 1H, H-5), 6.65 (d, J = 3.6, 1H, H-6), 6.83-
6.98 and 7.08-7.21 (2m, 4H Ar).  
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13C NMR (MeOD): δ 167.66, 162.67, 155.30, 151.11, 132.42, 130.45, 123.66, 115.11, 110.00, 
101.76, 50.49, 48.07, 25.08, 23.42, 14.82.  
MS: m/z [M+1]+ 357.  
 
4-(7-(4-Fluorobenzyl)-2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine 95g.  
 
Yield: 0.18 g, 51% 
Mp: 115-116 °C 
MW = 358.43 
Anal. calcd for C18H19N4FSO, C 60.32, H 5.34, N 15.63, S 8.95, found C 60.15, H 5.44, N 
15.63, S 8.70.                                                                                                                                                                             
1H NMR (CDCl3): δ 2.50 (s, 3H, SCH3), 3.75 (t, J = 5.4, 4H, 2 CH2N morph.), 3.87 (t, J = 5.4, 
4H, 2CH2O morph.), 5.24 (s, 2H, CH2N), 6.33 (d, J = 3.6, 1H, H-5), 6.69 (d, J = 3.6, 1H, H-6), 
6.84-6.98 and 7.06-7.23 (2m, 4H Ar).  
13C NMR (MeOD): δ 168.25, 162.67, 153.43, 151.84, 132.42, 130.45, 123.66, 115.11, 108.99, 
101.76, 50.49, 49.09, 26.01, 14.82. 
MS: m/z [M+1]+ 359.  
 
N-benzyl-7-(4-fluorobenzyl)-2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 95h.  
 
Yield: 0.14 g, 36% 
Mp: 95-96 °C 
MW = 378.47 
Anal. calcd for C21H19N4FS, C 66.64, H 5.06, N 14.80, S 8.47, found C 66.52, H 5.18, N 14.64, 
S 8.17.                                                                                                   
1H NMR (CDCl3): δ 2.51 (s, 3H, SCH3), 4.76 (d, J = 5.8, 2H, CH2NH), 5.22 (s, 2H, CH2N), 
6.17 (d, J = 3.6, 1H, H-5), 6.62 (d, J = 3.4, 1H, H-6), 6.83-6.97 and 7.07-7.38 (2m, 9H Ar), 
7.73 (br s, 1H, NH disappears with D2O).  
13C NMR (MeOD): δ 169.91, 162.67, 153.45, 147.86, 139.85, 132.42, 130.45, 128.43, 127.59, 
126.92, 125.95, 115.11, 103.57, 101.64, 50.49, 43.38, 14.82.  
IR (KBr): cm-1 3228 (NH). 
MS: m/z [M+1]+ 379.  
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7-(4-Fluorobenzyl)-2-(methylthio)-N-phenethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 95i. 
 
Yield: 0.15 g, 37% 
Mp: 61-68 °C 
MW = 392.49 
Anal. calcd for C22H21N4FS, C 67.32, H 5.39, N 14.27, S 8.17, found C 67.34, H 5.60, N 14.36, 
S 8.00.                                                                                                                                                          
1H NMR (CDCl3): δ 2.56 (s, 3H, SCH3), 2.92 (t, J = 6.8, 2H, CH2Ar), 3.81 (q, J = 6.8, 2H, 
CH2NH), 5.07 (br s, 1H, NH disappears with D2O), 5.21 (s, 2H, CH2N), 6.15 (d, J = 3.4, 1H, 
H-5), 6.64 (d, J = 3.4, 1H, H-6), 6.83-6.98 and 7.06-7.33 (2m, 9H Ar).  
13C NMR (MeOD): δ 170.01, 162.67, 154.48, 147.83, 139.08, 132.42, 130.45, 129.19, 128.83, 
126.13, 125.95, 115.11, 103.01, 101.64, 50.49, 43.75, 35.64, 14.82.  
IR (KBr): cm-1 3317 (NH).  
MS: m/z [M+1]+ 393.  
 
N-(4-chlorophenethyl)-7-(4-fluorobenzyl)-2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-4-
amine 95j.  
 
Yield: 0.13 g, 31% 
Mp: 141-143 °C 
MW = 426.94 
Anal. calcd for C22H20N4ClFS, C 61.89, H 4.72, N 13.12, S 7.51, found C 61.67, H 4.57, N 
13.10, S 7.33.                                                                                                        
1H NMR (CDCl3): δ 2.55 (s, 3H, SCH3), 2.90 (t, J = 6.8, 2H, CH2Ar), 3.83 (q, J = 6.8, 2H, 
CH2NH), 5.15 (br s, 1H, NH disappears with D2O), 5.25 (s, 2H, CH2N), 6.18 (d, J = 3.4, 1H, 
H-5), 6.67 (d, J = 3.4, 1H, H-6), 6.85-7.01 and 7.10-7.37 (2m, 8H Ar). 
13C NMR (MeOD): δ 170.01, 162.67, 154.48, 147.83, 136.26, 132.64, 132.42, 130.45, 130.05, 
129.35, 125.95, 115.11, 103.01, 101.64, 50.49, 43.75, 35.64, 14.82. 
MS: m/z [M+1]+ 428.  
 
 
 
Chapter 12. Experimental section   
176 
 
Design, synthesis and biological evaluation of pyrazolo-pyrimidines and related isosteres  
as inhibitors of protein kinases, potential antineoplastic agents 
Synthesis of 5-amino-1H-pyrazolo-4-carbonitrile 106. 
 
 
To a solution of 105 (4 g, 32.75 mmol) in absolute EtOH (20 mL), hydrazine monohydrate 
(1.65 mL, 34.06 mmol) was added, and the reaction mixture was stirred at reflux for 3 h. 
The ethanol was evaporated under reduced pressure. Cold water was added, the crude product 
was collected by filtration, washed with water (3 x 40 mL) and dried in the vacuum drying oven 
at 70 °C to give 106 as a brown solid. 
 
Yield: 2.87 g, 81% 
Mp: 172-174 °C  
MW = 108.10 
Anal. calcd for C4H4N4, C 44.44, H 3.73, N 51.83, found C 44.74, H 4.01, N 51.85.                                          
1H NMR ((CD3)2SO): δ 6.26 (s all., 2H, NH2, disappears with D2O), 7.57 (s, 1H, CH),  
11.98 (s all., 1H, NH, disappears with D2O). 
IR (KBr): cm-1 3420, 3416 (NH2), 1645 (CN).  
 
Synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amine 107.  
 
 
 
A solution of 106 (400 mg, 3.7 mmol) and formamide (5 mL, 125.8 mmol) was stirred at 200 
°C for 1 h. After cooling to room temperature, water was added (20 mL) and the obtained solid 
was filtered. The crude product was suspended in hot water (40 mL) and conc. HCl (5 mL), 
then charcoal (600 mg) was added and the mixture was boiled for 15 min. After charcoal 
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filtration, conc. NH3 was added and the precipitated solid was filtered, giving compound 107 
as a white solid. 
 
Yield: 0.40 g 
Mp: 353-356 °C 
MW = 135.13 
Anal. calcd for C5H5N5, C 44.44, H 3.73, N 51.83, found C 44.39, H 3.43, N 51.66. 
                                    
1H NMR ((CD3)2SO): δ 7.52 (s all., 2H, NH2), 8.07 (s, 1H, H-3), 8.13 (s, 1H, H-6),  
13.22 (s, 1H, NH).  
IR (KBr): cm-1 3401, 3360 (NH2).  
 
Synthesis of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 108. 
 
 
 
N-iodosuccinimide (2 g, 8.9 mmol) was added to a solution of 1H-pyrazolo[3,4-d]pyrimidin-4-
amine 107 (800 mg, 5.9 mmol) in dry DMF (5 mL) and the mixture was heated at 80 °C for 14 
h under nitrogen atmosphere. After cooling to room temperature, water was added (20 mL) and 
the precipitated solid was filtered and washed with water (50 mL). The crude product was 
recrystallized from absolute EtOH to give compound 108 as a light-yellow solid. 
 
Yield: 1.97 g, 85%  
Mp: 272-275 °C 
MW = 261.02 
Anal. calcd for C5H4N5I, C 23.01, H 1.54, N 26.83, found C 22.72, H 1.81, N 26.61. 
                                  
1H NMR (CDCl3): δ 8.15 (s, 1H, H-6), 9.18 (s all., 2H, NH2, disappears with D2O). 
IR (KBr): cm-1 3410, 3381 (NH2).  
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Synthesis of 2-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-phenylethanone 109. 
 
 
 
A solution of TBAF 1 M in THF (7.05 mL, 7.05 mmol) was added to a solution of 3-iodo-1H-
pyrazolo[3,4-d]pyrimidin-4-amine 108 (1.84 g, 7.05 mmol) in anhydrous toluene (40 mL), and 
the mixture was heated at 70 °C for 1 h. 2-Bromoacetophenone (1.7 g, 8.46 mmol) was added 
and the reaction was stirred at 70 °C for 2 h. After cooling to room temperature, toluene was 
evaporated, ethyl acetate (AcOEt) (50 mL) was added and the precipitated solid was filtered 
and washed with water (2 x 20 mL) and Et2O (3 x 15 mL). The crude product was recrystallized 
from absolute EtOH, to give compound 109 as a white solid. 
 
Yield: 1.26 g, 47% 
Mp: 227-231 °C 
MW = 379.16 
Anal. calcd for C13H10N5IO, C 41.18, H 2.66, N 18.47, found C 41.27, H 2.91, N 18.13. 
                                
1H NMR ((CD3)2SO): δ 6.01 (s, 2H, CH2), 7.74-7.56 (m, 5H Ar), 8.18 (s, 1H, H-6). 
 
Synthesis of 2-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-phenylethanol 110. 
 
 
 
To a solution of 109 (600 mg, 1.58 mmol) in MeOH (150 mL), NaBH4 (1.08 g, 28.48 mmol) 
was added and the mixture was stirred at 0 °C for 3 h. Water (40 mL) was added and the mixture 
was stirred for other 10 minutes. MeOH was evaporated then the suspension was extracted with 
CH2Cl2 (3 x 50 mL), the organic solution was washed with water (100 mL), dried (MgSO4), 
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filtered, and concentrated under reduced pressure. The crude oil was purified by column 
chromatography (Silica gel 220-440 mesh, 60 Å) using CH2Cl2/MeOH (95:5) as the eluant to 
afford the pure product 110. 
 
Yield: 0.19 g, 31%  
Mp: 186-188 °C 
MW = 381.17 
Anal. calcd for C13H12N5IO, C 40.96, H 3.17, N 18.37, found C 40.89, H 3.32, N 18.58. 
                            
1H NMR (CDCl3): δ 4.65-4.63 (m, 2H, CH2N), 5.30-5.25 (m, 1H, CHO), 6.75 (s all., 1H, OH), 
7.51-7.29 (m, 5H Ar), 8.34 (s, 1H, H-6). 
IR (KBr): cm-1 3465, 3294 (NH2), 3055 (OH). 
 
Synthesis of 1-(2-chloro-2-phenylethyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
111. 
 
 
SOCl2 (230 μL, 3.2 mmol) was added dropwise to a solution of the intermediate 110 (370 mg, 
0.97 mmol) in dry CH2Cl2 (15 mL), and the reaction was stirred at room temperature for 12 h 
under nitrogen atmosphere. Water (10 mL) and 1 N NaOH (2 mL) were added with caution and 
the aqueous phase was extracted with CH2Cl2 (3 x 15 mL). Then the organic phase was washed 
with water (30 mL), saturated NaCl solution (30 mL), dried (Na2SO4) and concentrated under 
reduced pressure. The crude product was purified by column chromatography (Silica gel 220-
440 mesh) using CH2Cl2/MeOH (95:5) as the eluant to afford the pure product 111. 
 
Yield: 0.13 g, 33% 
Mp: 204-209 °C 
MW = 399.62 
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Anal. calcd for C13H11N5ICl, C 39.07, H 2.27, N 17.53, found C 38.89, H 2.89, N 17.62.                
1H NMR (CDCl3): δ 5.06-4.69 (m, 2H, CH2N), 5.57-5.50 (m, 1H, CHO), 6.43 (s all., 2H, NH2), 
7.57-7.29 (m, 5H Ar), 8.34 (s, 1H, H-6). 
IR (KBr): cm-1 3452, 3301 (NH2).  
 
General procedure for the synthesis of compounds 104a,b. 
 
 
 
To a solution of 111 (50 mg, 0.125 mmol) in DME (2 mL) and H2O (0.3 mL), the appropriate 
boronic acid (0.5 mmol) was added, then Cs2CO3 (122 mg, 0.375 mmol) and Pd(dppf)Cl2 (5 
mg, 0.0125 mmol) were added and the mixture was stirred at 90° C for 14 h. The cooled mixture 
was extracted with AcOEt (3 x 5 mL). The organic layers were washed with water (30 mL), 
dried (MgSO4), filtered, and concentrated under reduced pressure. The crude product was 
purified by column chromatography (Silica gel 220-440 mesh) using AcOEt/n-Hexane (95:5) 
as the eluant to afford the pure products 104a,b. 
 
(4-(4-Amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-
yl)phenyl)methanol 104a. 
 
Yield: 27 mg, 57% 
Mp: 220-238 °C 
MW = 379.84 
Anal. calcd for C20H18N5ClO, C 63.24, H 4.78, N 18.44, found C 63.27, H 5.11, N 18.09. 
                  
1H NMR (CDCl3): δ 4.82-4.80 (m, 2H, CH2Ar), 8.38 (s, 1H, H-6), 7.78-7.25 (m, 9H Ar), 5.62-
5.59 (m, 1H, OH), 5.55-5.47 (m, 1H, CH), 5.08-5.03 (m, 2H, CH2N),  
IR (KBr): cm-1 3500, 3319 (NH2), 3083 (OH). 
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4-(4-Amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenol 104b. 
 
Yield: 28 mg, 62% 
Mp: 274-278 °C 
MW = 365.82 
Anal. calcd for C19H16N5ClO, C 62.38, H 4.41, N 19.14, found C 62.54, H 4.68, N 18.94. 
                      
1H NMR (CDCl3): 4.68-4.82 and 4.89-5.04 (2m, 2H, CH2N), 5.61-5.75 (m, 1H, CH), 6.88-7.52 
(m, 9H Ar), 8.21 (s, 1H, H-6). 
IR (KBr): cm-1 3479, 3302 (NH2), 3061 (OH). 
 
General procedure for the synthesis of compounds 114a-f.  
 
 
 
A 60% sodium hydride dispersion in mineral oil (1.21 g, 30.3 mmol) was added in small batches 
to a solution of malononitrile (1.00 g, 15.1 mmol) in anhydrous THF (25 mL) precooled at 0-5 
°C. After 30 min at 0-5 °C, the suitable acyl chloride (15.1 mmol) was added dropwise. The 
orange solution was stirred at room temperature for 2-12 h, then dimethylsulfate (1.75 mL, 18.2 
mmol) was slowly added and the solution was refluxed for 3-6 h. Finally, 2-hydrazino-1-
phenylethanol 80c (4.62 g, 30.2 mmol) dissolved in anhydrous THF (2 mL) was added and the 
reaction was refluxed for 3-6 h. After cooling to room temperature, water (25 mL) and conc. 
NH3 (5 mL) were added under stirring. After 15 min, THF was removed under reduced pressure 
and the aqueous phase was extracted with CH2Cl2 (3 × 30 mL). Organic phases were washed 
with water (15 mL) and saturated NaCl solution (15 mL), dried (Na2SO4), and evaporated under 
reduced pressure. The crude was purified by flash chromatography (IsoleraTM One Biotage) 
using Et2O/PE as the eluent, with a gradient elution (2:8 → 9:1) to afford compounds 104a-f. 
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5-Amino-3-(2-chlorophenyl)-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-4-carbonitrile 114a. 
 
Yield: 1.9 g, 37% 
Mp: 131-134 °C 
MW = 338.79 
Anal. calcd for C18H15N4ClO, C 63.81, H 4.46, N 16.54, found C 63.79, H 4.58, N 16.73.                 
1H NMR (CDCl3): δ 4.20-4.11 (m, 2H, CH2N), 5.19-5.16 (m, 1H, CHO), 7.48-7.29 (m, 9H Ar). 
IR (KBr): cm-1 3450-2800 (OH), 3426, 3327 (NH2), 2216 (CN). 
 
5-Amino-3-(3-chlorophenyl)-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-4-carbonitrile 114b. 
 
Yield: 2.0 g, 39% 
Mp: 172-180 °C 
MW = 338.79 
Anal. calcd  for C18H15ClN4O, C 63.81, H 4.46, N 16.54, found C 63.86, H 4.56, N 16.83.            
1H NMR (CDCl3): δ 4.21-4.09 (m, 2H, CH2N), 5.16-5.12 (m, 1H, CHO), 7.46-7.27 (m, 9H Ar). 
IR (KBr): cm-1 3450-2900 (OH), 3407, 3327 (NH2), 2218 (CN). 
 
5-Amino-3-(4-bromophenyl)-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-4-carbonitrile 114c.  
 
Yield: 2.4 g, 41% 
Mp: 185.7-188.4 °C 
MW = 383.24 
Anal. calcd for C18H15BrN4O, C 56.41, H 3.95, N 14.62, found C 56.52, H 4.01, N 14.25.               
1H NMR (CDCl3): δ 4.07-4.38 (m, 2H, CH2N), 5.20-5.25 (m, 1H, CHO), 7.28-7.82 (m, 9H Ar).  
IR (KBr): cm−1 3398 (OH), 3329 (NH2), 2194 (CN).  
 
5-Amino-1-(2-hydroxy-2-phenylethyl)-3-(4-iodophenyl)-1H-pyrazole-4-carbonitrile 114d.  
 
Yield: 2.4 g, 41% 
Mp: 173.4-177.2 °C 
MW = 430.24 
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Anal. calcd for C18H15IN4O, C 50.25, H 3.51, N 13.02, found C 50.55, H 3.56, N 13.30.                
1H NMR (CDCl3): δ 4.06-4.37 (m, 2H, CH2N), 5.19-5.23 (m, 1H, CHO), 7.29-7.77 (m, 9H Ar).  
IR (KBr): cm−1 3500-2800 (OH), 3398, 3329 (NH2), 2195 (CN). 
 
5-Amino-3-(4-ethylphenyl)-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-4-carbonitrile 114e. 
 
Yield: 2.2 g, 44% 
Mp: 160.6-163.5 °C 
MW = 332.40  
Anal. calcd for C20H20N4O, C 72.27, H 6.06, N 16.86, found C 72.14, H 6.14, N 16.55.                      
1H NMR (CDCl3): δ 1.28-1.32 (m, 3H, CH3), 2.69-2.73 (m, 2H, CH3CH2), 4.03-4.16 (m, 2H, 
CH2N), 5.09-5.13 (m, 1H, CHO), 7.27-7.43 and 7.81-7.84 (2m, 9H Ar).  
IR (KBr): cm−1 3500-2800 (OH), 3393, 3320 (NH2), 2216 (CN).  
 
5-Amino-1-(2-hydroxy-2-phenylethyl)-3-(4-propylphenyl)-1H-pyrazole-4-carbonitrile 114f. 
 
Yield: 2.5 g, 48% 
Mp: 106.7-109.3 °C 
MW = 346.43  
Anal. calcd for C21H22N4O, C 72.81, H 6.40, N 16.17, found C 72.68, H 6.72, N 16.45.                    
1H NMR (CDCl3): δ 0.94-1.01 (m, 3H, CH3), 1.63-1.70 (m, 2H, CH3CH2), 2.60-2.68 (m, 2H, 
CH3CH2CH2) 4.12-4.30 (m, 2H, CH2N), 5.22-5.28 (m, 1H, CHO), 7.24-7.83 (m, 9H Ar). 
 
General procedure for the synthesis of compounds 115a-f.  
 
 
 
A suspension of the suitable intermediate 114a-f (3 mmol) in formamide (18 mL, 450 mmol) 
was heated at 190 °C for 3-4 h and then poured into water (40 mL). The crude solid was filtered, 
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washed with water, suspended in EtOH, and boiled with charcoal for 10 min. The solid 
dissolved at the EtOH boiling point. After charcoal filtration, compounds 115a-f precipitated 
as pure solids.  
 
2-[4-Amino-3-(2-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-phenylethanol 115a. 
 
Yield: 0.5 g, 46% 
Mp: 126-129 °C 
MW = 365.82 
Anal. calcd for C19H16N5ClO, C 62.38, H 4.41, N 19.14, found C 62.77, H 4.45, N 19.47.             
1H NMR (CDCl3): δ 4.76-4.74 (m, 2H, CH2N), 5.38-5.26 (m, 1H, CHO), 7.53-7.29 (m, 9H Ar), 
8.35 (s, 1H, H-6). 
IR (KBr): cm-1 3600-2800 (OH), 3319, 3183 (NH2). 
 
2-[4-Amino-3-(3-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-phenylethanol 115b. 
 
Yield: 0.55 g, 50% 
Mp: 84-89 °C 
MW = 365.82 
Anal. calcd for C19H16N5ClO, C 62.38, H 4.41, N 19.14, found C 62.19, H 4.78, N 19.13.             
1H NMR (CDCl3): δ 4.73-4.70 (m, 2H, CH2N), 5.39-5.26 (m, 1H, CHO), 7.53-7.29 (m, 9H Ar), 
8.37 (s, 1H, H-6). 
IR (KBr): cm-1 3550-2800 (OH), 3319, 3180 (NH2). 
 
2-[4-Amino-3-(4-bromophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-phenylethanol 115c. 
 
Yield: 0.8 g, 65% 
Mp: 198.2-201.0 °C 
MW = 410.27   
Anal. calcd for C19H16BrN5O, C 55.62, H 3.95, N 17.07, found C 55.81, H 4.06, N 16.74.            
1H NMR (CDCl3): δ 3.63-3.88 and 4.70-4.87 (2m, 2H, CH2N), 5.29-5.39 (m, 1H, CHO), 7.28-
7.77 (m, 9H Ar), 8.35 (s, 1H, H-6).  
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IR (KBr): cm−1 3500-2900 (OH), 3406, 3293 (NH2). 
 
2-[4-Amino-3-(4-iodophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-phenylethanol 115d.  
 
Yield: 0.6 g, 44% 
Mp: 218.0-220.0 °C 
MW = 457.27   
Anal. calcd for C19H16IN5O, C 49.91, H 3.53, N 15.32, found C 50.13, H 3.53, N 15.27.                
1H NMR (CDCl3): δ 4.56-4.87 (m, 2H, CH2N), 5.23-5.40 (m, 1H, CHO), 7.29-7.46 and 7.81-
8.00 (2m, 9H Ar), 8.32 (s, 1H, H-6). 
 
2-[4-Amino-3-(4-ethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-phenylethanol 115e.  
 
Yield: 0.65 g, 60% 
Mp: 53.6-59.2 °C 
MW = 359.42   
Anal. calcd for C21H21N5O, C 70.17, H 5.89, N 19.48, found C 70.05, H 6.18, N 19.77.                       
1H NMR ((CD3)2SO): δ 1.20-1.28 (m, 3H, CH3), 2.46-2.70 (m, 2H CH3CH2) 4.27-4.61 (m, 2H, 
CH2N), 5.09-5.23 (m, 1H, CHO), 7.28-7.59 (m, 9H Ar), 8.21 (s, 1H, H-6).  
IR (KBr): cm−1 3600-2800 (OH), 3468, 3303 (NH2).  
 
2-[4-Amino-3-(4-propylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-phenylethanol 115f.  
 
Yield: 0.5 g, 45% 
Mp: 57.3-58.4 °C 
MW = 373.45   
Anal. calcd for C22H23N5O, C 70.76, H 6.21, N 18.75, found C 70.62, H 6.40, N 18.64.                   
1H NMR (CDCl3): δ 0.98-1.05 (m, 3H, CH3), 1.62-1.83 (m, 2H, CH3CH2), 2.67-2.77 (m, 2H, 
CH3CH2CH2) 4.68-4.71 (m, 2H, CH2N), 5.26-5.37 (m, 1H, CHO), 7.29-7.62 (m, 9H Ar), 8.31 
(s, 1H, H-6).  
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General procedure for the synthesis of compounds 104e-j.  
 
 
 
SOCl2 (80 μL, 1.1 mmol) was added dropwise to a solution of the suitable intermediate 115a-f 
(0.5 mmol) in anhydrous CH2Cl2 (5 mL), and the reaction was stirred at room temperature for 
12 h under nitrogen atmosphere. Water (5 mL) and 1 N NaOH (1 mL) were added with caution, 
and the aqueous phase was extracted with CH2Cl2 (2 × 5 mL). Then the organic phase was 
washed with water (5 mL) and saturated NaCl solution (5 mL), dried (Na2SO4), and 
concentrated under reduced pressure. The crude was purified by column chromatography using 
CH2Cl2/MeOH (98:2) as the eluent to afford compounds 104e-j. 
 
3-(2-Chlorophenyl)-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 104e. 
 
Yield: 75 mg, 39% 
Mp: 181-184 °C 
MW = 384.26 
Anal. calcd for C19H15N5Cl2, C 59.39, H 3.93, N 18.23, found C 59.60, H 3.95, N 17.93.                
1H NMR ((CD3)2SO): δ 4.95-4.78 and 5.13-4.96 (2m, 2H, CH2N), 5.76-5.62 (m, 1H, CHCl), 
7.60-7.33 (m, 9H Ar), 8.23 (s, 1H, H-6). 
IR (KBr): cm-1 3496, 3296 (NH2). 
 
3-(3-Chlorophenyl)-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 104f. 
 
Yield: 80 mg, 42% 
Mp: 162-163 °C 
MW = 384.26 
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Anal. calcd for C19H15Cl2N5, C 59.39, H 3.93, N 18.23, found C 59.54, H 4.00, N 18.46. 
                       
1H NMR ((CD3)2SO): δ 4.88-4.76 and 5.12-4.98 (2m, 2H, CH2N), 5.79-5.71 (m, 1H, CHCl), 
7.66-7.36 (m, 9H Ar), 8.28 (s, 1H, H-6).  
IR (KBr): cm-1 3473, 3294 (NH2). 
 
3-(4-Bromophenyl)-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 104g.  
 
Yield: 0.2 g, 42% 
Mp: 195.5-199.4 °C 
MW = 428.71   
Anal. calcd for C19H15BrClN5, C 53.23, H 3.53, N 16.34, found C 53.12, H 3.57, N 16.11. 
                 
1H NMR ((CD3)2SO): δ 4.74-4.89 and 4.92-5.12 (2m, 2H, CH2N), 5.68-5.88 (m, 1H, CHCl), 
7.36-7.75 (m, 9H Ar), 8.26 (s, 1H, H-6). 
IR (KBr): cm−1 3455, 3061 (NH2).  
 
1-(2-Chloro-2-phenylethyl)-3-(4-iodophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 104h.  
 
Yield: 0.1 g, 53% 
Mp: 214.8-218.4 °C 
MW = 475.71   
Anal. calcd for C19H15ClIN5, C 47.97, H 3.18, N 14.72, found C 47.99, H 3.35, N 14.66. 
                     
1H NMR ((CD3)2SO): δ 4.76-4.89 and 4.98-5.13 (2m, 2H, CH2N), 5.63-5.87 (m, 1H, CHCl), 
7.38-7.55 and 7.89-7.94 (2m, 9H Ar), 8.28 (s, 1H, H-6).  
 
1-(2-Chloro-2-phenylethyl)-3-(4-ethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 104i.  
 
Yield: 0.1 g, 53% 
Mp: 228.0-229.1 °C 
MW = 377.87   
Anal. calcd for C21H20ClN5, C 66.75, H 5.33, N 18.53, found C 66.91, H 5.40, N 18.56.                      
1H NMR ((CD3)2SO): δ 1.21-1.28 (m, 3H, CH3), 2.68-2.71 (m, 2H CH3CH2) 4.77-4.91 and 
4.99-5.11 (2m, 2H, CH2N), 5.69-5.87 (m, 1H, CHCl), 7.37-7.60 (m, 9H Ar), 8.27 (s, 1H, H-6).  
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1-(2-Chloro-2-phenylethyl)-3-(4-propylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 104j.  
 
Yield: 0.09 g, 46% 
Mp: 190.0-192.3 °C 
MW = 391.90   
Anal. calcd for C22H22ClN5, C 67.42, H 5.66, N 17.87, found C 67.63, H 5.36, N 17.60.                 
1H NMR ((CD3)2SO): δ 0.90-0.97 (m, 3H, CH3), 1.59-1.67 (m, 2H, CH3CH2), 2.60-2.63 (m, 
2H, CH3CH2CH2) 4.76-4.89 and 4.94-5.09 (2m, 2H, CH2N), 5.63-5.87 (m, 1H, CHCl), 7.35-
7.66 (m, 9H Ar), 8.27 (s, 1H, H-6).  
 
Synthesis of 2-bromo-N-(2-morpholinophenyl)acetamide 120. 
 
 
 
To a solution of bromoacetyl chloride (500 μL, 5 mmol) in Et2O, a solution of 2-
morpholinoaniline 121 (891 mg, 5 mmol) in Et2O (50 mL) was added dropwise, then the 
suspension was stirred at room temperature for 4 h. The solvent was evaporated, then 1 N NaOH 
(50 mL) was added and the suspension was extracted with CH2Cl2 (3 x 75 mL), washed with 
water (100 mL), dried (Na2SO4) and concentrated under reduced pressure. The crude was 
crystallized as a white solid by adding Et2O (20 mL). 
 
Yield: 1.17 g, 78% 
Mp: 140-142 °C  
MW = 299.16 
Anal. calcd for C12H15N2O2Br, C 48.18, H 5.05, N 9.36, found C 47.86, H 5.50, N 9.13.                                               
1H NMR (CDCl3): δ 3.22-3.31 (m, 4H, 2CH2N morph), 3.54-3.76 (2m, 4H, 2CH2O morph), 
4.30 (s, 2H, CH2Br), 6.66-6.96 (2m, 2H Ar), 7.32-7.36 (m, 1H Ar), 8.14-8.16 (m, 1H Ar). 
IR (KBr): cm-1 3268 (NH), 1670 (CO). 
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Synthesis of 2-((1-(2-hydroxy-2-phenylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-
d]pyrimidin-6-yl)thio)-N-(2-morpholinophenyl)acetamide 122. 
 
 
 
To a suspension of 83c (288 mg, 1 mmol), 122 (300 mg, 1.14 mmol) and anhydrous K2CO3 
(138 mg, 1 mmol) in anhydrous DMF (2 mL), the mixture was stirred at room temperature for 
24 h. Cold water was added to obtain a white solid that was filtered, washed with water (10 
mL) and recrystallized from AcOEt.  
 
Yield: 0.23 g, 46% 
Mp: 193-194 °C 
MW = 506.58   
Anal. calcd for C25H26N6O4S, C 59.27, H 5.17, N 16.59, S 6.33, found C 59.27, H 5.52, N 16.35, 
S 5.94.    
1H NMR (CDCl3): δ 3.35-3.70 (m, 4H, 2CH2N morph), 3.82-4.00 and 4.55-4.65 (2m, 4H, 
2CH2O morph), 4.83-5.10 (m, 4H, SCH2 + CH2N pyraz.), 5.56-5.61 (m, 1H, CHCl), 6.45 (s all, 
1H, NH disappears with D2O), 7.28-7.50 and 7.80-7.82 (2m, 9H Ar), 8.06 (s, 1H, H-3).  
IR (KBr): cm-1 3500-3030 (OH), 3322 (NH), 1704 (CO), 1685 (CO).  
 
General procedure for the synthesis of compounds 123 and 118a. 
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The Vilsmeier complex, previously prepared from POCl3 (4.6 g, 30 mmol) and anhydrous DMF 
(2.19 g, 30 mmol) was added to a suspension of 122 (506 mg, 1 mmol) in CH2Cl2 (10 mL). The 
mixture was refluxed for 4 h. After cooling at room temperature, 1 M NaOH was added (150 
mL) and the suspension was extracted with CH2Cl2 (3 x 20 mL), washed with water (2 x 20 
mL), dried (MgSO4), filtered and concentrated under reduced pressure. The yellow crude oil 
was purified by column chromatography (Silica gel 0.06-0200 mm, 40 Å) using Et2O as the 
eluant, to afford compound 123 and 118a. 
 
2-((4-Chloro-1-(2-chloro-2-phenylethyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-
yl)thio)-N-(2-morpholinophenyl)acetamide 123. 
 
Yield: 0.24 g, 44% 
Mp: 107-118 °C 
MW = 543.47   
Anal. calcd  for C25H24N6Cl2O2S, C 55.25, H 4.45, N 15.46, S 5.90, found C 55.55, H 4.48, N 
15.06, S 6.32.    
1H NMR (CDCl3): δ 3.35-3.70 (m, 4H, 2CH2N morph), 3.82-4.00 and 4.55-4.65 (2m, 4H, 
2CH2O morph), 4.83-5.10 (m, 4H, SCH2 + CH2N pyraz.), 5.56-5.61 (m, 1H, CHCl), 7.28-7.50 
and 7.80-7.82 (2m, 9H Ar), 8.06 (s, 1H, H-3). 
IR (KBr): cm-1 3011 (NH), 1730 (CO).  
 
2-((1-(2-Chloro-2-phenylethyl)-4-(dimethylamino)-4,5-dihydro-1H-pyrazolo[3,4-
d]pyrimidin-6-yl)thio)-N-(2-morpholinophenyl)acetamide 118a. 
 
Yield: 0.15 g, 28% 
Mp: 197-201 °C 
MW = 552.09   
Anal. calcd  for C27H30N7O2ClS, C 58.74, H 5.48, N 17.76, S 5.81, found C 58.74, H 5.49, N 
17.52, S 5.32.  
1H NMR (CDCl3): δ 2.55-2.70 (m, 4H, 2CH2N morph), 3.20-3.40 (s, 6H, 2CH3), 3.65-3.75 (2m, 
4H, 2CH2O morph), 3.98 (s, 2H, SCH2), 4.58-4.63 and 4.82-4.88 (2m, 2H, CH2N pyraz.), 5.44-
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5.46 (m, 1H, CHCl), 6.99-7.14, 7.26-7.43 and 7.82-7.84 (m, 8H Ar), 7.84 (s, 1H, H-3), 8.48-
8.50 (d, J = 8.0, 1H Ar), 9.53 (s, 1H, NH). 
IR (KBr): cm-1 3280 (NH), 1677 (CO).  
 
General procedure for the synthesis of compounds 118b-d. 
 
 
 
To a solution of 123 (543 mg, 1 mmol) in anhydrous toluene (5 mL), the appropriate amine (4 
mmol) was added and the reaction was stirred at room temperature for 48 h. The solution was 
washed with water (2 x 10 mL), dried (MgSO4), filtered and concentrated under reduced 
pressure. The crude oil was purified by column chromatography (Florisil®, 100-200 mesh), 
using Et2O as the eluent to obtain compounds 118b-d which crystallized by adding a 1:1 
mixture of Et2O and PE (bp 40-60 °C) to give a white solid. 
 
2-((1-(2-Chloro-2-phenylethyl)-4-(phenethylamino)-4,5-dihydro-1H-pyrazolo[3,4-
d]pyrimidin-6-yl)thio)-N-(2-morpholinophenyl)acetamide 118b. 
 
Yield: 0.32 g, 51% 
Mp: 128-132 °C 
MW = 628.19  
Anal. calcd  for C33H34N7O2ClS, C 63.09, H 5.46, N 15.61, S 5.10, found C 62.85, H 5.72, N 
15.48, S 4.85.   
1H NMR (CDCl3): δ 2.80-3.10 (m, 2H, CH2Ar), 3.40-3.50 and 3.52-3.62 (2m, 4H, 2CH2N 
morph), 3.80-3.96 (m, 4H, 2CH2O morph), 4.55-4.57 (m, 2H, CH2NH), 4.69-4.73 and 4.87-
5.01 (2m, 4H, SCH2 + CH2N pyraz.), 5.54-5.58 (m, 1H, CHCl), 7.23-7.41 (m, 15H, 14Ar + H-
3), 7.91 (s all., 1H, NH).  
IR (KBr): cm-1 3247 (NH), 3176 (NH), 1621 (CO). 
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2-((1-(2-Chloro-2-phenylethyl)-4-((4-fluorophenethyl)amino)-4,5-dihydro-1H-pyrazolo[3,4-
d]pyrimidin-6-yl)thio)-N-(2-morpholinophenyl)acetamide 118c. 
 
Yield: 0.25 g, 39%  
Mp: 130-132 °C 
MW = 646.18   
Anal. calcd  for C33H33N7O2ClFS, C 61.34, H 5.15, N 15.17, S 4.96, found C 61.42, H 5.33, N 
14.91, S 4.74.    
1H NMR (CDCl3): δ 2.80-3.05 (m, 2H, CH2Ar), 3.44-3.48 and 3.53-3.56 (2m, 4H, 2CH2N 
morf), 3.82-3.85 (2m, 4H, 2CH2O morph), 4.53 (m, 2H, CH2NH), 4.52-4.56 and 4.83-4.96 (2m, 
4H, SCH2 + CH2N pyraz.), 5.56-5.60 (m, 1H, CHCl), 6.97-7.01, 7.15-7.19, 7.26-7.36 and 7.40-
7.42 (4m, 13H, 12Ar + H-3), 7.7-7.73 (m, 1H Ar). 
IR (KBr): cm-1 3249 (NH), 3178 (NH), 1615 (CO).  
 
2-((1-(2-Chloro-2-phenylethyl)-4-((3-chlorophenethyl)amino)-4,5-dihydro-1H-pyrazolo[3,4-
d]pyrimidin-6-yl)thio)-N-(2-morpholinophenyl)acetamide 118d. 
  
Yield: 0.29 g, 44% 
Mp: 118-124 °C 
MW = 662.63   
Anal. calcd  for C33H33N7O2Cl2S, C 59.81, H 5.02, N 14.80, S 4.84, found C 59.55, H 4.95, N 
14.51, S 4.72.    
1H NMR (CDCl3): δ 2.94-2.98 (t, J = 6.8, 2H, CH2Ar), 3.45-3.48 and 3.54-3.56 (2m, 4H, 
2CH2N morph), 3.82-3.85 (m, 4H, 2CH2O morph), 4.53 (m, 2H, CH2NH), 4.70-4.75 and 4.83-
4.96 (2m, 4H, SCH2 + CH2N pyraz.), 5.57-5.59 (m, 1H, CHCl), 7.08-7.10 and 7.22-7.36 (2m, 
13H, 12Ar + H-3), 7.41-7.42 (m, 1H Ar). 
IR (KBr): cm-1 3300-3100 (NH), 1621 (CO). 
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Synthesis of 2-((1-(2-chloro-2-phenylethyl)-4-((3-chlorophenyl)amino)-4,5-dihydro-1H-
pyrazolo[3,4-d]pyrimidin-6-yl)thio)-N-(2-morpholinophenyl)acetamide 118e. 
 
A solution of 123 (543 mg, 1 mmol) and 3-chloroaniline (255 mg, 2 mmol) in absolute EtOH 
was refluxed for 5 h. After cooling at room temperature, the solvent was evaporated under 
reduced pressure, then water was added (20 mL) and the suspension was extracted with CH2Cl2 
(3 x 20 mL); washed with water (20 mL), dried (MgSO4), filtered and concentred under reduced 
pressure. The crude oil was crystallized by adding a 1:1 mixture of Et2O and PE (bp 40-60 °C) 
and finally the solid was recrystallized from absolute EtOH to obtain compound 118e as a white 
solid. 
 
Yield: 0.27 g, 42% 
Mp: 153-157 °C 
MW = 634.58   
Anal. calcd  for C31H29N7O2Cl2S, C 58.67, H 4.61, N 15.45, S 5.05, found C 58.76, H 4.88, N 
15.17, S 4.74.   
1H NMR (CDCl3): δ 3.40-3.44 and 3.52-3.56 (2m, 4H, 2CH2N morph), 3.80-3.84 (m, 4H, 
2CH2O morph), 4.67-4.73 and 4.80-4.99 (2m, 4H, SCH2 + CH2N pyraz.), 5.55-5.57 (m, 1H, 
CHCl), 7.15-7.41 (m, 14H, 13Ar + H-3). 
IR (KBr): cm-1 3286 (NH), 1634 (CO). 
 
Synthesis of 2-phenethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one 
125. 
 
 
To a solution of 124 (451 mg, 2 mmol) in 4 M HCl in dioxane (10 mL), 3-phenylproprionitrile 
(1.31 mL, 10 mmol) was added and the suspension was stirred at 60 °C for 20 h. The solvent 
was evaporated under reduced pressure, water was added (50 mL) and the suspension was 
extracted with AcOEt (3 x 50 mL), washed with saturated NaCl solution (50 mL), dried 
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(Na2SO4), filtered and evaporated under reduced pressure. The brown oil crystallized by adding 
a 1:1 mixture of Et2O and n-hexane to give a white solid. 
 
Yield: 0.61 g, 99% 
Mp: 234-235 °C 
MW = 310.41 
Anal. calcd for C18H18N2 SO, C 69.65, H 5.84, N 9.02, S 10.33, found C 69.57, H 6.09, N 8.95, 
S 10.10.                            
1H NMR (CDCl3): δ 1.80-1.95 (m, 4H, CH2-6 and CH2-7), 2.77-2.83 (m, 2H, CH2-9), 3.04-3.06 
(m, 4H, CH2-5 and CH2-8), 3.12-3.14 (m, 2H, CH2-10), 7.25-7.27 (m, 5H Ar), 12.35 (s all., 1H, 
NH). 
IR (KBr): cm-1 1663 (CO), 1594 (NH). 
 
Synthesis of 4-chloro-2-phenethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine 
126. 
 
 
 
A suspension of 125 (100 mg, 0.32 mmol) and POCl3 (1 mL, 10.73 mmol) was heated at 80 °C 
for 8 h. POCl3 was evaporated under reduced pressure, then a solution of NaHCO3 was added 
until pH ~ 7 (5 mL) and the suspension was extracted with AcOEt (3 × 10 mL), washed with 
water (10 mL), dried (Na2SO4), filtered and evaporated under reduced pressure. The brown oil 
crystallized by adding a mixture of Et2O and PE (bp 40-60 °C) to give a white solid. 
 
Yield: 65 mg, 62% 
Mp: 83-87 °C 
MW = 328.86 
Anal. calcd for C18H17N2SCl, C 65.74, H 5.21, N 8.52, S 9.75, found C 65.96, H 5.24, N 8.70, 
S 9.43.                                                             
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1H NMR (CDCl3): δ 1.81-1.98 (m, 4H, CH2-6 and CH2-7), 2.67-2.98 (m, 2H, CH2-9), 3.04-3.18 
(m, 6H, CH2-5, CH2-8 and CH2-10), 7.21-7.32 (m, 5H Ar). 
 
Synthesis of ethyl 2-((2-phenethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-
yl)amino)acetate 127. 
 
 
A solution of glycine ethyl ester hydrochloride (216 mg, 1.55 mmol) and TEA (628 μL, 4.50 
mmol) in absolute EtOH (15 mL) was stirred at room temperature for 5 min. 126 (443 mg, 1.35 
mmol) was added and the reaction was refluxed for 12 h. The solvent was evaporated under 
reduced pressure then water was added (50 mL) and the suspension was extracted with AcOEt 
(3 x 50 mL), washed with saturated NaCl solution (50 mL), dried (Na2SO4), filtered and 
evaporated under reduced pressure. The oil crystallized by adding a 1:1 mixture of Et2O and 
PE (bp 40-60 °C) to give a white solid. 
 
Yield: 0.38 g, 71% 
Mp: 128-129 °C 
MW = 395.52 
Anal. calcd for C22H25N3SO2, C 66.81, H 6.37, N 10.62, S 8.11, found C 66.55, H 6.27, N 10.50, 
S 8.00.                                                         
1H NMR (CDCl3): δ 1.35 (t, J = 7.2 Hz, 3H, CH3), 1.93-1.99 (m, 4H, CH2-6 and CH2-7), 2.88-
2.96 (m, 2H, CH2-9), 2.98-3.06 (m, 2H, CH2-10), 3.18-3.23 (m, 4H, CH2-5 and CH2-8), 4.28-
4.32 and 4.34-4.36 (2m, 4H, CH2 N + CH2O), 7.15-7.32 (m, 5H Ar). 
IR (KBr): cm-1 3340 (NH), 1741 (CO), 1580 (NH). 
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Synthesis of 2-((2-phenethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-
yl)amino)acetic acid 128. 
 
 
 
To a suspension of 127 (313 mg, 0.79 mmol) in absolute EtOH, a solution 1 N NaOH in absolute 
EtOH (6.7 mL) was added and the reaction was stirred at room temperature for 12 h. The solvent 
was evaporated under reduced pressure, water was added, then 1 N HCl was added until pH ~ 
2. Compound 128 precipitated as a white solid and was filtered and washed with cold water. 
 
Yield: 98% 
Mp: 208-210 °C 
MW = 367.47 
Anal. calcd for C20H21N3SO2, C 65.37, H 5.76, N 11.44, S 8.73, found C 65.36, H 6.08, N 11.23, 
S 8.81.                                                                                              
1H NMR ((CD3)2SO): δ 1.84-1.94 (m, 4H, CH2-6 and CH2-7), 2.50-2.52 (m, 2H, CH2-9), 2.70-
2.76 (m, 2H, CH2-10), 2.83-3.03 (m, 4H, CH2-5 and CH2-8), 4.08 (d, J = 5.0 Hz, 2H, CH2N), 
7.16-7.25 (m, 5H Ar). 
IR (KBr): cm-1 3417 (NH), 1721 (CO), 1579 (NH). 
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Synthesis of N1-(2-morpholinophenyl)-N2-(2-phenethyl-5,6,7,8-
tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)ethane-1,2-diamine 119a. 
 
 
 
To a suspension of 128 (100 mg, 0.27 mmol) and 2-morpholinoaniline (49 mg, 0.27 mmol) in 
ACN (2 mL) PCl3 was added dropwise (7.15 µL, 0.082 mmol) and the reaction was refluxed 
for 8 h. Then, NaHCO3 (50 mL) was added and the suspension was extracted with CH2Cl2 (3 x 
50 mL), washed with water (50 mL), dried (Na2SO4), filtered and evaporated under reduced 
pressure. The crude was purified by flash chromatography (IsoleraTM One Biotage) using 
CH2Cl2/MeOH as the eluent, with a gradient elution to afford compounds 119a. 
 
Yield: 50 mg, 35% 
Mp: 147-154 °C 
MW = 527.68 
Anal. calcd for C30H33N5O2S, C 68.28, H 6.30, N 13.27, S 6.08, found C 68.25, H 6.29, N 13.05, 
S 6.08.                                                                                                                       
1H NMR (CDCl3): δ 1.96-1.98 (m, 4H, CH2-6 and CH2-7), 2.68-2.72, 2.84-2.92 and 3.08-3.22 
(3m, 12H, CH2-5, CH2-8, CH2-9, CH2-10, CH2-11 and CH2-14), 3.48-3.57 (m, 4H, CH2-12 and 
CH2-13), 4.43 (d, J = 4.4 Hz, 2H, CH2NH), 6.25 (s all., 1H, NHCH2), 7.12-7.22 (m, 8H Ar), 
8.48 (d, J = 6 Hz, 1H Ar), 9.12 (s all., 1H, NHCO). 
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Synthesis of 2-phenethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine-4-thiol 
129. 
 
 
To a solution of 125 (310 mg, 1 mmol) in anhydrous dioxane (10 mL), P2S5 (108 µL, 1 mmol) 
was added and the reaction was refluxed for 8 h under nitrogen atmosphere. The reaction was 
poured in water (50 mL) to obtain a white solid. The suspension was heated at 100 °C for 1 h 
to obtain a solution, after cooling at room temperature, the reaction was extracted with AcOEt 
(3 x 100 mL), the organic phase was washed with saturated NaCl solution (150 mL), dried 
(Na2SO4), filtered and evaporated under reduced pressure. Et2O was added and the solid was 
filtered to obtain the pure compound 129. 
 
Yield: 0.33 g, quantitative 
Mp: 228-231 °C 
MW = 326.48 
Anal. calcd for C18H18N2S2, C 66.22, H 5.56, N 8.58, S 19.64, found C 66.03, H 5.63, N 8.25, 
S 19.68.                                                                                                                                                        
1H NMR ((CD3)2SO): δ 1.65-1.83 (m, 4H, CH2-6 and CH2-7), 2.65-2.81 (m, 2H, CH2-9), 2.76-
3.01 (m, 4H, CH2-5 and CH2-8), 3.08-3.21 (m, 2H, CH2-10), 7.19-7.29 (m, 5H Ar). 
IR (KBr): cm-1 3200-2900 (SH), 1525 (NH). 
 
Synthesis of 2-(4-methylpiperazin-1-yl)aniline 130. 
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To obtain 130, a Pd catalyzed hydrogenation was performed on 1-methyl-4-(2-
nitrophenyl)piperazine (1.15 g, 5.19 mmol), then the solvent was evaporated under reduced 
pressure to give a white solid. 
 
Yield: 0.96 g, 97% 
Mp: 101-103 °C 
MW = 191.27 
Anal. calcd for C11H17N3, C 69.07, H 8.96, N 21.97, found C 69.00, H 9.09, N 21.70.                                            
1H NMR (CDCl3): δ 2.42 (s, 3H, CH3), 2.51-2.65 (m, 4H, 2CH2NCH3), 2.98-3.02 (t, J = 4.8 
Hz, 4H, 2CH2N), 3.99 (s all, 2H, NH2), 6.74-6.81 and 6.93-7.07 (2m, 4H Ar). 
IR (KBr): cm-1 3389, 3293 (NH2), 1503 (NH). 
 
Synthesis of 2-bromo-N-(2-(4-methylpiperazin-1-yl)phenyl)acetamide 131. 
 
 
 
To a solution of bromoacetyl chloride (247 mg, 1.57 mmol), in anhydrous Et2O (4 mL), a 
solution of 130 (130 µL, 1.31 mmol) in anhydrous Et2O (15 mL) was added dropwise and the 
reaction was stirred at room temperature for 12 h under nitrogen atmosphere. 1 N NaOH was 
added and the reaction was extracted with AcOEt (3 × 15 mL) and CH2Cl2 (3 × 15 mL), the 
organic phase was washed with saturated NaCl solution (100 mL), dried (Na2SO4), filtered and 
evaporated under reduced pressure. The crude was purified by column chromatography (Silica 
gel 220-440 mesh, 60 Å), using AcOEt/MeOH (MeOH 3040%) as the eluent. 
 
Yield: 0.14 g, 34% 
Mp: 108-113 °C 
MW = 312.21 
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Anal. calcd for C13H18N3OBr, C 50.01, H 5.81, N 13.46, found C 50.20, H 5.80, N 13.16.                 
1H NMR (CDCl3): δ 2.43 (s, 3H, CH3), 3.62-3.78 (m, 4H, 2CH2NCH3), 2.95-3.00 (t, J = 4.6 
Hz, 4H, 2CH2N), 4.26 (s, 2H, CH2Br), 7.16-7.23 1(m, 3H Ar), 8.38-8.42 (m, 1H Ar). 
IR (KBr): cm-1 3317 (NH), 1669 (CO), 1528 (NH). 
 
Synthesis of N-(2-(4-methylpiperazin-1-yl)phenyl)-2-((2-phenethyl-5,6,7,8-
tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)thio)acetamide 119b. 
 
 
 
To a solution of 129 (70 mg, 0.214 mmol) and 131 (74 mg, 0.236 mmol) in anhydrous DMF, 
anhydrous K2CO3 (445 mg, 0.322 mmol) was added and the reaction was stirred at room 
temperature for 4 h under nitrogen atmosphere. The solvent was evaporated under reduced 
pressure, then, water (10 mL) was added and the suspension was extracted with CH2Cl2 (3 x 10 
mL). The organic phase was washed with saturated NaCl solution (15 mL), dried (Na2SO4), 
filtered and evaporated under reduced pressure. The crude oil was purified by column 
chromatography (Silica gel 220-440 mesh, 60 Å), using AcOEt/MeOH (95:5) as the eluent. A 
mixture of Et2O and PE (bp 40-60 °C) was added and the solid was filtered to obtain the pure 
compound 119b. 
 
Yield: 75 mg, 63% 
Mp: 124-126 °C 
MW = 557.78 
Anal. calcd for C31H35N5OS2, C 66.75, H 6.32, N 12.56, S 11.50, found C 66.85, H 6.38, N 
12.35, S 11.34.                       
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1H NMR (CDCl3): δ 1.94-1.99 (m, 4H, CH2-6 and CH2-7), 2.06 (s, 3H, CH3), 2.60-2.68, 2.82-
2.88 and 3.04-3.19 (3 m, 16 H, CH2-5, CH2-8 + 8H piperaz + CH2CH2Ar), 4.14 (s, 2H, CH2S), 
7.07-7.14 (m, 8H Ar), 8.41-8.44 (m, 1H Ar), 9 (s all., 1H, NH). 
IR (KBr): cm-1 3292 (NH), 1680 (CO), 1522 (NH). 
 
Synthesis of 3-methyl-1-(2-nitrophenyl)piperazine 132. 
 
 
 
To a suspension of 1-bromo-2-nitrobenzene (1.5 g, 7.42 mmol) in dioxane (30 mL), 2-
methylpiperazine (1.12 g, 11.14 mmol) and K2CO3 (5.13 g, 37.1 mmol) were added and the 
reaction was refluxed for 14 h. The suspension was filtered and washed with AcOEt (3 × 10 
mL). The solution was evaporated under reduced pressure and the crude was purified by flash 
chromatography (IsoleraTM One Biotage), using AcOEt/MeOH as the eluent, with a gradient 
elution to afford compounds 132 as an orange oil. 
 
Yield: 1.64 g, quantitative 
MW = 221.26 
Anal. calcd for C11H15N3O2, C 59.71, H 6.83, N 18.99, found C 59.99, H 7.02, N 18.65.                   
1H NMR (CDCl3): δ 1.12 (d, J = 6.2 Hz, 3H, CH3), 2.31 (s all., 1H, NH), 2.57(t, J = 11.2 Hz, 
1H piperaz), 2.82-2.95 and 3.06-3.19 (2m, 6H piperaz), 7.05-7.18 (m, 2H Ar, HB and HD), 7.49 
(dt, J = 6.4 Hz, J = 1.6 Hz, 1H Ar, HC), 7.78 (dd, J = 6.4 Hz, J = 1.6 Hz, 1H Ar, HA).    
IR (KBr): cm-1 1604, 1342 (νsim and νas NO2). 
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Synthesis of tert-butyl 2-methyl-4-(2-nitrophenyl)piperazine-1-carboxylate 133. 
 
 
  
To a solution of 132 (538 mg, 2.43 mmol) in anhydrous CH2Cl2 (10 mL), TEA (474 μL, 3.40 
mmol) and Boc2O (636 mg, 2.91 mmol) were added and the reaction was stirred at room 
temperature for 12 h. The solution was washed with NaHCO3 (2 × 10 mL), then was extracted 
with CH2Cl2 (10 mL), the organic phase was washed with saturated NaCl solution (10 mL), 
dried (Na2SO4), filtered and evaporated under reduced pressure to obtain 133 as an orange oil. 
 
Yield: 0.78 g, quantitative  
MW = 321.37 
Anal. calcd for C16H23N3O4, C 59.80, H 7.21, N 13.08, found C 59.49, H 7.35, N 13.29.                      
1H NMR (CDCl3): δ 1.3 (d, J = 6.8 Hz, 3H, CHCH3), 1.49 (s, 9H, 3CH3 tBut), 2.85 (dt, J = 16.0 
Hz, J = 4 Hz, 1H piperaz), 3.02-3.41, 3.82-3.96 and 4.22-4.40 (3m, 6H piperaz), 7.07-7.17 (m, 
2H Ar, HB and HD), 7.51 (t, J = 9.6 Hz, 1H Ar, HC), 7.72 (d, J = 9.6 Hz, 1H Ar, HA). 
IR (KBr): cm-1 1693 (CO), 1524, 1365 (νsim and νas NO2). 
 
Synthesis of tert-butyl 4-(2-aminophenyl)-2-methylpiperazine-1-carboxylate 134. 
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 To obtain 134, a Pd catalyzed hydrogenation was performed on 133 (800 mg, 2.49 mmol), then 
the solvent was evaporated under reduced pressure to give a red oil which was purified by 
column chromatography (Silica gel 220-440 mesh, 60 Å), using CH2Cl2 as the eluent to give a 
brown solid. 
. 
Yield: 0.50 g, 69% 
Mp: 119-122 °C 
MW = 291.39 
Anal. calcd for C16H25N3O2, C 65.95, H 8.65, N 14.42, found C 65.82, H 8.69, N 14.71.                                             
1H NMR (CDCl3): δ 1.40 (d, J = 6.6 Hz, 3H, CHCH3), 1.51 (s, 9H, 3CH3 tBut), 2.63-3.18, 3.21-
3.39, 3.94-4.07 and 4.28-4.42 (4m, 7H piperaz), 6.81-6.85 and 6.98-6.99 (2m, 4H Ar). 
IR (KBr): cm-1 3429, 3345 (NH2), 1686 (CO). 
 
Synthesis of tert-butyl 4-(2-(2-bromoacetamido)phenyl)-2-methylpiperazine-1-
carboxylate 135. 
 
 
To a solution of 134 (210 mg, 0.721 mmol) and bromoacetyl chloride (78 µL, 0.937 mmol) in 
anhydrous Et2O (7 mL), the reaction was stirred at room temperature for 3 h under nitrogen 
atmosphere. 1 N NaOH was added and the suspension was extracted with CH2Cl2 (3 x 20 mL), 
dried (Na2SO4) and evaporated under reduced pressure to obtain 135 as a white solid. 
 
Yield: 0.28 g, 95% 
Mp: 145-148 °C 
MW = 412.32 
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Anal. calcd for C18H26N3O3Br, C 52.43, H 6.36, N 10.19, found C 52.34, H 6.50, N 10.26.                     
1H NMR (CDCl3): δ 1.45 (d, J = 6.4 Hz, 3H, CHCH3), 1.52 (s, 9H, 3CH3 tBut), 2.58-3.01, 3.11-
3.21, 3.30-3.57 and 3.90-4.18 (4m, 6H piperaz), 4.27 (s, 2H, CH2Br), 4.38-4.58 (m, 1H piperaz), 
7.15-7.22 (m, 3H Ar), 8.38-8.42 (m, 1H Ar), 9.65 (s all, 1H, NH). 
IR (KBr): cm-1 3295 (NH), 1696 (CO estere), 1681 (CO ammide), 1531 (NH). 
 
Synthesis of tert-butyl 2-methyl-4-(2-(2-((2-phenethyl-5,6,7,8-tetrahydrobenzo[4,5] 
thieno[2,3-d]pyrimidin-4-yl)thio)acetamido)phenyl)piperazine-1-carboxylate 136. 
 
 
 
To a suspension of 135 (84 mg, 0.203 mmol) and 125 (60.5 mg, 0.185 mmol) in the presence 
of anhydrous K2CO3 (38.4 mg, 0.277 mmol) in anhydrous DMF (5 mL), the reaction was stirred 
at room temperature for 12 h under nitrogen atmosphere. The solvent was evaporated under 
reduced pressure, H2O (10 mL) was added and the suspension was extracted with CH2Cl2 (3 x 
10 mL), the organic phase was washed with saturated NaCl solution (15 mL), dried (Na2SO4), 
filtered and evaporated under reduced pressure. The crude oil was purified by column 
chromatography (Silica gel 220-440 mesh, 60 Å), using Et2O/PE (1:1) as the eluent to afford 
136 as a white solid. 
 
Yield: 0.11 g, 90% 
Mp: 156-157 °C 
MW = 657.89 
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Anal. calcd for C36H43N5O3S2, C 65.72, H 6.59, N 10.65, S 9.75, found C 65.57, H 6.69, N 
10.79, S 9.48.                      
1H NMR (CDCl3): δ 1.12 (d, J = 6.6 Hz, 3H, CHCH3), 1.48 (s, 9H, 3CH3 tBut), 1.85-2.01, 3.38-
3.31 and 3.45-3.41 (3m, 18H, 6H piperaz + CH2CH2Ar + 8H pyrano), 4.18 (s, 2H, CH2Br), 
4.21-4.28 (m, 1H piperaz), 7.07-7.20 (m, 8H Ar), 8.48 (d, J = 8.6 Hz, 1H Ar), 9.57 (s all, 1H, 
NH). 
IR (KBr): cm-1 3315 (NH), 1692 (CO ester), 1591 (CO amide), 1519 (NH). 
 
Synthesis of N-(2-(3-methylpiperazin-1-yl)phenyl)-2-((2-phenethyl-5,6,7,8-
tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)thio)acetamide 119c. 
 
 
 
To a solution of 136 (100 mg, 0.15 mmol) in anhydrous CH2Cl2 (10 mL), TFA (70 µL, 0.9 
mmol) was added dropwise and the reaction was stirred at room temperature for 12 h under 
nitrogen atmosphere. TFA was evaporated and 1 N NaOH was added, the suspension was 
extracted with CH2Cl2 (3 x 10 mL), the organic phase was washed with saturated NaCl solution 
(15 mL), dried (Na2SO4), filtered and evaporated under reduced pressure. Et2O (10 mL) was 
added and then evaporated to obtain 119c as a white solid. 
 
Yield: 62 mg, 75% 
Mp: 57-65 °C 
MW = 557.78 
Anal. calcd for C31H35N5OS2, C 66.75, H 6.32, N 12.56, S 11.50, found C 66.72, H 6.56, N 
12.48, S 11.14.                                                        
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1H NMR (CDCl3): δ 0.75 (d, J = 6 Hz, 3H, CH3), 1.94-2.01 (m, 4H, CH2-6 and CH2-7), 2.19-
3.21 (m, 15H, 7H piperaz, + CH2CH2Ar + CH2-5 and CH2-8), 4.12 (d, J = 5.2 Hz, 2H, CH2S), 
7.07-7.18 (m, 8H Ar), 8.5 (d, J = 8 Hz, 1H Ar), 9.62 (s, 1H, NH). 
IR (KBr): cm-1 3285 (NH), 1679 (CO), 1518 (NH).  
 
General procedure for the synthesis of compounds 139a-c.  
 
 
 
The appropriate hydrazine 138a-c (20 mmol) was added to a solution of 
ethyl(ethoxymethylene)cyanoacetate (3.38 g, 20 mmol) in anhydrous toluene (20 mL) and the 
mixture was heated at 80 °C for 8 h. The solution was concentrated under reduced pressure to 
half of the volume and allowed to cool to room temperature. The yellow pale solid was filtered 
and recrystallized from toluene to afford 139a-c as white solids. 
 
Ethyl 5-amino-1-(2-(4-fluorophenyl)-2-hydroxyethyl)-1H-pyrazole-4-carboxylate 139a. 
 
Yield: 4.11 g, 70% 
Mp: 163-164 °C 
MW = 293.29 
Anal. calcd for C14H16N3O3F, C 57.33, H 5.50, N 14.33, found C 57.31, H 5.72, N 14.25.             
1H NMR (CDCl3): δ 1.33 (t, J = 7.0, 3H, CH3), 3.73 (s all, 1H, OH, disappears with D2O), 3.90-
4.15 (m, 2H, CH2N), 4.29 (q, J = 7.0, 2H, CH2O), 5.01-5.18 (m, 1H, CHO), 5.36 (s all, 2H, 
NH2, disappears with D2O), 7.03-7.40 (m, 4H Ar), 7.55 (s, 1H, H-3). 
IR (KBr) cm-1: 3448, 3446 (NH2), 3300-3000 (OH), 1685 (CO). 
 
Ethyl 5-amino-1-(2-(4-chlorophenyl)-2-hydroxyethyl)-1H-pyrazole-4-carboxylate 139b. 
 
Yield: 4.65 g, 75% 
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Mp: 168-169 °C 
MW = 309.75 
Anal. calcd for C14H16N3O3Cl, C 54.29, H 5.21, N 13.57, found C 54.27, H 5.16, N 13.48.        
1H NMR (CDCl3): δ 1.38 (t, J = 7.0, 3H, CH3), 3.56 (s all., 1H, OH, disappears with D2O), 
3.91-4.19 (m, 2H, CH2N), 4.28 (q, J = 7.0, 2H, CH2O), 5.05-5.18 (m, 1H, CHO), 5.33 (s all., 
2H, NH2, disappears with D2O), 7.25-7.46 (m, 4H Ar), 7.59 (s, 1H, H-3). 
IR (KBr) cm-1: 3412, 3291 (NH2), 3219-3100 (OH), 1689 (C=O). 
 
Ethyl 5-amino-1-(2-(4-bromophenyl)-2-hydroxyethyl)-1H-pyrazole-4-carboxylate 139c. 
 
Yield: 4.60 g, 65% 
Mp: 164-165 °C 
MW = 354.20 
Anal. calcd for C14H16N3O3Br, C 47.47, H 4.55, N 11.86, found C 47.50, H 4.60, N 11.90.         
1H NMR (CDCl3): δ 1.28 (t, J = 7.2, 3H, CH3), 3.84-4.13 (m, 2H, CH2N), 4.21 (q, J = 7.2, 2H, 
CH2O), 5.03-5.12 (m, 1H, CHO), 7.14-7.24 and 7.37-7.47 (2m, 4H Ar), 7.55 (s, 1H, H-3). 
IR (KBr) cm-1: 3411, 3291 (NH2), 3157-2900 (OH), 1689 (C=O). 
 
General procedure for the synthesis of compounds 140a-c. 
 
 
 
To a suspension of the appropriate intermediates 139a-c (10 mmol) in formamide (10 g, 333 
mmol), the reaction was heated at 190 °C for 8 h. After cooling to room temperature, water 
was added (300 ml) and the obtained solid was filtered. The solid was solubilized in 2 M 
NaOH then charcoal (600 mg) was added and the mixture was boiled for 10 min. After 
charcoal filtration, acetic acid was added until pH 4 and the precipitated solid was filtered, 
washed with water and recrystallized from absolute EtOH. 
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1-(2-(4-Fluorophenyl)-2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 140a. 
 
Yield: 2.0 g, 73% 
Mp: 281-282 °C 
MW = 274.25                                                                                                    
Anal. calcd for C13H11N4O2F, C 56.93, H 4.04, N 20.43, found C 56.90, H 4.19, N 20.41.                          
1H NMR (CDCl3): δ 4.22-4.35 and 4.39-4.54 (2m, 2H, CH2N), 5.02-5.17 (m, 1H, CHO), 5.72 
(s all., 1H, OH, disappears with D2O), 7.03-7.19 and 7.24-7.38 (2m, 4H Ar), 8.02 (s, 1H, H-3), 
8.07 (s, 1H, H-6), 12.13 (s all., 1H, NH, disappears with D2O). 
IR (KBr): cm-1 3387 (NH), 3168-2900 (OH), 1737 (C=O). 
 
1-(2-(4-Chlorophenyl)-2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 140b. 
 
Yield: 2.27 g, 78% 
Mp: 259-260 °C 
MW = 290.71                                                                                                    
Anal. calcd for C13H11N4O2Cl, C 53.71, H 3.81, N 19.27, found C 53.60, H 3.77, N 19.01.                                            
1H NMR (CDCl3): δ 4.20-4.52 (m, 2H, CH2N), 4.97-5.17 (m, 1H, CHO), 5.94 (s all., 1H, OH, 
disappears with D2O), 7.20-7.42 (m, 4H Ar), 8.03 (s, 1H, H-3), 8.07 (s, 1H, H-6), 12.14 (s all., 
1H, NH, disappears with D2O). 
IR (KBr): cm-1 3390 (NH), 3200-2800 (OH), 1740 (C=O). 
 
1-(2-(4-Bromophenyl)-2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 140c. 
 
Yield: 2.35 g, 70% 
Mp: 269-270 °C 
MW = 335.16                                                                                                    
Anal. calcd for C13H11N4O2Br, C 46.59, H 3.31, N 16.72, found C 46.71, H 3.13, N 16.85.                                            
1H NMR (CDCl3): δ 4.14-4.43 (m, 2H, CH2N), 4.90-5.07 (m, 1H, CHO), 5.68 (s all., 1H, OH, 
disappears with D2O), 7.07-7.21 and 7.31-7.44 (2m, 4H Ar), 7.94 (s, 1H, H-3), 7.98 (s, 1H, H-
6), 12.04 (s all., 1H, NH, disappears with D2O). 
IR (KBr): cm-1 3274 (NH), 2900-3100 (OH), 1694 (C=O). 
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General procedure for the synthesis of compounds 141a-c. 
 
 
 
The Vilsmeier complex, previously prepared from POCl3 (15.33 g, 100 mmol) and anhydrous 
DMF (7.31 g, 100 mmol) was added to a suspension of appropriate intermediate 140a-c (10 
mmol) in CHCl3 (50 mL). The mixture was refluxed for 8-12 h. The solution was washed with 
water (2 x 20 mL), dried (MgSO4), and concentrated under reduced pressure. The crude oil was 
purified by column chromatography (Florisil®, 100-200 mesh) using Et2O.  
 
4-Chloro-1-(2-chloro-2-(4-fluorophenyl)ethyl)-1H-pyrazolo[3,4-d]pyrimidine 141a. 
 
Yield: 2.33 g, 75% 
Mp: 128-129 °C 
MW = 311.14                                                                                                    
Anal. calcd  for C13H9N4Cl2F, C 50.18, H 2.92, N 18.01, found C 50.05, H 2.86, N 17.84.                                               
1H NMR (CDCl3):  δ 4.73-4.88 and 4.92-5.08 (2m, 2H, CH2N), 5.38-5.54 (m, 1H, CHCl), 6.84-
7.06 and 7.18-7.45 (2m, 4H Ar), 8.10 (s, 1H, H-3), 8.68 (s, 1H, H-6).  
 
4-Chloro-1-(2-chloro-2-(4-chlorophenyl)ethyl)-1H-pyrazolo[3,4-d]pyrimidine 141b. 
 
Yield: 2.29 g, 70% 
Mp: 118-119 °C 
MW = 327.60 
Anal. calcd for C13H9N4Cl3, C 47.66, H 2.77, N 17.10, found C 47.78, H 2.86, N 17.25.                                                  
1H NMR (CDCl3): δ 4.72-4.85 and 4.91-5.05 (2m, 2H, CH2N), 5.38-5.50 (m, 1H, CHCl), 7.16-
7.36 (m, 4H Ar), 8.10 (s, 1H, H-3), 8.69 (s, 1H, H-6).  
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1-(2-(4-Bromophenyl)-2-chloroethyl)-4-chloro-1H-pyrazolo[3,4-d]pyrimidine 141c. 
 
Yield: 2.23 g, 60% 
Mp: 108-109 °C 
MW = 372.05                                                                                           
Anal. calcd for C13H9N4Cl2Br, C 41.97, H 2.44, N 15.06, found C 41.96, H 2.40, N 15.23.         
1H NMR (CDCl3): δ 4.82-4.87 and 4.90-5.05 (2m, 2H, CH2N), 5.46-5.50 (m, 1H, CHCl), 7.24-
7.30 and 7.35-7.46  (2m, 4H Ar), 8.15 (s, 1H, H-3), 8.74 (s, 1H, H-6). 
 
General procedure for the synthesis of compounds 142a-c. 
 
 
 
To a solution of 141a-c (10 mmol) in anhydrous toluene (20 mL), the appropriate amine (40 
mmol) was added and the reaction was stirred at room temperature for 24 h. The solution was 
washed with water (20 mL), dried (MgSO4), and concentrated under reduced pressure. The oil 
was crystallized by adding a 1:1 mixture of Et2O/PE (bp 40-60 °C). 
 
1-(2-Chloro-2-(4-fluorophenyl)ethyl)-N-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 142a. 
 
Yield: 2.17 g, 65% 
Mp: 139-140 °C 
MW = 333.79 
Anal. calcd for C16H17N5ClF, C 57.57, H 5.13, N 20.98, found C 57.76, H 5.21, N 21.20.                                            
1H NMR (CDCl3): δ 0.97 (t, J = 7.2, 3H, CH3), 1.59-1.76 (m, 2H, CH2CH3), 3.51 (q, J = 7.2, 
2H, CH2NH),  4.60-4.75 and 4.81-4.94 (2m, 2H, CH2N), 5.38-5.52 (m, 1H, CHCl), 5.73 (s all., 
1H, NH disappears with D2O), 6.90-7.00 and 7.23-7.44 (2m, 4H Ar), 7.81 (s, 1H, H-3), 8.27 (s, 
1H, H-6). 
IR (KBr): cm-1 3227 (NH). 
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1-(2-Chloro-2-(4-chlorophenyl)ethyl)-N-(4-chlorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
amine 142b. 
 
Yield: 3.25 g, 75% 
Mp: 153-157 °C 
MW = 432.73 
Anal. calcd for C20H16N5Cl3, C 55.51, H 3.73, N 16.18, found C 55.72, H 4.03, N 15.90.              
1H NMR (CDCl3): δ  4.62-4.84 (m, 4H, CH2N +CH2Ar), 5.38-5.50 (m, 1H, CHCl), 7.16-7.36 
(m, 8H Ar), 7.76 (s, 1H, H-3), 8.31 (s, 1H, H-6).  
IR (KBr): cm-1 3201 (NH). 
 
1-(2-(4-Bromophenyl)-2-chloroethyl)-N-(3-chlorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
amine 142c. 
 
Yield: 2.86 g, 60% 
Mp: 142-143 °C 
MW = 477.18 
Anal. calcd for C20H16N5BrCl2, C 50.34, H 3.38, N 14.68, found C 50.37, H 3.69, N 14.36.                                                        
1H NMR (CDCl3): δ 4.43-4.85 (m, 4H, CH2N + CH2Ar), 5.43-5.59 (m, 1H, CHCl), 7.01-7.49 
(m, 8H Ar), 7.80 (s, 1H, H-3), 8.41 (s, 1H, H-6). 
IR (KBr): cm-1 3243 (NH). 
 
General procedure for the synthesis of compounds 137a-c. 
 
 
 
To a solution of NaOH (0.3 g, 7.5 mmol), a solution of the appropriate 142a-c (1 mmol) in 
EtOH 95% was added and the reaction was refluxed for 5 h. After cooling to room temperature, 
the precipitated solid was filtered, washed with water and recrystallized from absolute EtOH. 
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1-(4-Fluorostyryl)-N-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 137a. 
 
Yield: 0.18 g, 61% 
Mp: 232-235 °C 
MW = 297.33 
Anal. calcd for C16H16N5F, C 64.63, H 5.42, N 23.55, found C 64.83, H 6.00, N 23.63.                                                                      
1H NMR (CDCl3): δ 0.93 (t, J = 7, 3H, CH3), 1.58 (quint, J = 7, 2H, CH2CH3), 3.42 (t, J = 7, 
3H, CH2N), 6.99-7.40 (m, 5H, 4Ar + CH=), 7.70 (d, Jtrans = 14.4, 1H, CH=), 7.99 (s, 1H, H-3), 
8.76 (s, 1H, H-6). 
IR (KBr): cm-1 3216 (NH), 1662 (C=C). 
 
N-(4-chlorobenzyl)-1-(4-chlorostyryl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 137b. 
 
Yield: 0.21 g, 58% 
Mp: 238-240 °C 
MW = 369.27 
Anal. calcd for C20H15N5Cl2, C 60.62, H 3.82, N 17.67, found C 60.54, H 4.10, N 17.39.                                              
1H NMR (CDCl3): δ 4.65-4.80 (m, 2H, CH2Ar), 7.16-7.40 (m, 9H, 8Ar + CH=), 7.69 (d, Jtrans 
= 14.3, 1H, CH=) 7.78 (s, 1H, H-3), 8.30 (s, 1H, H-6). 
IR (KBr): cm-1 3203 (NH), 1658 (C=C). 
 
1-(4-Bromostyryl)-N-(3-chlorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 137c. 
 
Yield: 0.22 g, 51% 
Mp: 222-223 °C 
MW = 440.72 
Anal. calcd for C20H15N5ClBr, C 54.50, H 3.43, N 15.89, found C 54.39, H 3.65, N 15.73.            
1H NMR (CDCl3): δ 4.60-4.67 (m, 2H, CH2Ar), 7.20-7.43 (m, 9H, 8Ar + CH=), 7.70 (m, 1H, 
CH=) 7.81 (s, 1H, H-3), 8.31 (s, 1H, H-6). 
IR (KBr): cm-1 3234 (NH), 1659 (C=C). 
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Synthesis of 1-(2-hydroxy-2-phenylethyl)-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidin-
4(5H)-one 143. 
 
 
A solution of 83c (10 mmol) and methyl iodide (7.10 g, 50 mmol) in anhydrous THF 
(20 mL) was refluxed for 12 h. After cooling at room temperature, the solvent was removed 
under reduced pressure. CHCl3 was added and the precipitated solid was filtered and 
recrystallization from absolute EtOH. 
 
Yield: 2.17 g, 72% 
Mp: 207-209 °C 
MW = 302.35 
Anal. calcd for C14H14N4O2S, C 55.61, H 4.67, N 18.53, S 10.61, found C 55.46, H 4.34, N 
18.71, S 10.31.                                        
1H NMR (CDCl3): δ 2.52 (s, 3H, SCH3), 4.27-4.50 (m, 2H, CH2N), 5.04-5.18 (m, 1H, CHO), 
5.68 (d, 1H, OH), 7.20-7.42 (m, 5H Ar), 7.97 (s, 1H, H-3). 
IR (KBr): cm-1 3544 (NH), 1678 (C=O). 
 
Synthesis of 4-chloro-1-(2-chloro-2-phenylethyl)-6-(methylthio)-1H-pyrazolo[3,4-
d]pyrimidine 144. 
 
 
The Vilsmeier complex, previously prepared from POCl3 (6.13 g, 40 mmol) and anhydrous 
DMF (2.92 g, 40 mmol) was added to a suspension of 143 (3.02 g, 10 mmol) in CHCl3 (20 mL). 
The mixture was refluxed for 8 h. The solution was washed with water (2 x 20 mL), dried 
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(MgSO4), filtered, and concentrated under reduced pressure. The crude oil was purified by 
column chromatography (Silica gel 0.06-0200 mm, 40 Å), using a mixture of Et2O/PE (bp 40-
60 °C) (1:1) as the eluant to afford the pure product 144.  
 
Yield: 2.2 g, 65% 
Mp: 95-96 °C 
MW = 339.24 
Anal. calcd for C14H12N4SCl2, C 49.57, H 3.57, N 16.52, S 9.45, found C 49.92, H 3.44, N 
16.89, S 9.40.                                                                      
1H NMR (CDCl3): δ (s, 3H, CH3S), 4.77-5.05 (m, 2H, CH2N), 5.45-5.56 (m, 1H, CHCl), 7.29-
7.46 (m, 5H Ar), 8.02 (s, 1H, H-3). 
 
Synthesis of 1-(2-chloro-2-phenylethyl)-6-(methylthio)-4-morpholin-4-yl-1H-
pyrazolo[3,4-d]pyrimidine 145. 
 
 
To a solution of 144 (3.39 g, 10 mmol) in anhydrous toluene (20 mL), morpholine (3.48 g, 40 
mmol) was added and the reaction mixture was stirred at room temperature for 24 h. The 
mixture was washed with water, the organic phase was dried (MgSO4) and evaporated under 
reduced pressure; the residue oil crystallized by adding PE (bp 40-60 °C) (10 mL), to give the 
desired products. 
 
Yield: 2.92 g, 75% 
Mp: 116-117 °C 
MW = 389.90 
Anal. calcd for C18H20N5OSCl, C 55.45, H 5.17, N 17.96, S 8.22, found C 55.48, H 5.32, N 
18.19, S 8.09.                                                                      
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1H NMR (CDCl3): δ 2.57 (s, 3H, CH3), 3.77-3.87 and 3.89-3.98 (2m, 8H, 4CH2morph.), 4.71-
4.98 (m, 2H, CH2N), 5.51-5.61 (m, 1H, CHCl), 7.26-7.49 (m, 5H Ar), 7.82 (s, 1H, H-3).  
 
Synthesis of 6-(methylthio)-4-morpholin-4-yl-1-(-2-phenylvinyl)-1H-pyrazolo[3,4-
d]pyrimidine 146. 
 
 
A solution of NaOH (300 mg, 7.5 mmol) in water (2.15 mL) was added to a suspension of 145 
(390 mg, 1 mmol), in 96% EtOH (12 mL), and the mixture was refluxed for 5 h. After cooling, 
the white solid was filtered, washed with water, and recrystallized from absolute EtOH. 
 
Yield: 0.26 g, 75% 
Mp: 161-162 °C 
MW = 353.44 
Anal. calcd for C18H19N5OS, C 61.17, H 5.42, N 19.81, S 9.07, found C 61.25, H 5.48, N 19.81, 
S 8.88.                                                                      
1H NMR (CDCl3): δ 2.63 (s, 3H, CH3S), 3.80-3.89 and 3.91-3.99 (2m, 8H, 4CH2 morph.), 7.21-
7.55 (m, 6H, 5H Ar + CH=), 7.95 (s, 1H, H-3), 8.01 (d, Jtrans =14.6, 1H, CH=).  
IR cm-1: 1658 (C=C). 
 
Synthesis of 6-(methylsulfonyl-4-morpholin-4-yl-1-(2-phenylvinyl)-1H-pyrazolo[3,4-
d]pyrimidine 147. 
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3-Chloroperoxybenzoic acid (2 mmol of 77% suspension in mineral oil) was added portion wise 
to a solution of 146 (350 mg, 1 mmol) in CHCl3 (10 mL) at 0 °C. The mixture was stirred at 
room temperature for 6 h; the organic phase was washed with saturated NaHCO3 solution (2 x 
20 mL), then with water (20 mL), dried (MgSO4), and evaporated under reduced pressure. The 
crude oil crystallized by adding a mixture of Et2O/PE (bp 40-60 °C) (1:1). 
 
Yield: 0.34 g, 87% 
Mp: 215-216 °C (dec.) 
MW = 385.44 
Anal. calcd for C18H19N5O3S, C 56.09, H 4.97, N 18.17, S 8.32, found C 56.18, H 5.07, N 17.86, 
S 8.64.                                                                      
1H NMR (CDCl3): 3.41 (s, 3H, SO2CH3), 3.86-3.97 and 4.02-4.16 (2m, 8H, 4CH2 morph.), 
7.27-7.59 (m, 6H, 5Ar + CH=), 8.04 (d, Jtrans = 14.4, 1H, CH=), 8.16 (s, 1H, H-3).  
IR cm-1: 1658 (C=C), 1315, 1128 (SO2).  
MS: m/z 385 [M+1]+. 
 
Synthesis of 2-{[4-morpholin-4-yl-1-(2-phenylvinyl)-1H-pyrazolo[3,4-d]pyrimidin-6-
yl]amino} ethanol 137d. 
 
 
2-Aminoethanol (180 mg, 3 mmol) was added to a suspension of 147 (385 mg, 1 mmol) in 1-
butanol (16 mL) and DMSO (4 mL), and the mixture was heated at 90 °C for 12 h. After cooling, 
1-butanol was removed under reduced pressure; then water was added, and the solution was 
extracted with AcOEt (2 x 20 mL); the organic phase was washed with water (20 mL), dried 
(MgSO4), and evaporated under reduced pressure. The white solid was filtered and 
recrystallized from absolute EtOH. 
 
Yield: 0.25 g, 68% 
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Mp: 177-178 °C 
MW = 366.42 
Anal. calcd for C19H22N6O2, C 62.28, H 6.05, N 22.94, found C 62.23, H 6.19, N 23.25.                              
1H NMR (CDCl3): δ 3.70 (q, J = 4.0, 2H, CH2), 3.81-3.96 (m, 10H, 4CH2 morph. + CH2), 4.06 
(br s, 1H, disappears with D2O), 5.52 (br s, 1H, disappears with D2O), 7.19-7.52 (m, 6H, 5H Ar 
+ CH=), 7.87 (s, 1H, H-3), 7.88 (d, Jtrans = 14.4, 1H, CH=).  
IR cm-1: 3250-3150 (OH + NH), 1656 (C=C).  
MS: m/z 366 [M+1]+. 
 
Synthesis of 2-[4-amino-3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-
phenylethanol 148. 
 
 
To a solution of 110 (100 mg, 0.26 mmol) in THF (5 mL), phenylacetylene (35 mg, 0.34 mmol) 
was added, then Pd(PPh)3Cl2 (9 mg, 0.0079 mmol), CuI (3 mg, 0.016 mmol) and Et3N (50 mg, 
0.52 mmol) were added and the mixture was refluxed for 14 h. The cooled mixture was filtered 
and the solution was evaporated under reduced pressure. The crude product was purified by 
column chromatography using AcOEt/n-hexane (8:2) as the eluent to afford the pure product 
148.  
 
Yield: 42 mg, 45% 
Mp: 188-190 °C 
MW = 355.39 
Anal. calcd for C21H17N5O, C 70.97, H 4.82, N 19.71, found C 70.88, H 4.96, N 19.41.                
1H NMR ((CD3)2SO): δ 4.32-4.37 and 4.47-4.53 (2m, 2H, CH2N), 5.61-5.62 (m, 1H, CHO), 
6.22 (s all., 2H, NH2), 7.23-7.74 (m, 10H Ar), 8.23 (s, 1H, H-6).  
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Synthesis of 1-(2-chloro-2-phenylethyl)-3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-
4-amine 137e. 
 
 
SOCl2 (150 μL, 2.01 mmol) was added dropwise to a solution of the intermediate 148 (150 mg, 
0.40 mmol) in dry CH2Cl2 (5 mL), and the reaction was stirred at room temperature for 12 h 
under nitrogen atmosphere. Ice and 1 N NaOH were added with caution and the aqueous phase 
was extracted with CH2Cl2. Then the organic phase was washed with water, dried (Na2SO4) and 
concentrated under reduced pressure to give a white solid. The crude product was purified by 
column chromatography using CH2Cl2/CH3OH (95:5) as the eluent to afford the pure product 
137e. 
 
Yield: 69 mg, 43% 
Mp: 186-187 °C 
MW = 373.84 
Anal. calcd for C21H16N5Cl, C 67.47, H 4.31, N 18.73, found C 67.54, H 4.16, N 18.75.               
1H NMR ((CD3)2SO): δ 4.74-5.11 (m, 2H, CH2N), 5.57-5.50 (m, 1H, CHCl), 6.82 (s all., 2H, 
NH2), 7.39-7.77 (m, 10H Ar), 8.29 (s, 1H, H-6).  
 
Synthesis of 3-(phenylethynyl)-1-(-2-phenylvinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
137f. 
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A solution of NaOH (48 mg, 1.2 mmol) in water (360 µL) was added to a suspension of 137e 
(60 mg, 0.16 mmol), in 96% EtOH (4 mL), and the mixture was refluxed for 5 h. After cooling, 
the white solid was filtered, washed with water, and recrystallized from absolute EtOH to obtain 
compound 137f. 
 
Yield: 22 mg, 35% 
Mp: 245-252 °C 
MW = 337.38 
Anal. calcd for C21H15N5, C 74.76, H 4.48, N 20.76, found C 74.57, H 4.23, N 20.93.                    
1H NMR ((CD3)2SO): δ 7.16 (s all., 2H, NH2), 7.33-7.82 (m, 10H Ar), 8.04-8.12 (m, 2H, 
CH=CH), 8.38 (s, 1H, H-6).  
 
Synthesis of 1-(2-hydroxy-2-phenylethyl)-6-(isopropylthio)-1H-pyrazolo[3,4-
d]pyrimidin-4(5H)-one 149a. 
 
 
A mixture of 83c (2.88 g, 10 mmol), 2-bromopropane (1.25 g, 10.14 mmol) and anhydrous 
K2CO3 (1.38 g, 10 mmol) in anhydrous DMF (10 mL) was stirred at room temperature for 8 h. 
The mixture was poured in cold water; the white solid obtained was filtered, washed with water 
and recrystallized from absolute EtOH to afford 149a as a white solid. 
 
Yield: 1.22 g, 37%  
Mp: 194-195 °C 
MW= 330.41 
Anal. calcd for C16H18N4O2S, C 58.16, H 5.49, N 16.96, S 9.70, found C 58.37, H 5.22, N 16.88, 
S 9.82. 
1H NMR ((CD3)2SO): δ 1.44 (d, J = 6.2, 6H, 2CH3), 3.90 (d, 1H, OH, disappears with D2O), 
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3.98 (sept, J = 6.2, 1H, CHS), 4.38-4.48 and 4.50-4.58 (2m, 2H, CH2N), 5.19-5.22 (m, 1H, 
CHOH), 7.24-7.37 (m, 5H Ar), 8.06 (s, 1H, H-3), 11.06 (br s, 1H, NH disappears with D2O).  
IR (KBr): cm-1 3300-3100 (NH + OH), 1704 (CO).  
 
Synthesis of 6-(cyclopentylthio)-1-(2-hydroxy-2-phenylethyl)-1H-pyrazolo[3,4-
d]pyrimidin-4(5H)-one 149b. 
 
 
 
A mixture of 83c (2.88 g, 10 mmol), bromocyclopentane (1.5 g, 10.14 mmol) and anhydrous 
K2CO3 (1.38 g, 10 mmol) in anhydrous DMF (10 mL) was stirred at room temperature for 8 h. 
The mixture was poured into cold water, the white solid was filtered, washed with water, and 
recrystallized from absolute EtOH to afford 149b as a white solid. 
 
Yield: 1.96 g, 55%  
Mp: 213-214 °C 
MW = 356.44  
Anal. calcd for C18H20N4O2S, C 60.65, H 5.66, N 15.72, S 9.00, found C 60.31, H 5.82, N 15.70, 
S 8.90. 
1H NMR ((CD3)2SO): δ 1.42-1.74 and 1.94-2.27 (2m, 8H, 4CH2 cyclopentyl) 3.76-3.97 (m, 1H, 
CHS), 4.17-4.42 (m, 2H, CH2N), 4,92-5.12 (m, 1H, CHOH), 5.57 (d, 1H, OH disappears with 
D2O), 7.03-7.28 (m, 5H, Ar), 7.87 (s, 1H, H-3), 12.19 (br s, 1H, NH disappears with D2O). 
IR (KBr): cm-1 3150-2850 (NH+OH), 1703 (CO). 
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General procedure for the synthesis of compounds 150a,b. 
 
 
 
The Vilsmeier complex, previously prepared from POCl3 (1.22 g, 8 mmol) and anhydrous DMF 
(580 mg, 8 mmol) was added to a suspension of 149a,b (1 mmol) in CH2Cl2 (10 mL). The 
mixture was refluxed for 6-8 h. The solution was washed with water (2 x 10 mL), dried 
(MgSO4), filtered, and concentrated under reduced pressure. The crude oil was purified by 
column chromatography (Florisil, 100-200 mesh), using Et2O as the eluent, to affοrd the pure 
products. 
 
4-Chloro-1-(2-chloro-2-phenylethyl)-6-(isopropylthio)-1H-pyrazolo[3,4-d]pyrimidine 150a. 
 
Yield: 0.27 g, 74%  
Mp: 67-68 °C 
MW = 367.29  
Anal. calcd for C16H16N4Cl2S, C 52.32, H 4.39, N 15.25, S 8.73, found C 52.37, H 4.29, N 
15.33, S 8.90. 
1H NMR ((CD3)2SO): δ 1.45 (d, J = 6.2, 3H, CH3), 1.49 (d, J = 6.2, 3H, CH3), 4.00 (sept, J = 
6.2, 1H, CHS), 4.74-4.82 and 4.88-4.97 (2m, 2H, CH2N), 5.45-5.55 (m, 1H, CHCl), 7.21-7.50 
(m, 5H, Ar), 8.00 (s, 1H, H-3). 
 
4-Chloro-1-(2-chloro-2-phenylethyl)-6-(cyclopentylthio)-1H-pyrazolo[3,4-d]pyrimidine 
150b. 
 
Yield: 0.25 g, 63%  
Mp: 70-71 °C 
MW = 393.33  
Anal. calcd for C18H18N4Cl2S, C 54.96, H 4.61, N 14.24, S 8.15, found C 54.88, H 4.73, N 
Chapter 12. Experimental section   
222 
 
Design, synthesis and biological evaluation of pyrazolo-pyrimidines and related isosteres  
as inhibitors of protein kinases, potential antineoplastic agents 
14.31, S 8.24. 
1H NMR ((CD3)2SO): δ 1.54-1.85 and 2.10-2.32 (2m, 8H, 4CH2 cyclopentyl), 3.93-4.07 (m, 
1H, CHS), 4.67-4.80 and 4.82-4.97 (2m, 2H, CH2N), 5.38-5.50 (m, 1H, CHCl), 7.19-7.42 (m, 
5H, Ar), 7.94 (s, 1H, H-3). 
 
General procedure for the synthesis of compounds 137g,h.  
 
 
 
The 3-aminophenol (545 mg, 5 mmol) was added to a solution of the suitable 4-chloro 
derivative 150a,b (1 mmol) in absolute EtOH (10 mL), and the mixture was refluxed for 3-5 h. 
After cooling to room temperature, the solvent was evaporated under reduced pressure and the 
crude was solved in AcOEt (10 mL), washed with 0.1 N HCl solution (2 x 10 mL), 1 N NaOH 
solution (10 mL) and saturated NaCl solution (2 x 10 mL), dried (MgSO4), filtered, and 
concentrated under reduced pressure to give a brown oil which crystallized at 4 °C by adding a 
1:1 mixture of Et2O/PE (bp 40−60 °C). The solid obtained was purified by column 
chromatography (Silica gel 0.06-0200 mm, 40 Å) using CH2Cl2 as the eluent.  
 
3-((1-(2-Chloro-2-phenylethyl)-6-(isopropylthio)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-
4-yl)amino)phenol 137g.  
 
Yield: 339 mg, 77%  
Mp: 198-199 °C.  
MW = 439.96 
Anal. calcd for C22H22N5OClS, C 60.06, H 5.04, N 15.92, S 7.29, found C 60.17, H 4.94, N 
16.21, S 7.38. 
1H NMR ((CD3)2SO): δ 1.46 (d, J = 6.0 Hz, 3H, CH3), 1.49 (d, J = 6.0 Hz, 3H, CH3), 3.97-4.07 
(m, 1H, SCH), 4.70-4.75 and 4.83-4.88 (2m, 2H, CH2N) 5.48-5.51 (m, 1H, CHCl), 6.78-6.80, 
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6.94-7.02 and 7.21-7.41 (3m, 10H, 9 Ar + H-3).  
IR (KBr): cm−1 3300-3100 (NH + OH).  
MS: m/z 441 [M + 1]+.  
 
3-((1-(2-Chloro-2-phenylethyl)-6-(cyclopentylthio)-4,5-dihydro-1H-pyrazolo[3,4-
d]pyrimidin-4-yl)amino)phenol 137h.  
 
Yield: 359 mg, 77% 
Mp: 160-161 °C 
MW = 466.00 
Anal. calcd for C24H24N5OClS, C 61.86, H 5.19, N 15.03, S 6.88, found C 61.95, H 4.97, N 
15.18, S 7.01. 
1H NMR ((CD3)2SO): δ 1.62-2.24 (m, 8H, 4CH2 cyclopent), 4.03-4.22 (m, 1H, SCH), 4.75-
4.95 (m, 2H, CH2N), 5.45-5.56 (m, 1H, CHCl), 6.80-7.60 (m, 9H Ar), 8.06 (s, 1H H-3), 10.20 
(br s, 1H, disappears with D2O).  
IR (KBr): cm−1 3500-3000 (NH + OH).  
MS: m/z 467 [M + 1]+.  
 
Synthesis of ethyl 5-amino-1-(2-phenylpropyl)-1H-pyrazole-4-carboxylate 152. 
 
 
 
A solution of (2-phenylpropyl)hydrazine 151 (1.50 g, 10 mmol) and 
ethyl(ethoxymethylene)cyanoacetate (1.69 g, 10 mmol) in absolute EtOH was refluxed for 5 h. 
The solvent was evaporated under reduced pressure and the crude was purified by column 
chromatography (Florisil 100-200 mesh) using Et2O as the eluent, to afford the pure product 
152 as a yellow oil. 
 
Yield: 1.65 g, 60%  
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Mp: 85-86 °C 
MW = 273.33 
Anal. calcd for C15H19N3O2, C 65.91, H 7.01, N 15.37, found C 65.90, H 6.99, N 15.25.                 
1H NMR (CDCl3): δ 1.06-1.20 (m, 6H, 2CH3), 3.24-3.26 (m, 1H, CHCH3), 3.78-3.83 and 3.89-
3.91 (2m, 2H, CH2N), 4.10 (q, J = 7.0, 2H, CH2O), 4.79 (br s, 2H, NH2 disappears with D2O), 
7.00-7.16 (m, 5H Ar), 7.55 (s, 1H, H-3). 
IR (KBr): cm-1 3398, 3291 (NH2), 1681 (CO). 
MS: m/z 273 [M+1]+. 
 
Synthesis of ethyl-5-{[(benzoylamino)carbonothioyl]amino}-1-(2-phenylpropyl)-1H-
pyrazole-4-carboxylate 153. 
 
 
 
A suspension of 152 (2.73 g, 10 mmol) and benzoyl isothiocyanate (1.7 g, 11 mmol) in 
anhydrous THF (20mL) was refluxed for 12 h. The solvent was evaporated under reduced 
pressure, and the crude was crystallized as a white solid by adding Et2O (30 mL). 
 
Yield: 2.75 g, 73% 
Mp: 112-113 °C 
MW = 436.53 
Anal. calcd for C23H24N4O3S, C 63.28, H 5.54, N 12.83, S 7.35, found C 63.35, H 5.48, N 12.86, 
S 7.51. 
1H NMR (CDCl3): δ 1.21-1.29 (m, 6H, 2CH3), 3.43-3.49 (m, 1H, CHCH3), 4.17-4.22 (m, 4H, 
CH2N + CH2O), 7.07-7.89 (m 10H Ar), 7.93 (s, 1H, H-3), 9.19 (br s, 1H, NH disappears with 
D2O), 11.60 (br s, 1H, NH disappears with D2O).  
IR (KBr): cm-1 3384, 3129 (NH), 1696 (COOEt), 1666 (CONH). 
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MS: m/z 437 [M+1]+. 
 
Synthesis of 1-(2-phenylpropyl)-6-thioxo-1,5,6,7-tetrahydro-pyrazolo[3,4-d]pyrimidin-4-
one 154. 
 
 
A solution of 153 (4.38 g, 10 mmol) in 2 M NaOH (40 mL) was boiled for 10 min and 
successively diluted with water (40 mL). The solution was acidified with glacial acetic acid. 
After 12 h of standing in a refrigerator, the crystallized solid was filtered and recrystallized from 
absolute EtOH to give a white solid. 
 
Yield: 1.72 g, 60% 
Mp: 192-193 °C (dec) 
MW = 286.35 
Anal. calcd for C14H14N4OS, C 58.72, H 4.93, N 19.57, S 11.20, found C 58.83, H 4.98, N 
19.78, S 11.45. 
 1H NMR (CDCl3): δ 1.22-1.60 (m, 3H, CH3), 3.36-3.42 (m, 1H, CHCH3), 4.26-4.32 and 4.45-
4.51 (2m, 2H, CH2N), 7.12-7.31 (m 5H Ar), 7.82 (s, 1H, H-3), 10.49 (br s, 1H disappears with 
D2O). 
IR (KBr): cm-1 3455-2867 (NH + OH), 1677 (CO). 
MS: m/z 286 [M+1]+. 
 
Synthesis of 6-(ethylthio)-1-(2-phenylpropyl)-1,5-dihydro-4Hpyrazolo[3,4-d]pyrimidin-4-
one 155.  
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A mixture of 154 (286 mg, 1 mmol), iodoethane (172 mg, 1.1 mmol), and K2CO3 (138 mg, 1 
mmol) in anhydrous DMF (2 mL) was stirred at room temperature for 20 h. The mixture was 
poured into cold water (50 mL). The obtained solid was filtered, washed with water, and 
recrystallized from absolute EtOH.  
 
Yield: 192 mg, 61% 
Mp: 155-156 °C 
MW = 314.41 
Anal. calcd for C16H18N4OS, C 61.12, H 5.77, N 17.82, S 10.20, found C 61.09, H 5.77, N 
17.86, S 10.10. 
1H NMR (CDCl3): δ 1.22 (d, J = 7.0 Hz, 3H, CH3CH), 1.36 (t, J = 7.2, 3H, SCH2CH3), 3.17 (q, 
J = 7.2 Hz, 2H, SCH2), 3.40-3.50 (m, 1H, CHCH3), 4.26-4.50 (m, 2H, CH2N), 7.07-7.30 (m, 
5H Ar), 7.94 (s, 1H, H-3), 12.10 (br s, 1H, NH disappears with D2O).  
IR (KBr): cm−1 3110-2800 (NH), 1681 (CO).  
MS: m/z 315 [M + 1]+. 
 
Synthesis of 4-chloro-6-(ethylthio)-1-(2-phenylpropyl)-1H-pyrazolo[3,4-d]-pyrimidine 
156.  
 
 
The Vilsmeier complex, previously prepared from POCl3 (0.74 mL, 8 mmol) and anhydrous 
DMF (590 mg, 8 mmol) was added to a suspension of 155 (300 mg, 1 mmol) in CH2Cl2 (10 
mL). The mixture was refluxed for 6 h. The solution was washed with water (2 x 10 mL), dried 
(MgSO4), filtered, and concentrated under reduced pressure. The crude oil was purified by 
column chromatography (Florisil, 100-200 mesh), using Et2O as the eluent, to affοrd the pure 
product. 
 
Yield: 300 mg, 90%  
Mp: 161-163 °C 
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MW = 332.85 
Anal. calcd for C16H17N4ClS, C 57.73, H 5.15, N 16.83, S 9.63, found C 57.67, H 5.00, N 16.77, 
S 9.55. 
1H NMR (CDCl3): δ 1.31 (d, J = 7.2 Hz, 3H, CH3CH), 1.47 (t, J = 7.4 Hz, 3H, SCH2CH3), 3.21 
(q, J = 7.4 Hz, 2H, SCH2), 3.48-3.63 (m, 1H, CHCH3), 4.42-4.66 (m, 2H, CH2N), 7.12-7.31 (m, 
5H Ar), 8.01 (s, 1H, H-3).  
MS: m/z 334 [M + 1]+.  
 
Synthesis of 3-{[6-(ethylthio)-1-(2-phenylpropyl)-1H-pyrazolo[3,4-d]-pyrimidin-4-
yl]amino}phenol 137i.  
 
 
The 3-aminophenol (545 mg, 5 mmol) was added to a solution of 156 (330 mg, 1 mmol) in 
absolute EtOH (10 mL), and the mixture was refluxed for 3-5 h. After cooling to room 
temperature, the solvent was evaporated under reduced pressure and the crude was solved in 
AcOEt (10 mL), washed with 0.1 N HCl solution (2 x 10 mL), 1 N NaOH solution (10 mL) and 
saturated NaCl solution (2 x 10 mL), dried (MgSO4), filtered, and concentrated under reduced 
pressure to give a brown oil which crystallized at 4 °C by adding a 1:1 mixture of Et2O/PE (bp 
40−60 °C). The solid obtained was purified by column chromatography (Silica gel 0.06-0200 
mm, 40 Å) using CH2Cl2 as the eluent.  
 
Yield: 296 mg, 73%  
Mp: 184-186 °C 
MW = 405.52 
Anal. calcd for C22H23N5OS, C 65.16, H 5.72, N 17.27, S 7.91, found C 65.35, H 5.69, N 17.11, 
S 7.67. 
1H NMR (CDCl3): δ 1.22 (d, J = 6.8 Hz, 3H, CH3CH), 1.44 (t, J = 7.6 Hz, 3H, SCH2CH3), 3.19 
(q, J = 7.6 Hz, 2H, SCH2), 3.46-3.52 (m, 1H, CHCH3), 4.36-4.89 (m, 2H, CH2N), 6.82-6.84, 
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6.93-6.95, 6.99-7.05 and 7.16-7.24 (4m, 10H, 9 Ar + H-3).  
IR (KBr): cm−1 3200-2900 (NH + OH).  
MS: m/z 407 [M + 1]+.  
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